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Abstract 
In the first 3 years of the Obama Administration, 2009–2011, the number of warning 
letters issued to pharmaceutical firms for manufacturing and quality issues increased by 
81% to 49 letters. Only 9 letters were issued in the last 3 years of the George W. Bush 
Administration. Shortfalls in compliance and product quality led to medicine shortages 
that affected patients’ treatment and health. This quantitative study sought to learn to 
what extent, if any, the independent variables, management behaviors and financial 
indicators at pharmaceutical firms in the United States, correlated with, or predicted, the 
dependent variable, compliance with the FDA regulations. FDA’s enforcement actions on 
the firms were the treatment event. A shift in the relationship between the variables 
occurred after the FDA interventions, which highlighted a new level of compliance. Of 
the 1144 SurveyMonkey invitations sent to the members of the International Society of 
Pharmaceutical Engineers, only 21 completed the survey’s 133 questions. Three research 
questions were addressed using correlations and linear regressions. The theory of planned 
behavior was applied to correlate behavioral constructs with the compliance of the firms 
leading to the rejection of the null hypothesis. By establishing an inverse relation between 
financial indicators and the firms’ level of compliance, the study offers awareness and 
insight to senior leaders regarding their behaviors and the decision-making process. 
Enhancing managers’ decision-making processes in light of their beliefs, along with their 
control over financial indicators, could reinforce the presence of effective quality systems 
among pharmaceutical manufacturers minimizing medicine shortages.  
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Chapter 1: Introduction to the Study 
Since 2009, interventions and enforcement actions against U. S. pharmaceutical 
manufacturers by the Food and Drug Administration (FDA) have increased. Many of the 
interventions were due to a lack of compliance with current good manufacturing practices 
(CGMP). In short, patented or generic pharmaceuticals sold to the public were not 
available or were substandard in quality. Attitudes and behaviors of management in 
pharmaceutical firms with an over-commitment to financial results have led to the lack of 
the expected compliance with regulations, thus declining organizational performance. 
This performance has a direct impact on internal and external stakeholders, which needs 
to be addressed to achieve the desired positive social change of avoiding shortages of 
medicines. Pharmaceutical management consists of all individuals that have the authority 
to make-decisions that could impact compliance with the FDA regulations and to direct 
financial decisions within the pharmaceutical firms.  According to Pollack (2013), the 
drug shortages were caused by (a) pharmaceutical management decisions to limit 
investments in enhanced quality systems and (b) insufficient manufacturing capacity. 
To project the complexity of addressing the change process, management 
decision-making processes, and possible theoretical frameworks need to be implemented 
by pharmaceutical management. The essential change process to avoid medicine 
shortages has to evolve through the typical change cycle of what, how, and why (Kezar, 
2001). The potential impact on stakeholders, especially drug shortages, constituted the 
“why” for conducting this study. Influencing the organizational performance, by 
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modifying management behaviors and financial indicators, is expected to minimize or 
eliminate the impact on stakeholders, leading to positive social change. 
Chapter 1 includes the background of the study, the specific details of the problem 
statement, and the purpose of the study. Then, the impact on social change by the study 
was followed by the theoretical framework of the study, the research questions and 
hypotheses, and the design that guided this quantitative study. Chapter 1 concludes with 
the definitions, scope of the study, assumptions, limitations, and delimitations in this 
study. 
Background of the Study 
A series of FDA interventions and enforcement actions against pharmaceutical 
manufacturers in the past 5–6 years led to medicine shortages in the United States 
(Nguyen, Seoane-Vazquez, Rodriguez-Monguio, & Montagne, 2013). Manufacturing 
shortfalls made essential medicines unavailable for the treatment of patients (FDA, 
2013). Manufacturing shortfalls implied that quality management and manufacturing 
systems were not empowered or properly staffed to adequately support the critical 
functions of the pharmaceutical firms (Woodcock, 2012). The loss of sales, penalties, and 
cost of remediation directly influenced the profit, and thus affected the worth of the 
stockholders and the firms’ market value. 
In this dissertation, I promoted positive social change by influencing the 
elimination or minimization of medicine shortages. Medicine shortages placed the 
patients’ health in significant danger (FDA, 2011). Also, medicines that are substandard 
in quality, purity, strength, and identity do not address the intended health treatment 
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(Woodcock, 2012). Given that the firms’ revenues were affected, both the patients and 
the stockholders could be perceived as the victims of management decisions. 
Pharmaceutical manufacturing management’s attitude towards limited compliance and 
based on extreme control over the cost of goods presented the challenge and disconnect 
in the management decision-making process. Burd and Chrai (2004) challenged the 
attitudes and behaviors of pharmaceutical management, as well as their drive for financial 
results. For pharmaceutical firms, lack of compliance with FDA regulations could be 
devastating. The results could include loss of the market value of the firms, loss of sales, 
diminished reputation, and increased expenses to recover or achieve remediation. If an 
FDA intervention were to evolve into a consent decree, which is a legal agreement to 
resolve the shortfalls in compliance by the firm, the magnitude of all these elements 
could multiply and become an unacceptable historical benchmark within the industry. 
Problem Statement 
The general problem investigated in this study was a significant increase in the 
number of pharmaceutical firms cited for noncompliance with federal quality guidelines 
during the past 5-6 years. In the first 3 years of the Obama Administration, 2009 through 
2011, the number of warning letters issued for manufacturing and quality issues increased 
from 9 letters (in the last 3 years of the George W. Bush Administration) to 49 letters 
(Nguyen, Seoane-Vazquez, Rodriguez-Monguio, & Montagne, 2013), for an increase of 
about 81%. This percentage reflected FDA’s emphasis on assuring compliance by the 
pharmaceutical companies. The lack of compliance with CGMP led to pharmaceuticals 
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manufacturing facility closures, loss on revenues, unavoidable penalty fees, loss of 
reputation, and significant investments to address remediation of their non-conformances 
to the FDA regulations (Asotra, Cossin, & Yacobi, 2012). The FDA, in a letter, dated 
October 31, 2011, to pharmaceuticals manufacturers, indicated that about 54% of drug 
shortages were a result of manufacturers’ quality issues (Food Drug Administration 
[FDA], 2011). Collectively, the evidence suggested that the number of FDA interventions 
and enforcement actions, against pharmaceutical manufacturers, have increased in the 
recent years. 
The specific problem addressed in this study related to shortfalls in compliance 
performance and product quality leading to medicine shortages that affected patients’ 
treatment and health. According to Pollack (2013) the shortfall in investment decisions 
for enhancing quality systems and the limited manufacturing capacity caused the 
medicine shortages. Price competition to attain market share, financial benefits on market 
value, and management incentives skewed against investing in plant improvements drove 
pharmaceutical manufacturing leaders’ decisions and behaviors away from compliance 
(Asotra, Cossin, & Yacobi, 2012). Senior leaders’ attitudes towards the lack of focus on 
quality systems prevail in their management decision-making process (Woodstock, 
2012). Mehta (2013) suggested that implementing the principles and guidelines 
developed by the International Conference on Harmonization could be a significant step 
in facilitating senior leaders’ understanding of the compliance expectations. Correcting 
CGMP violations by the pharmaceutical manufacturing leaders implies that productivity-
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financial indicators need assessment and that management behaviors require 
modification. 
Purpose of the Study 
The purpose of this quantitative study was to determine to what extent, if any, 
management behavior and financial indicators at the pharmaceutical firms were 
correlated with their compliance with FDA regulations. From the review of the literature, 
the gap consisted in the limited research that would create awareness and offer guidance 
to managers in their decision-making process and risk assessment process regarding their 
(a) FDA compliance responsibility, (b) corporate financial mandate, and (c) stakeholders’ 
expectations. This research was driven by the limited information on what are the 
interdependencies or correlations between the need to grow revenue and the behaviors 
within the pharmaceutical management decision-making process. 
Management’s resolve to meet the firms’ intended quality, integrity, strength, and 
purity influences the level of compliance. Other factors include the pressures to enhance 
productivity, fund research, support marketing plans, and reduce the cost of goods. 
FDA’s enforcement actions were used as the treatment event to reestablish the expected 
level of compliance. A shift in the relationship between the variables was expected after 
the FDA intervention, thus highlighting the new level of compliance. The resulting level 
of compliance is expected to enhance the financial performance of the pharmaceutical 
firms and minimize drug shortages. 
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Significance of the Study 
This research study was directed to address an area of limited research on the 
management behaviors and financial decision-making of senior management in 
pharmaceuticals companies. Management behaviors and financial decision-making could 
have led to significant shortages of medicines in the last 5-6 years. Drug shortage events 
increased from 61 in 2005 (Barlas, 2014) to 251 in 2011 (FDA, 2013). According to 
Woodcock (2012), many of these medicine shortages were caused directly by shortfalls 
in compliance with FDA regulations. The outcome of the study provided insight to the 
management decision process on what senior leaders’ behaviors should be considered 
and accentuated the need to modify financial drivers, which limit the presence of 
effective quality systems in pharmaceutical manufacturing companies. 
For pharmaceutical firms, lack of compliance with the FDA regulations could be 
devastating. Lack of compliance could impact sales and reputation, and could increase in 
the level of expenses to recover or achieve remediation. These performance indicators 
also correlated to the market value of the firms. If the FDA intervention escalates into a 
consent decree, the magnitude of all these elements could multiply and become an 
unacceptable historical benchmark within the industry. Legal actions against 
pharmaceutical firms’ leadership could be inevitable. This study pursued the potential to 
highlight the undesired behaviors in management and accentuated the concept that 
compliance is a competitive business advantage for the pharmaceutical companies. 
This study could raise the awareness of pharmaceutical management about how 
their decisions, based on their attitudes and behaviors, could avoid interruptions in the 
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supply of some essential patented or generic drugs. The social responsibility of the 
organization would be perceived to be non-existent and detached from the mission of 
providing quality medicines for the treatment of patients. Some examples of the 
experienced shortages are Tylenol for cold symptoms in 2011, Doxil for ovarian cancer 
in 2012, and Levoxyl for thyroid hormone replacement in 2013 (FDA, 2013). The goal of 
this study was to provide clarity about the desired behaviors to management. The findings 
of the study are expected to transform leadership tactics to meet the organization goals 
and mission, while sustaining compliance with the CGMP regulations. 
The target of the study, as previously described, was directed to avoid placing the 
patients in danger with medicine shortages (Hensley, 2011). In their study, Becker et al. 
(2013) found that the number of oncology drug shortages affecting patients’ treatments 
increased from 2010 to 2011. Also, stockholders’ equity could be affected if management 
does not recognize the detachment from their mission leading to the costs associated with 
the FDA intervention and high financial penalties. The effectiveness of this study 
depended on the degree of honesty in the participants’ responses and on how well the 
responses represented the actual behavior or intended future actions of the participants. 
Secret agendas were not detected. Unscrupulous managers could have presented an 
obstacle to enhance quality systems and compliance as indicated by Woodcock (2012). 
The actual performance could continue with old practices and behaviors, leading to poor 
product quality and further medicine shortages, while increasing the risk to patients and 
the losses to stockholders. 
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The study has implications for positive social change directed to encourage 
managers of pharmaceutical organizations to operate and behave in compliance with the 
FDA regulations.  The main potential social change was to avoid having medicine 
shortages, due to decisions about non-compliance by pharmaceutical manufacturing 
management. Avoiding shortages of patented or generic medicines would minimize or 
eliminate the risk to patients’ health. 
Research Questions and Hypotheses 
In this quantitative study, I sought to determine the correlation, if any, between 
the management behaviors and financial indicators of pharmaceutical firms that have 
been impacted by FDA enforcement actions. The compliance present in the 
pharmaceutical firms prior to the FDA intervention were compared to the compliance 
after the FDA intervention to better understand its influence on the firms’ compliance 
with the CGMP regulations. The independent variables that could lead to enforcement 
actions by the FDA were the behavior of the pharmaceutical managers and the firms’ 
financial indicators. The dependent variable was the level of compliance of the 
pharmaceutical company. 
•   Correlations between management (independent variable) behaviors and 
compliance (dependent variable): 
Research Question 1 (RQ1):  To what extent, if any, does management 
behaviors correlate to compliance with FDA regulations at the pharmaceutical 
firms in the United States? 
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H1₀: r = 0. There is no difference in management behaviors towards 
compliance at pharmaceutical firms, as a result of FDA enforcement actions in 
the United States. 
H1₁: r ≠ 0. There are differences in management behaviors towards 
compliance at pharmaceutical firms, as a result of FDA enforcement actions in 
the United States. 
•   Correlations between financial indicators (independent variable) and compliance 
(dependent variable): 
Research Question 2 (RQ2):  To what extent, if any, do financial indicators 
correlate to compliance with FDA regulations at the pharmaceutical firms in 
the United States? 
H2₀: r = 0. There is no difference in compliance with FDA related to financial 
indicators at pharmaceutical firms, as a result of FDA enforcement actions in 
the United States. 
H2₁: r ≠ 0. There are differences in compliance with FDA related to financial 
indicators before and after the FDA enforcement actions in the United States. 
•   Financial indicators (independent variable) impact on compliance (dependent 
variable): 
Research Question 3 (RQ3):  To what extent, if any, do financial indicators 
impact compliance with FDA regulations at the pharmaceutical firms in the 
United States? 
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H3₀:  β₁ = β₂ = … = β7 = 0. There is no impact in compliance with FDA 
related to financial indicators at pharmaceutical firms, as a result of FDA 
enforcement actions in the United States. 
H3₁:  At least one β₁ ≠ 0. There is an impact in compliance with FDA related 
to financial indicators before and after the FDA enforcement actions in the 
United States. 
The βs in Hypothesis 3 were the regression coefficients of the following multiple 
regression equation: 
0 1 1 2 2 3 3 4 4 5 5 6 6 7 7Y X X X X X X X                  (1) 
Where,  
Y= FDA related compliance 
X1 = Cost of goods 
X2 = Investment 
X3 = Process compliance 
X4 = Change in sales 
X5 = Change in revenues 
X6 = Change in market value of the firms 
X7 = Change in stockholders equity 
ԑ   = Error of the regression 
11 
 
 
Theoretical Framework 
The purpose of a theoretical framework is to identify a theory that could relate the 
independent and the dependent variables (Creswell, 2009). Creswell indicated that a 
deductive approach should apply when selecting the theoretical framework for a 
quantitative study. Frankfort-Nachmias and Nachmias (2008) suggested that a systematic 
link between the conceptual and operational definitions is needed for a practical approach 
to the theory. In this study, the theory before research approach was applied as written by 
Frankfort-Nachmias and Nachmias (2008). This systematic approach allowed assessing 
and predicting the interrelation between the selected variables. 
The theory of planned behavior (TPB) was developed by Ajzen (1991). In this 
study, it was used to assess behaviors of the pharmaceutical managers. The central point 
of TPB is that there is a direct relationship between intention and actual behavior. TPB 
highlights that any behavior could be explained and that behaviors are not difficult to 
predict. For this study, the intention of the pharmaceutical industry management to 
comply with the regulations of the FDA, as well as the financial limitations and 
complexity, created an excellent scenario to assess with TPB. 
As presented by Langham, Paulsen, and Härtel (2012), the relationship between 
intention and actual behavior is essential to the understanding of the willingness to 
comply and of the actual action of non-compliance. Consequently, predicting intention to 
comply is as important as predicting the actual compliance behavior. TPB also evaluates 
the topic of behavioral control, including the concepts of perceived behavioral control 
and actual control. Perceived behavioral control consists of the individual’s ability to 
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control behavior and willingness to apply the required behavior. Actual control is 
essential for investigating behaviors that require the individual to overcome performance 
hurdles. Attitudes and values are specific elements in this approach. Understanding the 
factors that led to the unwillingness to comply or drive to ignore compliance facilitate the 
probable prevention measures accompanying any FDA intervention. TPB provided 
mechanisms of comparison, correlation, and prediction to understand how to reinforce 
the intention that could modify future compliance. 
Nature of the Study 
The nature of the study intended to address the research questions to raise 
management’s awareness avoiding interruptions in the supply of some essential patented 
or generic pharmaceutical drugs. The study highlighted that (a) avoiding FDA actions 
provides business sustainability and (b) compliance is a competitive advantage for 
pharmaceutical companies. The design of the research sought to predict the outcome of 
the dependent variable, that is, compliance with FDA regulations. 
Selection of Study Methodology  
The comparison between experimental methods could be centered in two foci, 
either in an exploratory study of a new topic (qualitative) or on the degree of achieving or 
understanding the causation relation between variables (quantitative). The quantitative 
research method predicts, investigates relationships between variables, or assesses 
possible impacts or influences on outcomes. The qualitative research method is an 
approach to study the implicit, as well as the explicit of the targeted study or phenomena. 
The qualitative method evaluates personal perceptions and people’s experiences as their 
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reality (Patton, 2002). Typically, the qualitative data interprets words during the 
quantitative data analyzes numbers. The significant difference is that qualitative research 
is inductive and quantitative research is deductive (Colorado State University, 2012). 
Both research strategies consider research questions and purpose of the study. However, 
in qualitative research, a hypothesis is not used. Quantitative research method requires 
hypotheses to predict or direct the study (Creswell, 2009). 
To address the research question and test the hypotheses of this quantitative study, 
a deductive approach was adequate to confirm the correlation between the variables. The 
responses from the participants were the input to the data analysis. Based on the 
correlations between management behaviors and financial indicators on the compliance 
with the CGMP regulations, I was able to determine the firms’ compliance before and 
after the FDA intervention with the pharmaceutical company. Management attitudes and 
financial metrics required statistical instruments and probability methods to predict the 
mindset of management and the financial indicators about the outcomes of compliance 
with FDA regulations.  
Study Design and Variables 
The study consisted of a correlation design including the application of statistical 
tools. This approach allowed making comparative statistical analysis to establish 
correlations and make predictions after a treatment, the FDA intervention. The variability 
in this study and the goal to predict outcomes also led to the application of regression line 
analyses. For this study, the compliance conditions prior to the FDA intervention were 
the scenarios that led to enforcement actions by the FDA. The independent variables or 
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predictors were management behaviors and financial indicators. The treatment event was 
the application of the enforcement action by the FDA. The level of compliance of the 
firms was the dependent variable or outcome. 
Other quantitative methods were evaluated for the study but found not appropriate 
to test the research questions and hypotheses of the study. The concept that the FDA 
intervention could create a change in behaviors was the primary design parameter. The 
control over the extrinsic and intrinsic factors was very limited about companies’ sizes, 
organizational structures, and the portfolio of products. Consequently, a classical 
experiment design did not apply in this study. Considering cross-sectional design, the 
independent variable cannot be typically manipulated to establish before and after 
comparisons. As stated by Frankfort-Nachmias and Nachmias (2008), there is a need to 
incorporate control and manipulation over the independent variables to be able to infer 
causation from them. The cross-sectional design did not apply to the study since the focus 
was in the influence generated between the variables by the FDA intervention. 
Since a pre-experimental design is the weakest in the validity of the design 
(Frankfort-Nachmias & Nachmias, 2008), it did not applied. The causation could not be 
easily defined. Time implementation of treatment was not applicable since the FDA 
intervention tends to occur in one instance, while pursuing the desired compliance. The 
target was to study the correlation in the variables with emphasis driving towards the 
compliance outcome from the FDA intervention. Comparison of the compliance 
conditions pre-intervention of the FDA (pre-FDA) and post-intervention of the FDA 
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(post-FDA) in the pharmaceutical organization were evident because of the outcome of 
the FDA intervention. 
Definitions 
Definitions for the study were aligned to the FDA definitions of the corresponding 
regulations or guidance. Terms like management and medicine are associated with the 
relevant FDA definition. Citations from the FDA documents allowed assurance that the 
definitions’ terms were clear for the intent of the study. 
CGMP Regulations: 
 
The CGMP regulations for drugs contain minimum requirements for the methods, 
facilities, and controls used in manufacturing, processing, and packing of a drug 
product. The regulations make sure that a product is safe for use, and that it has 
the ingredients and strength it claims to have. (Food Drug Administration [FDA], 
2012, “Drug Applications and Current,” para. 1). 
Compliance with CGMP: 
Decisions regarding compliance with CGMP regulations are based upon 
inspection of the facilities, sample analyzes, and compliance history of the firms. 
(FDA, 2012, “Drug Applications and Current,” para. 2). 
FDA Form 483: 
An FDA Form 483 is issued to firms’ management at the conclusion of an 
inspection when an investigator(s) has observed any conditions that in their 
judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act 
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and related Acts. (Food Drug Administration [FDA], 2013, “Frequently Asked 
Questions,” para. 1). 
High management agent (management): 
…(A) an officer or director of a corporation or an association, (B) a partner of a 
partnership, or (C) any employee or other agent of a corporation, association, or 
partnership, having duties such that the conduct of such officer, director, partner, 
employee, or agent may fairly be assumed to represent the policy of the 
corporation, association, or partnership, and (2) includes persons having 
management responsibility for - (A) submissions to the Food and Drug 
Administration regarding the development or approval of any drug product, (B) 
production, quality assurance, or quality control of any drug product,…  (FDA, 
2012, “FD&C Act,” p. 35). 
Warning Letter: 
…a correspondence that notifies regulated industry about violations that FDA has 
documented during its inspections or investigations. A Warning Letter is one of 
the Agency’s principal means of achieving prompt voluntary compliance with the 
Act. (Food Drug Administration [FDA], 2012, “Regulatory Procedures Manual,” 
p. 5). 
Scope of the Study 
The scope of the study addressed the process to determine to what extent, if any, 
pharmaceutical management’s behaviors and financial indicators correlated to 
compliance with the FDA regulations at the pharmaceutical firms. Shortfalls in 
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compliance with FDA regulations have led to significant shortages of medicines to 
patients in the last five years (FDA, 2013). Pollack (2013) indicated that these medicine 
shortages have been a direct consequence of shortfalls in compliance with the FDA 
regulations. The population for the study consisted of the pharmaceutical firms that were 
been impacted by FDA enforcement activities due to manufacturing violations. All listed 
members of the International Society of Pharmaceutical Engineers (ISPE) in public U. S. 
pharmaceutical firms were invited to participate in the survey: executives and operational 
managers who had the authority to make compliance and financial decisions. 
The survey instrument consisted of a four-section survey, structured as a Likert-
type scaled questionnaire. Two sections focused on the behavior of the participants and 
the financial indicators of the pharmaceutical firms in the pre-FDA and post-FDA 
interventions. The third section collected demographical information from the 
participants. The fourth section focused in the firms’ historical compliance.  
The TPB questionnaire guidelines developed by Fishbein and Ajzen (2010) were 
modified for the behavioral section of the survey instrument. Ajzen (2002) suggested the 
essential elements for the construction of a survey for a TPB questionnaire, including the 
use of a pilot study to set the potential drivers of the behaviors. The conducted pilot study 
enhanced the level of clarity, content validity, and feedback on the questions in the 
instrument as indicated by Creswell (2009). The financial indicators’ sections of the 
intended survey instrument were based on typical indicators that could be impacted by 
the expenses needed to support remediation from FDA interventions. The validity and 
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reliability of the intended survey instrument were essential to allow for the 
trustworthiness of the data as explained by Frankfort-Nachmias and Nachmias (2008). 
For the sampling size determination of completed surveys, three approaches were 
followed to address the three research questions and hypotheses. For research questions 
one and two, the sampling size determination of completed surveys considered Krejcie & 
Morgan (1970) equation and Cohen’s power (1992) as the basis for calculation. The 
sample size of completed surveys for RQ3 was established by using G*Power software 
(Faul, Erdfelder, Lang, & Buchner, 2014).  
The study population consisted of pharmaceuticals firms that have been impacted 
within the last 5–6 years by enforcement activities from the FDA in the United States. 
This population was estimated to be about 272 pharmaceutical manufacturing firms based 
on the FDA information (FDA, 2015). The sampling size of completed surveys indicated 
by Krejcie & Morgan (1970) to be considered was about 160. The intended survey 
participants were selected from executives and operational management levels of the 
firms. These participants, based on their self-disclosed position titles in the ISPE 
database, had the authority to make compliance and financial decisions for their firms. 
SurveyMonkey was the electronic survey applied to estimate the optimum sample 
size assuming a normal distribution. For a target of 160 completed questionnaire, the 
SurveyMonkey sampling estimator initially indicated that the number of potential 
participants should be about 400 at a 90% confidence level and a 5% margin of error. 
This sample of 400 participants projected about 162 completed surveys with a 90% 
probability that the sample of participants could reflect the attitudes of the intended 
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population. Also, the margin of error of 5% intended to minimize the deviation from the 
true value at the selected confidence limit of 90%. For this scenario, the expected 
response rate based on SurveyMonkey sampling estimator implied a participation of 
40.5%. 
A response rate of 40.5% was initially considered too optimistic. The expected 
response rate was set at 20% to ensure the probability of attaining the targeted 160 
completed surveys. This scenario required about 800 participants at 20% response rate. 
The SurveyMonkey sampling estimator indicated that for 800 targeted participants at a 
90% confidence level, the margin of error could be expected at 6%. As a precaution, 
1144 members in the directory of the International Society of Pharmaceutical Engineers 
(ISPE) were invited to complete the survey. These participants had an e-mail address and 
meet the participants’ criteria.  
Assumptions of the Study 
The assumptions included elements related to participants and financial 
indicators. In this study, I made the following six assumptions:  
 The responses to the pilot study and the main survey were honest.  
 The participants were not to expect any repercussions from their supervisors 
or senior officials of the pharmaceutical company for participating in the 
study.  
 The participants were assumed to have the same definition of the compliance 
elements as presented in the definitions section based on the FDA. 
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 Also, the survey participants, based on their position titles, had the authority 
to make compliance and financial decisions within the pharmaceutical firms. 
 Financial information provided by the participants was based on the complete 
financial disclosure by the pharmaceutical firms and not in their perceptions.  
 The financial responses provided by the participants was accurate illustrating 
the financial indicators of the firms, before and after the FDA intervention. 
Limitations of the Study 
Limitations that were not controlled by the researcher included accessibility by 
intended participants to the Internet or the presence of a firewall on the Internet. Access 
to participants’ e-mails was obtained from the International Society of Pharmaceutical 
Engineers (ISPE), a professional organization related to pharmaceutical firms under the 
FDA regulation. The managers of the targeted pharmaceuticals firms were expected to be 
members of the professional organizations. 
The length of the main study proved to be a major limitation. The pilot study had 
about 40 questions. The main study had 133 questions. The number of participants that 
initiated the survey was about 90 of which 45 progressed through all the questions. Only 
21 participants provided completed surveys for the study. This low participation had a 
significant impact to the completeness of the study. 
The low level of participation limited the study depth and significance of the 
findings. The rationale for the low participation could have been to the sensitivity of the 
topic in the pharmaceutical industry for the shortfall of quality product to the patients. 
Also, the participants could had personal concerns on the confidentiality of the survey, 
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despite the consent form with the IRB endorsement. In the technical side of 
communications, the internet firewalls in the pharmaceutical firms limiting e-mails to 
reach the participants. The limited participation was a major obstacle for the assessment 
of the financial indicators. 
Timely access to FDA reports about a particular firms might be limited by the 
time to process the information. By using the FDA public database for all intervention 
with pharmaceutical firms in the last 5–6 years provided a reasonable level of 
completeness and minimized the constrained by the complexity of the FDA interventions 
to the pharmaceutical firms. Typically, FDA information from a given intervention to a 
pharmaceutical firms could take 6–8 months before publication or post on the FDA web 
page. 
Delimitations of the Study 
Privately owned and international pharmaceutical sites that had received FDA 
interventions were not part of the study. The financial results of privately owned 
pharmaceutical firms are not available.  The focus of the research study included only 
pharmaceutical companies in the United States. Personal interviews were not performed 
due to participants’ limited accessibility. 
Any new FDA intervention or medicine shortage that might occur concurrently to 
this study was not be included. Concurrent FDA interventions might not have triggered 
remediation expenses at the time of the study through 2015. Changes in behaviors of the 
pharmaceutical management might not have occurred concurrently with the FDA 
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intervention. The time required to develop a remediation plan by the affected firms, and 
the actual execution of the plan, makes concurrent FDA interventions inaccessible. 
Summary 
By conducting this quantitative experimental research study, the findings allowed 
me to determine to what extent, if any, management behaviors and financial indicators 
correlate with compliance with FDA regulations at pharmaceutical firms. Chapter 1 
included the background of the general problem and the specific area of study. The 
purpose and the significance of the study led the discussion into the positive social 
change to patients, managers, and stockholders of the pharmaceutical firms. The section 
on the nature of the study allowed me to highlight the justification for a quantitative 
approach to the research and data analysis. The three research questions and the 
hypotheses to address the problem statement were listed. The assumptions, limitations, 
and delimitations of the study were presented to clarify the scope of the study. 
The gap was addressed in this study by providing awareness and guidance to 
managers on their behaviors, decisions, and risk assessment processes, when considering 
their FDA compliance responsibility, corporate financial mandate, and stakeholders’ 
expectations.  The expected managers’ modified behaviors could lead to a reduction in 
the number of FDA interventions and enforcement actions, against pharmaceutical 
manufacturers, resulting in fewer medicines’ shortages to patients. 
Chapter 2 includes the literature review conducted to identify existing research on 
the dependent variable, the independent variables, and the theoretical framework. The 
gap in the literature is discussed in Chapter 2. The section on the theoretical framework 
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presents the theory of planned behavior utilized to develop and execute this quantitative 
study. Also, in Chapter 2, an analysis of issues, trends, and concepts formalize the 
literature review for what needs to change, the how to change, and the why to change. 
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Chapter 2: Literature Review 
 Chapter 2 contains an in-depth review of the literature on the problem statement 
revealing the gap in the literature, which was addressed by this study. The discussion 
about the independent variables and the dependent variable emphasized the expected 
correlations. The FDA strategy of enforcement since 2009 and its relation to drug 
shortages was summarized from the literature (Roman, 2014). The theory of planned 
behavior and the approach to change management were detailed, and the implication of 
the study discussed. In the last sections of Chapter 2, change models, continuous 
improvement strategy, and managing change resistant or impediments are presented. 
 Strengths and weaknesses of the variables, as found in the literature, facilitated 
the introduction to the literature discussion. I analyzed issues, trends, and concepts to 
manage the review of the literature. Details of the influence of the independent variables 
and their correlation with the level of compliance were analyzed. The theoretical 
framework literature review provided the basis for the research tools supporting the 
selected research methodology. The relevance of the study and its impact on social 
change was presented to address the research gap in the literature and clarify what needed 
to be changed. 
 Interventions and enforcement actions against pharmaceutical manufacturers by 
the FDA are due to the lack of compliance with CGMP (Woodstock, 2012). The 
correlation between attitudes and management behaviors with an over commitment to 
financial results lead towards a lack of the expected compliance with regulations. This 
performance needs to be modified to achieve the desired positive social change of 
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avoiding medicine shortages. As presented by Asotra, Cossin, and Yacobi (2012), focus 
on financials with low CGMP compliance also leads to an undesired financial 
performance, which has a direct impact on stockholders. 
The required change process to attain the desired state of avoiding medicine 
shortages has to evolve through the typical life change cycle of what, how, and why 
(Kezar, 2001). Management trends and possible theoretical frameworks were presented to 
project the complexity of addressing the change process. The future impacts on the 
stakeholders were the “why” to conduct the study, delineating the required attributes that 
influenced the organizational performance to achieve positive social change. 
Literature Search Strategy 
Research databases, associated with management and business, were used. 
ABI/Inform Global and ProQuest were the most used databases in the literature search 
process. Walden University’s library and Goggle Scholar were the main search engines in 
this effort. A search log, in ReadCube® and in Word, provided indexing of the literature 
by creating clusters of relevance by topic. The search log included article information and 
comments on significant ideas. The search log served as the vehicle to review, reflect, 
and plan the direction of the next stage of the literature search strategy. The process was 
repeated to reinforce the link between the selected literature pieces, emphasizing each 
specific topic and accentuating the interrelations of the variables. 
In Table 1, the span of the references that were evaluated and researched is 
presented. Potential articles from the databases search and the keywords applied to the 
Goggle Scholar were over 700 sources. The total of references included in this study was 
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101. A total of 39 peers reviewed articles, 26 professional organizational articles, 13 
Internet pages, and 12 government documents constituted the platform of the literature 
review for this study. A total of 11 books were also consulted to enhance the theoretical 
basis of the study, especially in the areas of behaviors, change management, and 
motivation. The focus of the literature search was based mainly on current sources. The 
reference list consists of 62% of sources less than five years for the current situation, and 
of 38% older references. About 21% of the references are from the last year 2014, 2015, 
and 2016. The references focused in the description of the problem statement, the 
variables of the correlation, subject matter experts, the theoretical framework for the 
study, and management topics. The totals in Table 1 include the referenced articles in this 
study.  
Table 1 
Evaluated and Research Literature 
 Peer- Reviewed 
Articles 
Professional 
Organizational 
Articles 
Books 
Internet 
Pages 
Government 
Documents 
Problem 
Statement 
5 17 0 6 9 
Dependent 
Variable 
5 2 0 1 1 
Independent 
Variables 
2 4 1 0 2 
Theory (TPB) 8 2 2 2 0 
Change and 
Management 
Theories 
19 1 8 4 0 
Totals 39 26 11 13 12 
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Table 2 presents the list of the keywords used in the research. Keyword alerts 
were set to maintain a continuous search the keywords with emphasis on FDA, change, 
and medicine shortages, theory of planned behavior and CGMP compliance. Google 
Scholar’s listing was frequently revised to ensure updates for the literature review. The 
independent variables, management behavior and financial indicators as related to the 
study presented limited options. 
Table 2 
Keywords Used for Research 
Problem 
Statement 
Dependent 
Variable 
Independent 
Variables 
Theories 
Framework 
Management 
Theories/Method 
Warning 
Letters 
FDA 
CGMP 
Compliance 
Behavior Theory of Planned 
Behavior 
Change 
 
Medicine 
Shortages 
 
 
 
Financial 
Indicators 
 
 
 
Organizational 
Structure 
 
Background of the Literature Review 
 The number of FDA interventions and enforcement actions against 
pharmaceutical manufacturers has led to several medicine shortages. The lack of 
compliance with CGMP has resulted in facility closures, loss of revenues, unavoidable 
penalty fees, and significant investments to address remediation of the violations of the 
FDA regulations (Burd & Chrai, 2004). In addition, the loss of sales, penalties, and cost 
of remediation influence directly the profit line, impacting the worth of the stockholders 
and the firms’ market value. Achieving and maintaining FDA compliance makes business 
sense and provide a competitive advantage as discussed by Smart (2013). The primary 
28 
 
 
social impact is that essential patented drugs or generic pharmaceutical drugs, provided to 
the general public, could have been substandard for quality, purity, strength, and identity, 
placing the patient health in significant danger and probably not addressing the intended 
treatment. 
The purpose of this quantitative dissertation research study was to determine to 
what extent, if any, management behaviors and financial indicators correlated to 
compliance with FDA regulations at the pharmaceutical firms that have been impacted by 
FDA enforcement actions in the United States. This quantitative design was directed 
towards correlations and regression analyses. The conditions before to the FDA 
intervention in the pharmaceutical firms were compared to the conditions after the FDA 
intervention to predict compliance with the CGMP regulations. The independent 
variables that could lead to enforcement actions by the FDA were behaviors of the 
pharmaceutical managers and the firms’ financial indicators. The level of compliance of 
the pharmaceutical company was the dependent variable. 
In Figure 1, a conceptual map is presented to illustrate the interrelations between 
the variables, management behaviors, and leadership skills, leading to the need for 
change management to drive the expected behaviors and compliance with the FDA. The 
problems affecting pharmaceutical-organizational performance were considered to be 
attitudes and management behaviors with an over-commitment by pharmaceutical 
management to financial results, leading to a lack of the required compliance with 
regulations. The problem statement had a direct impact on stakeholders. The impact on 
stakeholders needed to be addressed to achieve the desired positive social change of 
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avoiding medicine shortages. Management trends to address “what is needed” were listed 
in the bottom-right of Figure 1. Areas that could be studied and possible theoretical 
frameworks (How is it done) were enumerated in the bottom-center of Figure 1 to project 
the complexity of addressing the change process. The desired impacts that are listed in 
the left-bottom of Figure 1 were the “why is it needed” to conduct the study, delineating 
the attributes influencing the firms’ performance to achieve positive social change. 
From the concept map in Figure 1, the use of change management and 
adaptability emphasized the need and reinforced the notion that ethical behaviors need to 
be modified.  The benefit from the concept map structure (Novak & Cañas, 2006) was 
obtained by the hierarchical flow from the initial problem position to the outcome in the 
concept map.  The concept map provided a means to capture the transition from the 
problem (“as is”) to the outcome (“desired state”).  By addressing the problem statement 
to achieve social positive change, leaders of pharmaceutical organizations, who are 
involved with FDA interventions, should modify their behaviors and financial metrics, 
avoiding medicine shortages to patients and minimizing risk to stockholders. 
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Figure 1. Conceptual map of the problem statement and the change process elements to 
influence the sustainability of the change. 
Management Factors Affecting     
Organizational Performance 
Attitudes and 
Behavior 
Over Commitment 
to Financial Results 
Impact on Stakeholders: 
 Patients – Shortage of Medicines and Product Quality 
 FDA – Violation of Regulations by the Organization 
 Stockholders – Loss of Equity 
 Transformational 
Leadership 
 Contingency Leadership 
 Learning Organization 
from Archetypes and 
Interdependencies 
 Self-Assessment of 
Leaders  
 Evaluation of Policies  
 Clarification of Goals 
and Rewards 
 Willingness to Change 
 Capacity for Adapting 
What is 
needed? 
How is it 
done? 
Why is it 
needed? 
 Pursuing Adaptability and 
Flexibility – From Crisis 
Management to Compliance 
Management 
 Applying Change 
Management – Change 
Process Control – Monitoring 
and Measuring Progress 
 Aligning Mission of the 
Organization with 
Performance 
 Sharing Vision 
 Reinforcing Ethics and Goals 
 Optimizing Work Climate 
and Delegation 
 Implementing Learning 
Organization 
 Positive Social Change 
 Corporate Social 
Responsibility 
 No Medicine Shortages 
 Product Quality to 
Patients 
 Stockholders’ Equity 
 Reputation of the Firms 
 Long-term 
Sustainability 
Trends to Address 
Current Problems 
Possible Areas to Study and 
Apply Theoretical Framework 
Desired Impact of the 
Study on Stakeholders 
Problem 
Statement 
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Gap in the Literature  
From the review of the literature, the gap was the lack of research providing 
awareness and guidance to managers in their decision and in their risk assessment 
process, regarding their FDA compliance responsibility, corporate financial mandate, and 
stakeholders’ expectations within the pharmaceutical manufacturing industry. The 
approach to determine the gap to prompt the research was based on the limited 
information available on what drives non-compliance decisions in pharmaceutical 
organizations that have experienced FDA interventions. The limited published data on the 
interdependencies between the need to grow revenue and the intent to behave within 
senior management decision process in the pharmaceutical manufacturing industry drove 
the development of this research. The short-term financial pressures, the high costs of 
innovation, and the firms’ reputation have been identified as causes, but no direct 
research on the correlation with behavior has been published that can be directly 
associated with the pharmaceutical industry. 
The avoidance of medicine shortages drove the need to understand what 
motivated or distracted management from compliance behavior. There are published 
studies in behavior related to tax evasions (Langham, Paulsen, & Härtel, 2012), academic 
misconduct (Stone, Jawahar, & Kisamore, 2009), digital piracy (Yoon, 2011), and 
Sarbanes-Oxley (Hess, 2007). These studies were used in this dissertation study as 
templates for approaching the study in the pharmaceutical organizations by also applying 
Ajzen (1991)’s theory of planned behavior. This study addressed a gap in the literature 
related to the limited direct studies providing awareness and guidance to pharmaceutical 
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manufacturing industry managers in their decision and risk assessment processes. The 
study specifically addressed the gap in regards to the pharmaceutical manufacturing 
industry managers’ FDA compliance responsibility, corporate financial mandate, and 
stakeholders’ expectations. 
Dependent Variable 
The selected statistical tools, correlations and regression analyses, provided 
clarity in the relationships between the variables. The purpose of the study was to predict 
the outcome of the dependent variable, compliance with the FDA. Linear regressions 
provided the assessment between the pre-FDA conditions and the post-FDA conditions 
focusing on the scenarios before and after of the FDA intervention. With the selected 
study design, the correlations and linear regression method were applied twice, pre-FDA 
and post-FDA interventions. All variables were considered continuous in the pre-FDA 
and post-FDA interventions. 
Compliance by pharmaceutical management with the FDA regulations in the 
production of medicines pursues the intended integrity, purity, and quality of the products 
for the expected medical treatment of the patients’ conditions (FDA, 2013). Management 
decision-making in the manufacturing processes within the pharmaceutical organization 
need to demonstrate alignment to the expectations of the FDA regulations. The trust of 
the public in both the FDA and the pharmaceutical firms can be considered as a “given” 
fact as perceived by the patients, the medical community, and the investors in the 
pharmaceutical company. 
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The manufacturing of medicines follows a very intensive process of research for a 
given disease cure: discovery of a molecular entity, clinical trials in animals and human 
volunteers, and approval process by the FDA. Once the medicine is defined and as part of 
the development, a production process is defined and validated to manufacture the 
medicine always to the same level of the approved-intended integrity, purity, and quality. 
FDA regulations (FDA, 2013) indicated to the pharmaceutical organizations to always 
follow the same validated manufacturing processes and systems. The execution by the 
pharmaceutical management of production processes and systems is obliged to follow the 
CGMPs. The pharmaceutical organization and its management are expected to apply, 
implement, and follow the CGMP at all times. 
Manufacturing of medicines requires significant investment in facilities, 
personnel know-how, equipment, active medicine ingredients, and other raw materials. 
The investments in these factors in addition to on-going operational manufacturing 
expenses, as energy and distribution mechanisms represent cash flow, which is not 
recovered until the medicine is sold to the end users, the patients. The CGMPs 
expectations require a significant level of documentation as evidence of compliance. 
Procedures, training records, and data integrity in the laboratories demand precise and 
current documentation (Dutton, 2014). Computerized systems have also become a 
significant investment and operational expense in the production operations to 
demonstrate compliance to achieve the intended product quality as indicated by the FDA 
announcement (FDA, 2016). 
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The operational cash flow for manufacturing is typically represented by the idea 
of the cost of goods, including the depreciation of capital investment and inventory cost 
of material in the process. Allocation of funds to achieve the manufacturing of medicines 
is added to the cost of sales and other significant accounting entries in the pharmaceutical 
company’s income statement and balance sheet. Controlling the cost of goods is an 
established operational practice to achieve an acceptable competitive financial position 
by the firms. Management reward programs and employees’ performance is based on 
continuous improvements that are typically biased towards cost improvements, besides 
improvement in processes and systems. The general assumption is that the product 
quality and quality systems that warrant consistency are not to be impacted by the 
improvement changes. Removing process variability like in Lean-6-Sigma initiatives is 
promoted to improve consistency and reduce cost (Longo, 2012). The principles are 
reasonable, but the rewards to the incumbent managers are typically based on dollars 
saved in production. Compliance with CGMPs is promoted as non-negotiable, but not 
necessarily, a high factor for the basis of the rewards and performance recognition from 
the business improvements. 
Pharmaceutical management also has to achieve a balance between cost of sales, 
like promotion and sales personnel, and the cost of goods to maintain products 
competitiveness at adequate pricing strategy, especially in a global platform. Medicine 
pricing practices around the world receive pressure from local governments and 
competition. Except for Medicare practices, these pricing pressures are usually not a 
strong influence (Graham, 2012). In addition, the financial market expectations of a 
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return on investment to stockholders augment the financial pressures on the 
pharmaceutical management. The decision on where to use the cash flow between these 
business pressures and the cost of goods requirements has led to scenarios in which 
quality systems and production capacity have been second priority, as concluded by 
Pollack (2013) and Woodstock and Wonsinka (2013). 
The purpose of compliance and the written policies, directing the conduct to the 
best decision for the patient, has been expressed in pharmaceutical companies’ vision and 
mission statements. These statements and policies have been deployed with the internal 
stakeholders, like employees, and with the external stakeholders, such as patients and 
stockholders, to gain trust and credibility (Pfizer, 2015; Johnson and Johnson, 2015; 
Bristol Myers-Squibb, 2015). The challenge, to maintain a balance to assure compliance 
with CGMPs and with the business expectations, creates a relationship influencing actual 
management behaviors and quality systems’ robustness in pharmaceutical companies. 
Compliance with FDA regulations, CGMPs, requires commitment and firmness in 
management in front of financial pressures (Asotra, Cossin, & Yacobi, 2012). The 
balance between intended behavior and actual behavior by management in the 
pharmaceutical organizations, in which FDA has initiated regulatory intervention, needed 
to be better understood. The information about which FDA interventions have impacted 
pharmaceutical organizations can be found in the FDA web page and through the 
Freedom of Information Act. For those companies that are public financial firms, the 
financial reports are public. These financial reports include the cost of goods, as well as 
other essential elements in their published profit statements and balance sheet. Public 
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press releases are also available from the management of these firms, addressing their 
approach to correct and align with the CGMP regulations as stated by the FDA 
interventions (Impax, 2014; Novartis, 2012; Ben Venue, 2011). The firms’ reaction to the 
FDA observations about the lack of conformance leads to corrective action with 
significant financial impact typically documented in the firms’ financial reports. 
The level of sustainability of the corrective actions by the pharmaceutical 
organizations that has been impacted by FDA regulatory interventions depends on the 
degree of change that management embraces and accepts (Asotra, Cossin, & Yacobi, 
2012). The compliance history, following the initial FDA regulatory intervention, 
allowed measuring the effectiveness of the change in behavior. Financial indicators from 
the published financial reports could also provide the information of the new level of cost 
of goods and investment in manufacturing to attain the desired state of operations in 
compliance, indicating a more robust level of quality systems in the production of the 
medicines. For this study, I depended on the participants’ knowledge and recollection of 
the information regarding financial indicators in their forms. 
The interrelation of the degree of compliance with the predictors, behaviors and 
financial indicators, caused changes in the correlations and the regression analyses in this 
study. The intent of the study was to predict the outcome of the dependent variable, 
compliance with the FDA. Considering that there was a logical expectation that the FDA 
intervention was going to force a change in management attitudes, the changes in 
correlations and linear regression analyses were not a surprise. The analysis of the TPB 
questionnaire responses allowed to compare the relationships before and after the FDA 
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intervention. Concurrently, the financial indicators information collected in the survey 
provided the financial environment of the firms before and after the FDA intervention. 
Also, establishing the regression line, between the variables after the treatment, could 
assist on assessing the long-term effect in compliance, allowing for follow-ups and self-
corrections by the firms. 
An electronic survey was be the vehicle utilized for management attitude 
assessment, due to the limited accessibility to the participants (pharmaceutical 
management). The cost of remediation and financial indicators from the survey assisted 
in determining the financial correlations. Figure 2 illustrates the interrelations and 
expected outcome between the independent variables, the dependent variable, and the 
FDA intervention. 
                                                                                            FDA 
                                                                                    Intervention 
      Independent                                     Dependent                         Outcome 
 
                                                                                                    CGMP compliance 
Management Behaviors                                                
                                                         CGMP compliance 
 
Financial Indicators 
  
                        Number of Drug Shortages: pre-FDA 
 
                                                                                                      post-FDA 
 
Figure 2. Interrelations of variables and outcome as a reaction to the FDA intervention in 
the pharmaceutical firms. 
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As discussed by Woodcock (2012), manufacturing shortfalls implied that quality 
management and systems were not empowered or properly staffed to support adequately 
the critical functions within the pharmaceutical company. Many of the drug shortages 
events have been associated with manufacturers issues (Woodcock, 2012). Historical 
trends of drug shortages represent an increase from 61 shortages in 2005 (Barlas, 2014) 
to 251 shortages in 2011 (FDA, 2013). The FDA issues warning letters if the 
pharmaceutical firms has not addressed the violations observed during FDA audits to the 
manufacturing establishments or facilities. These violations, listed on Form 483 of the 
FDA audit, indicate that the quality management and systems in the audited 
pharmaceutical firms were below expectations, implying low CGMP compliance. From 
2009 to 2010, the FDA’s observed violations in the operations of medicine manufacturers 
increased from 550 to 646 (Huitt, 2014). In the first three years of Obama’s 
administration, 2009 through 2011, the number of warning letters issued for 
manufacturing and quality issues increased to 49 letters versus nine letters in the last 
three years of George W. Bush’s administration (Nguyen, Seoane-Vazquez, Rodriguez-
Monguio, & Montagne, 2013). In a brief look over the past 15 years, the previously 
referred FDA interventions through a Warning Letter can be summarized in the timeline 
shown in Figure 3.  
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      1999 
 
 
 1999 Canal Panama 
 1999 EURO  
 2000 Y2K Scare 
 2001 09/11  
 
  
Figure 3. Time line between 1999 and 2013 illustrating the trend of warning letters and 
medicine shortages in comparison to significant global events. 
 
Independent Variables 
The approach to determine the gap for the research was based on the limited 
information available on what drives non-compliance in the pharmaceutical organizations 
that have experienced FDA interventions. The limited data that prompt this study 
consisted on what are the interdependencies between the need to grow revenue and the 
intent to behave within the management decision process. The factors of financial short-
term pressures, the high costs of innovation, and the firms’ reputation have been 
identified as causes of non-desired behaviors (Hess, 2007; Langham, Paulsen, & Härtel, 
2012; Yoon, 2011). No direct research on the correlation with behavior associated with 
the pharmaceutical manufacturing has been published. 
The purpose of this study was to determine to what extent, if any, the independent 
variables, pharmaceutical management’s behaviors and financial indicators correlated to 
compliance, the dependent variable, with the FDA regulations at the pharmaceutical 
2013 Bush --- Obama 
Great 
Recession 2008 
 
Clinton --- Bush 
Iraq War 
9 Warning Letters 49 Warning Letters 
From 65 to 251 drug shortages 
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firms. Compliance with CGMP regulations has led to significant shortages of medicines 
to patients in last five years (FDA, 2013). These medicine shortages have been signaled 
as a direct consequence of shortfalls in compliance with the FDA regulations 
(Woodstock, 2012; Pollack, 2013). Significant efforts to generate risk assessments and 
action plans have been created by organizations like the Parenteral Drug Association 
(PDA) (Technical Report No.68, 2014) and the International Society of Pharmaceutical 
Engineers (ISPE) (Prevention Plan, 2014). These documents addressed several topics like 
FDA role, supply and demand, and culture for quality systems. The concern from 
Woodcock (2012) that manufacturing is sometimes managed as a second citizen falls into 
the category of management’s decision-making and not on shortfalls in intention or 
intended behavior. 
The study’s potential influence on positive social change was based on the intent 
to encourage managers of pharmaceutical organizations to operate and behave with a 
sound mental model or thinking pattern. Managers should optimize the financial 
performance of the firms while considering the availability and quality of the medicines 
that they produce. The avoidance of medicine shortages was the key positive social 
change pursued by this research study. 
Management Behaviors 
In the U.S., corporations are directed legally to pursue profits for their 
stockholders (Bakan, 2004). Bakan addressed the legal implications around the fact that 
the corporations are set to maximize the returns to the stockholders. The legal concept 
implies that it is illegal for a corporation to divert revenues to social responsibilities 
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without considering the financial implications to the stockholders. Sfeir-Younis (2009) 
discussed that the current compensation systems for management are mainly focused in 
rewarding for profit results. There is no mechanism to link society justice and 
environmental sustainability to the success of the corporations. In the interview by 
Tavanti, Sfeir-Younis (2009) indicated that efforts towards Corporate Social 
Responsibility could be perceived as being accompanied by a background of insincerity. 
Considering the corporation, Bakan (2004) discussed that the corporations could 
be considered manipulative, superficial, and self-interested. Lack of empathy, non-social 
considerations, refusal of responsibility, and lack of remorse could be associated with 
corporations when setting priorities in front of society’s interests. Bakan (2004) 
introduced the need for being skeptical when looking at social responsibility in the annual 
reports and management messages. These documents are based on the self-interest of the 
corporation that has to be meet financial expectations before any social consideration. 
About members of the management team, Bakan (2004) discussed the concept of 
double personality or dual moral lives. The corporate manager was expected to behave in 
favor of the firms’ stockholders. Once at home, the personal values and interests 
prevailed and were focused on the well-being of the community or society. The ability to 
navigate in this contradiction in morals, between corporate and personal behaviors, could 
be considered a type of schizophrenia, as presented by Bakan. 
Even if Maslow’s (2000) Hierarchy of Needs drives the leaders’ motivation to 
achieve a self-actualization state, the conflicting pressures of attaining compliance with 
CGMP regulations present opposite-directional vectors to personal motivation between 
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rewards and personal values. Considering Adler’s (as cited by Boeree, 2007) theory of 
complexes and superiority, the leader usually pursue personal motivation by striving for 
perfection and overcoming complexes. In this endeavor, if the manager cannot achieve a 
positive lifestyle (being of help to others), it could create the sense of not achieving, 
leading to personal failure, even in the presence of financial rewards.  
The corporation and stockholders’ drive for profit projects, which is a perception 
that prevails in the financial environment. The only change in expectations of these 
parties could allow the manager to perform and strive for sustainability and balance 
between financial goals and compliance with regulations. The decision-making process’s 
complexity exponentially grows when considering consumers’ expectations, religion 
beliefs, and cultural diversity. 
Management is expected to behave with a high sense of ethics. Ethical behavior is 
valued and considered as non-negotiable in society. Respect for what others believes and 
their dignity as human beings, as presented by Resick, Hanges, Dickson, and Mitchelson 
(2006), is considered as an acceptable definition of ethical conduct and behavior. 
Leaders’ influence is associated with several factors, including the use of power, the 
projection of authority, and having a balanced behavior in front of employees and society 
members. Resick et al. (2006) discussed six elements related to ethical leadership. These 
traits or characteristics were a character with integrity, ethical awareness, community and 
people orientation, motivating, encouraging/empowering, and managing ethical 
accountability. 
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Providing quality pharmaceutical products projects good citizenship. The firms is 
valued and understood as one of caring for the well-being of the patients. The elements 
included in this perception range from providing medicine to alleviate the health issues to 
attaining an effective treatment of the patient’s medical situation. The intended behavior 
to comply with regulations and to manufacture a quality product should lead to the 
adequate financial outcomes. The intent to do something versus the actual action could 
accentuate that there is a potential disconnect if the drive is for the financial bottom line 
and not for compliance. 
Making ethical decisions requires values and beliefs that the action taken is the 
best option. The definition of the best choice requires a balance between desire linked to 
personal satisfaction and financial rewards. The decision to sustain the status quo or 
ignore non-compliance behavior by management could create critical impediments to the 
organization, leading to FDA interventions. Elements consisting of slow information 
flow, change resistance by personnel, loss of customer loyalty, and inflexibility by 
leaders in challenging mental models could accentuate the scenario leading to non-
compliance. The decision to ignore the current state could be the catalyst for the loss of 
resilience and adaptability to change. The climate of the organization to allow for a 
prompt response and active participation, in front of the undesired scenario, requires 
intensity and transparency to drive the desired behavior at all levels of the organization. 
Sharing leadership vision projects a genuine message, which enhances the 
enrollment and participation of followers (Senge, 2006). Leaders need to share their 
vision and expose their reasoning to demonstrate an honest approach to share the vision 
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and sense of urgency, as indicated by Kotter (2007). The management vision should 
accentuate compliance with the regulations, and provide the right level of investment for 
compliance. Listening to the employees’ opinions should open the dialog towards the 
adequate priorities to sustain compliance. A dialogue should minimize tension and 
conflict, allowing for transparency in the flow of information between individuals. Open 
discussions are required to assess options and make decisions. Sharing the vision is 
possible and attainable by encouraging inquiry, advocacy, and reflection, as discussed by 
Senge (2006). The scenario of “us-and-them” does not serve or benefits any party, nor the 
patients or the stockholders. 
Organizational structures can be related to different management theories and the 
drivers of behaviors. The selected organizational structure and the leaders’ style dictate 
the interrelationships and links within the organization (Morgan, 2006). The 
organizational structure influences the thinking, defines the learning, and shapes the 
behaviors. Morgan (2006) presented several examples of organizational structures and 
the internal interdependencies and expected behaviors using metaphors. “Open-learning” 
organizations allowed for participation and sharing of knowledge, dictating behaviors and 
adaptability. The perceived controls by the individual and the opinion of others 
(including supervisors) according to the TPB were two constructs assessed in this study. 
Engle and Nehrt (2011) indicated that when considering emotional intelligence, the 
behaviors were mainly driven by the leaders’ ability to control their emotions, while 
pursuing maturity and intellectual growth. Elements considered as the base for emotional 
intelligence are self-awareness, self-control, and social awareness. To control or regulate 
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behaviors, leaders needs to have a significant maturity to appraise their emotions, 
understand emotions from others, regulate emotions internally, and take advantage of 
emotions to drive performance (Engle & Nehrt, 2011). Leaders should have insight into 
the followers’ emotions and feelings, with the corresponding reasons behind them. As per 
Engle and Nehrt (2011), being self-confident, in their internal assessment and the 
corresponding conclusions is a critical trait in the leaders. 
Providing quality pharmaceutical products projects good citizenship. The firms 
are valued and understood as one of caring for the well-being of the patients. The 
elements included in this perception range from providing medicine to alleviate the health 
issues to attaining an effective treatment of the patient’s medical situation. The intended 
behavior to comply with regulations and to manufacture a quality product should lead to 
the adequate financial outcomes. The intent to do something versus the actual action 
could accentuate that there is a potential disconnect if the drive is for the financial bottom 
line and not for compliance. In this study, thought correlations, linear regressions, and the 
theory of plan behavior, the researcher linked the independent variables to the dependent 
variable of compliance with the FDA. A comparison was made between the pre-FDA and 
post-FDA scenarios regarding the compliance with the FDA regulations. 
Financial Indicators 
For the pharmaceutical firms, the lost sales, the impact on their reputation, and the 
significant level of expenses to recover or achieve remediation of the lack of compliance 
with the FDA could be devastating. This scenario could also impact the firms’ market 
value. If the FDA intervention escalates into a consent decree, which is a legal action 
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against the company, the magnitude of all these elements could multiply and become an 
unacceptable historical benchmark within the industry (Asotra, Cossin, & Yacobi, 2012). 
Furthermore, legal actions by the FDA against the firms’ leadership could be inevitable 
(Burd & Chrai, 2004). This study has the potential to raise the awareness about undesired 
behaviors in management and accentuate the concept that compliance is a competitive 
business advantage for the pharmaceutical companies. 
 The complexity of regulations, price pressures, and compressed time to market 
contributes to the financial pressures in front of medicine manufacturers (Dutton, 2014; 
Duffy, 2014). The cost of development a new drug has been noted to be is some cases up 
to 1 billion dollars (Adams & Brantner, 2010). Management decision-making is typically 
driven by current cash flow and future opportunities to grow revenue, including decisions 
on research and development investments (Scherer, 2001). Thus, optimizing fixed assets 
utilization supports both concepts. Controlling or reducing the cost of goods allows a 
positive impact on available cash flow to invest in new products research, support 
marketing-sales challenges, and neutralize price challenges from the competition and 
abroad. 
 Organizational knowledge is based on the individuals within the organization. 
Organizational structure, work climate, and leadership styles have a significant impact on 
the growth and performance of employees (Morgan, 2006). Investing in training, 
procedural systems, data integrity systems, and equipment requires determination to 
continuous improvement while enhancing quality systems (Koberstein, 2014). Also, 
attaining the proper quality and operational staff within a manufacturing firms provides 
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consistency and stability of the knowledge base. These elements in pharmaceutical 
manufacturing enhance the reliability of quality systems. Manufacturing shortfalls 
implies that quality management and systems are not empowered or adequately staffed to 
adequate support the critical functions of the pharmaceutical firms (Woodcock, 2012). 
The concept of empowerment is linked to the leadership style in elements as trust, 
transparency, and sharing (Senge, 2006). Knowledge, the level of staffing, empowerment, 
and continuous improvement are essential to attain the level of compliance in front of 
complex regulations and global business (Koberstein, 2014). As indicated by Woodcock 
(2012), for some management, these factors imply incremental cost and expenses of the 
manufacturing systems, instead of continuous improvement in quality systems. 
 If the attitude to accommodate the investment towards knowledge, facilities, and 
equipment is not assessed by management, the new launches or expiration of product 
products could create pressures, postponing critical investments. The technological 
movement from the traditional chemical manufacturing to cell manufacturing 
(biotechnology) has also introduced the need for new facilities with different 
technologies, equipment, and personnel knowledge (Merchuck & Toren, 2013). The 
minimal education provided by a high school diploma is no longer adequate for 
understanding fermentation and enzyme process dynamics in product manufacturing. The 
cost of goods and allocation of overheads requires detailed assessment for decisions in 
technology, processes, and geographical network strategies (Khinast, Fraser, & Dujmovic 
2014). Remodeling an existing facility might not be feasible for the new technology. The 
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costs of closure of old chemical facilities and severances pay for the long time employees 
add cash flow pressures on pharmaceutical decision makers.  
 In addition, high waste from production, low reimbursement on investment, and 
no proper pricing contracts were some of the inefficiencies driving good-compliance 
manufacturers away from producing quality low-cost generic medicines as per Woodcock 
in an interview with Koberstein (2014). Management behaviors’ and financial indicators’ 
impact on compliance and product quality require change management, leading to the 
expected outcome of fewer drug shortages. Woodcock also inferred that pharmaceutical 
manufacturers that implement high-quality systems could be financial productive by 
reducing waste, customer complaints, and product recalls (Koberstein, 2014). Financial 
efficiency implied an adequate cost of goods and proper utilization of resources. 
Managing financial indicators by attaining financial effectiveness led to a climate of less 
operational pressure allowing attention to quality systems. 
 The elements that could affect the quality of products leading to potential FDA 
intervention and undesired product shortages depend on management decisions. 
Management decisions that could impact the quality of products are limiting quality 
systems in manufacturing, avoiding investment in improvements to facility and 
equipment, lacking proper raw material selection, and accepting inadequately 
knowledgeable staff. Changes led to reducing operating expenses, even with the intention 
of lean manufacturing practices, could drive to limited quality systems (Woodcock, 
2012). Quality systems should evolve with technology and consistency in procedures. 
Unfortunate, the enhancement to the quality system typically occurs after FDA 
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interventions, following evidence that the pharmaceutical company has been operating in 
a non-compliance scenario in front of the CGMP regulations (Asotra, Cossin, & Yacobi, 
2012). Drivers and decisions to reduce the cost of goods without maintaining a balance 
with quality systems could lead to an unconscious situation of applying procedures 
without considering all the FDA expectations for a quality product (Woodcock & 
Wonsinska, 2013). Although CGMPs are common sense, sometimes management 
assumes that all common sense is CGMPs. This mental model leads to non-compliance 
and reduction in resources to attain the expected compliance level for product quality and 
quality systems within the pharmaceutical organization. 
 Financial factors like loss of sales to competition or new medicines, as well as 
loss in financial value of the firms in the financial markets, could generate significant 
financial pressures on the decision makers in the pharmaceutical firms. The reduction in 
the pipeline of new products, by the loss of patent of blockbusters medicine products, and 
due to growing pricing practices from the globalization of medicine and generics markets 
have raised the pressures in the cash flow of the pharmaceutical industry (Duffy, 2014). 
Even the generic sector of the pharmaceutical industry is subject to these factors and has 
been subject to FDA interventions for non-compliance in the production operations. 
 The annual pharmaceutical sales, with no-growth or marginal growth from year-
to-year, have influences in the financial market value, impacting stockholders’ 
investment. Reputation of the firms could be significantly affected by FDA interventions, 
in relation to the perceived management conduct, undesired behaviors, and lack of social 
responsibility of the pharmaceutical firms (Asotra, Cossin, & Yacobi, 2012). Typically, 
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operational management changes follow the FDA intervention. The loss in sales could be 
caused by patients and the medical community looking for treatment options, avoiding 
inferior quality products, or as a reaction to the medicine shortages. Asotra et al. (2012) 
indicated that disclosure of these changes influences the credibility and reputation of the 
firms with suppliers and investors. 
 In this quantitative study, the financial indicators of the factors discussed were 
assessed for the pre-FDA and post-FDA interventions, by applying correlations and 
regression analyses. The pre-FDA conditions are the scenarios (independent variables: 
behaviors and financial indicators) that led to enforcement actions by the FDA. The 
treatment event was the application of the enforcement action by the FDA. The level of 
compliance of the pharmaceutical company was the dependent variable. The post-
condition was the outcome after the remediation activity was completed, which could be 
measured in behavioral attitude (management “decision making” survey), financial 
results (remediation investments and cost from financial statements), and level of 
compliance (FDA observations). 
FDA Interventions 
 The FDA interventions examined by this study consisted of an action initiated by 
the FDA towards a pharmaceutical firms. These actions were based on the FDA’s 
observations obtained during manufacturing facility audits, during assessing of patient 
complaints, or during medical patients’ reactions related to the level of compliance in the 
manufacturing operations and to the quality of the medicine. The FDA interventions 
commonly consist of 483 observations (FDA, 2013, “Frequently Asked Questions,” para. 
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1) followed by warning letters (FDA, 2012,  “Regulatory Procedures Manual,” p. 5) in 
the case that the pharmaceutical firms continue a non-compliance attitude or not address 
the observations. In the event that the pharmaceutical firms does not demonstrate 
commitment and due diligence to address the FDA actions, a consent decree issued by 
the FDA could follow to force a cease and desist to the senior management of the firms. 
Arguments relating the FDA as the driver of medicine shortages has gained 
strength. The intensity and firmness of the FDA, ensuring that CGMP compliance by the 
pharmaceutical firms in recent years, are signaled as the cause of the medicine shortages 
(Graham, 2012; Roman, 2014). Graham (2012) went as far as indicating that the FDA 
was over-regulating with the increased in inspections to injectable manufacturers. 
According to Roman (2014), the FDA’s approach to enforcing instead of working action 
plans, especially in critical medicines, promoted shortages of the medicines. 
Pharmaceutical manufacturers’ decisions have to be based on a balance of 
profitability and market value of the firms. If the FDA intervention leads to an unstable 
financial position, the firms could be forced to close and stop manufacturing as in the 
case of Ben Venue and Hospira in 2013 (Roy, 2012). Closures and discontinuation of 
manufacturing processes led to interruptions in the supply of medicines. Roy (2012) and 
Roman (2014) both concluded that the consequence of the FDA intensity and firmness in 
ensuring the CGMP regulations was a shortage of critical cancer drugs affecting patients 
with no alternate treatment. 
Medicine shortages have been associated in recent years, with FDA interventions 
to pharmaceutical firms. Roman (2014) indicated that the medicine shortages between 
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2010 and 2013 resulted from an unnecessary approach by the FDA. The FDA’s 
interventions to assure compliance with CGMPs caused pharmaceutical facilities to 
remodel facilities, re-train personnel, and change processes, when the manufactured 
drugs’ quality was acceptable and in some cases meeting specifications (Kweder & Dill, 
2013). Gottlieb (2013) concluded that the remediation activities led to facility closure and 
long recovery of the supply of the critical medicines. Roman (2014) insisted that 
negotiation and tolerance by the FDA with the pharmaceutical firms would have avoided 
medicine shortages. The interruption in the supply of medicines to patients needs a 
different approach. 
Haninger, Jessup, and Koehler (2011) focused the shortage of medicines in the 
economics relation between supply and demand and not in the FDA interventions. 
Manufacturer’s capacity, inventory practices by Group Purchasing Organizations (GPO), 
pricing strategies by pharmaceutical firms, and the FDA approval process of new 
manufacturer capacity led the rationale in the discussion of this study. Manufacturer’s 
quality shortfalls were assessed as a contributor but not the primary factor in the supply 
and demand relationship to medicines’ shortages. Although the statistics based on 
Medicare indicators supported the arguments, the fact that 54% (FDA, 2011) of the 
medicine shortages were associated with manufacturers’ quality problems fell as a 
secondary factor. Haninger et al. (2011) indicated that manufacturer’ problems 
highlighted by the FDA during manufacturer’s facility inspections need to be assessed 
against the risk of affecting the supply of medicines, a message similar to Roman (2014). 
The causes prompting management behaviors to create manufacturer’s non-conformance 
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issues with the FDA guidelines were not addressed nor recognized as a particular solution 
by Haninger et al. (2011). Any relation between the FDA interventions in the 
manufacturer firms’ performance remained in the background or as a second theme. 
The approach to compliance versus the risk of creating a shortage of medicines 
was a growing concern. Several recent studies have concluded that the FDA needs to 
balance between firmness of compliance and the benefits of drugs (Gottlieb, 2013; 
Roman, 2014; Roy, 2012). In the other side of the argument, Woodcock in an interview 
with Koberstein (2014) inferred that high waste from production, low reimbursement on 
investment, and no proper pricing contracts are some of the inefficiencies influence 
manufacturers away from producing low-cost quality medicines. The cause of the 
medicine shortages relates to manufacturing quality shortfalls (Fox & Tyler, 2013 and 
Woodcock, 2012). Enhancing CGMP compliance while avoiding patients’ treatments 
needs high level of attention by pharmaceutical manufacturers. 
A survey conducted by the American Hospital Associations (2011) revealed that 
82% of the responding hospital had to delay patients’ treatment because medicine 
shortages. The FDA approach towards manufacturing firms that lack compliance or are 
not focused on the CGMP expectations on quality was a crucial element in the well-being 
of patients, both from the quality as well as the supply of the medicines (Schweitzer, 
2013). A proposal by Schweitzer (2013) directed the efforts by the FDA to grade the 
manufacturers on a scale from highest quality to unsafe standards. This approach could 
provide a measurement of when manufacturing practices need attention and the degree of 
modification to maintain supply to avoid medicine shortages. An action plan, as suggest 
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by Roman (2014) and Gottlied (2013), might then be implemented to keep supply and 
allow reasonable time for the remediation plan to meet the non-conformance found by the 
FDA during an inspection of the manufacturer’s facility. 
The FDA’s new guideline, published in 2013 and based on the Executive Order 
from President Obama (Exec. Order No. 13,588, 2011) for managing medicine shortages, 
presented a reasonable approach to address a balance between enforcement, 
communication, and medicine availability (Barlas, 2014; Roman, 2014). In this new rule, 
Food and Drug Administration Safety and Innovation Act, the FDA requires that the 
manufacturing firms have to notify the FDA of upcoming medicine shortages and the 
FDA specifies the corresponding timing of the firms’ notifications (FDA, 2013). Rooney 
(2014) presented the scenario in which the GPOs have been cooperating with the FDA 
and manufacturers to mitigate shortages, raise awareness related to the supply chain, and 
facilitate the understanding of the demand for drugs and generic medicines. From another 
point of view, Elzawawy (2015) challenged the drivers of the market economics like 
GPOs and global regulators to focus on enhancing the incentives to manufacturers by 
addressing pricing strategies. Elzawawy (2015), Rooney (2014), and Ventola (2011) 
concluded that a reliable supply of essential medicines was the critical responsibility of 
all involved. 
The FDA role continues to be the same:  “FDA ensures the quality of drug 
products by carefully monitoring drug manufacturers' compliance with its Current Good 
Manufacturing Practice (CGMP) regulations” (FDA, 2012, “Drug Applications and 
Current,” para. 1). The FDA published goals for the five years from 2014 through 2018 
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that enumerate and emphasize the FDA’s role, including minimizing medicine shortages 
(FDA, 2014). A common theme presented by almost all the sources agreed on the need 
for communication, coordination, and collaboration. These theme requires commitment 
by all parties, the manufacturer’s management, the GPO’s, health providers, and the 
FDA. 
Theory to Support the Change 
Theory of Planned Behavior (TPB) 
One method of assessing the predictability of behaviors is by applying the theory 
of planned behavior. Ajzen (1991) developed TPB to provide a model of measuring 
attitudes and dispositions to predict behavior. TPB infers the existence of a direct 
relationship between intention and actual behavior. Also, attitudes and norms can explain 
any behavior following the principles of TPB. This study applied TPB to understand and 
predict the intention of pharmaceutical management to comply with the FDA regulations. 
The structure of the flow diagram supporting TPB is presented in Figure 4. 
According to TPB, three types of behaviors direct and influence human behavior: beliefs 
(attitudes), normative behaviors, and perceived behavioral control (Ajzen, 2002). The 
interrelations between these beliefs influence the intention towards a given behavior. 
Intentions are the predecessors of behaviors (Ajzen, 1991). The relation between 
intention and behavior depends on the strength of the attitude from behavioral beliefs, the 
social pressures leading to subjective beliefs, and the level of perceived control that the 
person has in front of the decision process. Actual behavioral control results from the 
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limitations or obstacles to perform the intention. If adequate control exists, an 
individual’s intention predicts the actual behavior, as a direct outcome. 
 
 
 
 
 
 
 
 
Figure 4. A diagram of process flows according to the theory of planned behavior. 
Reprinted from “Constructing a theory of planned behavior questionnaire: Conceptual 
and methodological considerations.”  by I. Ajzen (September 2002), Constructing a 
theory of planned behavior questionnaire: Conceptual and methodological considerations. 
Copyright 2006 by Iczek Ajzen. 
 
Intentions. Ajzen (1991) indicated that motivational elements create the basis for 
intentions. The willingness of a person to execute a behavior and the level of effort 
placed in the planning the behavior can be used to infer the probability of the actual 
behavior (Ajzen, 1991). The performance of a given behavior depends on the level of 
strength of the motivational factors forming the attitude of the person. Ajzen (1991) 
emphasized that the intention can only become a behavior if the behavior meets the 
condition of the volitional control. The person has to be able to decide if the behavior is 
executed or not. The elements or resources influencing volitional control are for example 
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time, money, and the cooperation of others (Ajzen, 1985). If these elements are under the 
perceived control of the person, the intention should transform into the behavior. 
Salient beliefs. TPB relies on the dependent connection between behaviors and 
the person’s beliefs (Ajzen, 1991). The beliefs or information relevant to the intended 
behavior are the predecessors to the attitudes and perceived controls of the person 
towards a given behavior. Ajzen labels the relevant beliefs or information as salient 
beliefs. In TPB, intention towards a particular behavior depends on three salient beliefs:  
“behavioral beliefs produce a favorable or unfavorable attitude toward the behavior; 
normative beliefs result in perceived social pressure or subjective norm; and control 
beliefs give rise to perceived behavioral control” (Ajzen, 2002, par. 1).  The 
determinants of behavior depend on the attitudes, perceived social pressures, and the 
control around the intention. According to TPB, the elements inducing a person to 
execute or not to execute a desired behavior are the intentions and the perceived controls 
that are outcomes of the salient beliefs of the person. 
Applications of TPB 
Predicting intention to comply with regulations is as important as predicting the 
actual compliance behavior. According to Langham, Paulsen, and Härtel (2012), applying 
of TPB produces a direct relationship between intention and actual behavior. This 
relationship is essential to the understanding of the willingness to comply and of the 
actual undesired action of non-compliance. By applying TPB, the researchers also 
evaluate the topic of behavioral control including the concepts of perceived behavioral 
control and actual control. Perceived behavioral control is directed to the intention to 
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behave. In addition, perceived behavioral control consists of the individual’s ability to 
control their behavior and willingness to apply the required behavior (Ajzen, 1991). 
Actual control is essential for investigating behaviors that require the individual to 
overcome performance hurdles. Langham et al. (2012) concluded that attitudes and 
values are essential elements in the application of the TPB approach. 
In an academic setting, Stone, Jawahar, and Kisamore (2009) attempted to 
demonstrate that academic misconduct seems to be increasing. Stone et al. (2009) also 
claimed that identification of factors that influence academic misconduct was a 
significant task due to its potential tie to the workplace later on. The study examined 
elements that could influence or lead to academic misconduct using TPB (Ajzen, 1991). 
Stone et al. (2009) concluded that understanding and reducing academic misconduct 
could dictate behaviors and values in future leaders. 
Stone, Jawahar, and Kisamore (2009) applied two mediation regression equations. 
The population was from a self-selected sample. The data collection was through a 
survey. In their survey, Stone et al. used Likert-type scales. Relationships between the 
subscales of attitudes, subjective norms, behavioral control, intentions, justifications, and 
cheating were analyzed. The Cronbach’s alphas for the six subscales were calculated 
establishing the reliability of the questionnaire. All Cronbach’s alpha values were at or 
above 0.80. Some elements were signaled as “reversed” to obtain the reported 
Cronbach’s alpha values. The Cronbach’s alpha values obtained by Stone et al. (2009) 
indicated that the relations between the variables met the expectations for the application 
of the TPB questionnaire. 
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Stone, Jawahar, and Kisamore (2009) presented convergent validity and 
discriminant validity to address the construct validity of their study. Stone et al. (2009) 
concluded that the validity of their study was met. Shuttleworth (2013) discussed the 
difference between convergent and discriminant validity. Convergent validity tests 
whether constructs that should be related are indeed related. Discriminant validity tests 
whether believed unrelated constructs are indeed unrelated. In this study, the correlations 
between the two predictors and the Cronbach’s alpha values in the questionnaire were 
assessed to prove convergent validity. Results of t-tests and the confidence interval tests 
should provide a means to test for discriminatory validity. 
In an attempt to better understand and predict the intent of taxpayers to comply 
with tax regulations in Australia, Langham, Paulsen, and Härtel (2012) used TPB. 
Langham et al. (2012) demonstrated that TPB could be a predictor of compliance with 
tax regulations, using their findings to develop a particular model describing this process. 
For the first equation, multiple regression was performed for the TPB variables (attitude, 
norms, and behavioral control). For the second equation to predict compliance, a logistic 
regression was utilized, since the researchers indicated that the assumption of normality 
was violated. The results presentation and hypotheses discussions were adequate and easy 
to follow. Finally, a discriminatory analysis was conducted for each scenario, using a 
Wilks’ lambda to establish the correctness of the prediction. 
Understanding the factors that lead to unwillingness to comply or drive to ignore 
compliance should facilitate the probable prevention measures accompanying any FDA 
intervention. Intention and attitudes were assessed in this study. TPB were used to 
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identify behaviors to understand better how to predict behavior, reinforce intention, and 
probably modify future compliance with the FDA regulations. 
Criticisms of the Theory of Planned Behaviors (TPB) 
 Several researchers have criticized the predictability and applicability of TPB. 
Ajzen (2011) analyzed and addressed criticism related to elapsed time, emotions, habits, 
personality traits, and background factors. Ajzen concluded that these elements “can 
expand and enrich our understanding of human social behavior” (Ajzen, 2011, p. 1124). 
Ajzen (2011) did not concur, however, with the argument that elapsed time affects 
the predictive validity of the TPB as raised by Conner, Sheeran, Norman, and Armitage 
(2000). Ajzen contrasted Conner et al.’s (2000) position with that of Kor and Mullan 
(2011), who found that intentions were also affected in short time intervals. In relation to 
past behaviors or habits, Ajzen (2011) explained that the basis in TPB relates to recent 
beliefs relevant to the intention towards a particular behavior. In contrast, the arguments 
in favor of habits by Norman and Cooper (2011) inferred that the frequency of executing 
a given behavior creates stability and influences control over the behavior. Ajzen (2011) 
concluded the discussion on this topic by indicating that habit’s strength over behaviors 
needs further studies. 
 Rivis, Sheeran, and Armitage (2011) assessed the role of the “big five” 
personality traits as a predecessor to intentions and behaviors. Ajzen (2011) judged that 
the results indicated small effect between the personality’s traits and behaviors. 
Background factors such as demographics and emotions influence beliefs that are 
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antecedents to the salient beliefs. Ajzen (2011) explained that the origin of these factors 
affects the beliefs and indirectly the attitudes and control that are already part of TPB. 
Change in Behavior (What, Why, How) 
The required change process to attain the desired state of avoiding medicine 
shortages could evolve through the typical life cycle of what, how, and why (Kezar, 
2001). Management trends and possible theoretical frameworks presented in Figure 1 
project the complexity of addressing the change process. The future impacts on the 
stakeholders were the “why” to conduct the study, delineating the required attributes 
influencing the management performance to achieve positive social change. 
What Needs to Change 
The lack of compliance with CGMP has led to pharmaceuticals manufacturing 
facility closures, loss of revenues, unavoidable penalty fees, loss of reputation, and 
significant investments to address remediation of their violations to the FDA regulations 
(Asotra, Cossin, & Yacobi, 2012). Manufacturing shortfalls implied that quality 
management and systems are not empowered or properly staffed to support adequately 
the critical functions within the pharmaceutical firms (Woodcock, 2012). In the first three 
years of the Obama Administration, 2009 through 2011, the number of warning letters 
issued to manufacturing and quality issues increased to 49 letters versus nine letters in the 
last three years of the George W. Bush Administration (Nguyen, Seoane-Vazquez, 
Rodriguez-Monguio, & Montagne, 2013). The FDA, in a letter to pharmaceuticals 
manufacturers in October 2011, indicated that about 54% of drug shortages were a result 
of manufacturers’ quality problems (FDA, 2011). Collectively, the evidence suggested 
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that the number of FDA interventions and enforcement actions against pharmaceutical 
manufacturers have increased in the recent years. Also, as shared in Anisfeld (2009), the 
FDA has issued warning letters to international generics firms, establishing import bans 
of their products into the U.S. 
Why the Need for Change 
For pharmaceutical firms, the lack of compliance with the FDA regulations could 
be devastating. The results from the lack of compliance include loss in sales, impact on 
reputation, and an increase in the level of expenses to recover or achieve remediation. 
These performance indicators typically also impact the market value of the firms. If the 
FDA intervention escalates into a consent decree, Asotra, Cossin, and Yacobi (2012) 
explained that the magnitude of all these elements could multiply and become an 
unacceptable historical benchmark within the industry.  
This dissertation promoted positive social change by eliminating or minimizing 
medicine shortages. Medicine shortages place the patients’ health in significant danger. 
In addition, medicines that are substandard in quality, purity, and identity probably do not 
address the intended treatment (Woodcock, 2012). The potential mistrust by the public on 
companies’ lack of commitment towards social responsibilities could be kept to a 
minimum. 
How to Pursue the Change 
 The gap between the present situation and the desired state was the basis for 
justifying the need for change. How to pursue the desired change could have several 
approaches. Market dynamics, survival of the organization, personnel needs, new 
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technology, regulatory requirements, or a mixed of all the above items is an excellent 
basis to influence the metrics of how the change is pursued. The FDA proposed the 
establishing of quality metrics to control operations and change (Koberstein, 2014). 
Internal and external elements create the scenario of interdependencies and archetypes to 
be dealt with in the road to the desired state as generalized by Senge (2006). The 
complexity of designing the strategy of how to pursue change depends on the 
understanding of the interdependencies and archetypes. 
 In the area of motivation and inspiration, Ilies, Judge, and Wagner (2006) 
designed a conceptual model to illustrate the impact of transformational leadership on the 
motivation of subordinates or followers. The effect of affective and cognitive approach to 
motivation was presented in three areas: direction of the action, effort intensity, and 
persistence. Charismatic leadership and motivational leadership were linked to actual 
followers’ reaction. The analysis focused on how leaders should approach team members 
while considering the diversity in attitude and individual skills. The theory of multiple 
intelligences, as described by Kornhaber, Krechevsky, and Gardner (1990), could further 
highlight the need for an individualized approach to teams. Motivation theories like 
Maslow’s (2000) hierarchy of needs could be part of the leaders training. 
The organizational goals and working climate drive the change strategy to be 
selected and implemented by the organization leaders. The flexibility and adaptability of 
the management decision-making process and the existing environmental factors of the 
organization create boundaries in the potential change process. As explained by 
Chadwick-Coule (2011), the effectiveness of the change process and the sustainability of 
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the outcomes are highly dependable on who sets the target, the approach to the execution 
of the change, and the impact of the change on stakeholders. 
The selection of the change strategy typically depends on leadership style and 
organizational structure. Peng and Weichun (2011) concluded that leaders have a 
significant influence on organizational performance. In reference to leadership style, 
Vroom and Lago (2007) described contingency leadership, and Deluga (1990) studied the 
impact of transformational, transactional, and laissez-faire leadership. Morgan (2006) 
compared different organization models, emphasizing that the organizational model set 
the internal dynamics of operation and change management. For effective change 
management, Senge (2006) indicated that sharing vision, effective communication, and 
confirming change effectiveness are essential elements. The effectiveness of the change 
strategy converse in the integration of all these elements. The implied interdependencies 
of these elements provide a robust scenario to ensure the execution of the change strategy 
and hopefully, its sustainability. 
Resistance to change is a critical item that needs to be understood and managed. 
Stakeholders’ mental model of “what is in” for me is a sensitive topic driven by 
motivation, individual psychology, emotional intelligence, and learning style. Maslow’s 
(2000) hierarchy of needs and the pursuit of self-actualization, as well as Adler’s theory 
(as cited by Boeree, 2007) of complex management by striving for superiority, cannot be 
ignored by leaders when selecting a change strategy and setting the corresponding 
execution plan. The idea is to engage the stakeholders, and not to apply intimidation. 
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Motivation and improvement to the self-esteem of the followers could allow 
leaders to delegate and grant opportunities for participation. As demonstrated by Leana 
(1987), the climate of participation, as well as the willingness for delegation by the 
leaders, is associated with the level of trust and the understanding by the leader of the 
degree of competence demonstrated by the subordinates. Leaders should consider the 
person’s lifestyle to optimize the individual’s motivation. Adler’s (as cited by Boeree, 
2007) concept “of being useful” could be linked directly to the organizational climate. 
The employee should feel satisfied that is valuable to the team and is in the pursued of 
the targeted goals. 
Change Models 
The selected model of change or strategy to be followed typically includes team 
building, new relationships, and technological support. The geographical characteristics 
of the organization could also influence the selection of the change model. The 
systematic approach to change implementation, execution, and measurement should 
attain the desired transformation as summarized by Kupritz and Cowell (2011). 
Deming’s Cycle 
In the twentieth century, quality and reduction of variability became the backbone 
of continuous improvement with concepts like Deming’s improvement cycle and the 14 
quality principles, which were followed by many others like Crosby, Shingo, and Peters 
(Hussai, 2004). The concept of planning change, for improvement versus purely reacting 
to external environment factors or internal weaknesses, became a significant trait to attain 
transformation and long-term sustainability of outcomes. Focusing on Deming’s Quality 
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Management 14 principles, total quality management (TQM) implies a process of 
continuous improvement, by applying the cycle of plan, do, check, and act to the 
organizational and leadership transformation to pursue the expected level of compliance 
with the FDA regulations. Also, leadership’s adaptability and flexibility are typically 
associated with strategic planning and organizational development (Beinhocker, 2006). 
These changes could be considered both transformational as well as transactional since 
usually a mix of changes is implemented. 
Kotter’s Model 
Kotter (2007) discussed the critical factors that constitute the model for the change 
process. The effectiveness of the implementation depended on essential elements, 
requiring attention and monitoring. The eight phases or errors to avoid were integrated to 
prevent failure in a change process. Kotter’s (2007) eight phases or errors to avoid 
consist of 
 Establish a sense of urgency 
 Create a guiding coalition 
 Develop a vision and strategy 
 Communicate the change vision 
 Empower broad-based action 
 Generate short-term wins 
 Consolidate gains and produce more change 
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These eight phases or errors to avoid are essential to assure the transformation in 
behavior to attain the expected level of compliance with the FDA regulations. The 
notice of violation from the FDA explicitly set the level of urgency to the operational 
management to avoid and minimize the impact to the supply of the medicines and the 
revenues of the pharmaceutical firms. The undesired impact on sales and reputation of 
the firms most likely results from the FDA intervention, raising the urgency and 
expectations of the management of the firms. The next two phases require senior 
management to establish a clear guidance and vision on the need to change the behavior 
from the supervisors to the operational personnel. Strategies and tactics need to be 
developed, leading to changes in processes, styles, and deliverables. 
The fourth stage in Kotter’s model is the next critical step: communication. As 
stated by Senge (2006), sharing the new vision of compliance and desired behavior 
tends to engage all levels of decision-making and operations. Establishing subject matter 
experts and delegating to teams should accelerate the transformation, assuming that 
management can evolve from crisis management into participative leadership. 
The next stage is to set clear short-term targets to highlight a clear direction of 
change and the expected level of compliance. The notice of violation from the FDA sets 
the general tone. Quality systems need overall review and probably significant changes. 
Mehta (2013) suggested that implementing principles and guidelines, as developed by the 
International Conference on Harmonization, could be a significant step in facilitating 
leaders’ understanding of the compliance expectations. To correct the events of CGMP 
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violations implies that productivity indicators, financial metrics need to be assessed while 
management behaviors need to be modified. 
A systematic review of progress and hurdles during the implementation plan needs 
to be established to assure measurement of progress. In addition, a time most be set aside 
to adjust in front of any failure or delay. Sensitivity to the employees’ engagement and 
citizenship to support the overall change process needs to be recognized to ensure 
effectiveness and sustainability of the change. An overall continuous process should 
allow management to secure the new compliance behavior and assure sustainability for 
the long term. 
Continuous Improvement Measurement 
To assess continuous improvement, a holistic approach is required across all 
disciplines to measure performance. Chan, Qi, Chan, Lau, and Ip (2003) presented a 
process-based approach to measuring performance for supply chain management. The 
measurements cover the traditional supply chain indicators in cost, time, capacity, 
capability, resource utilization, and reliability. Accurate data could be collected to 
compare the performance of the two scenarios: before and after the FDA intervention. 
The application of this type of tool to measure continuous improvement could support the 
process of managing the change process, allowing for adjustment when the indicators are 
not as expected. Influencing the change process implies an open flow of information, the 
share of knowledge, experimentation, and tolerance of autonomy, allowing fast response 
to adapt and adjust as changes are being implemented. 
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 With the FDA intervention creating new pressures and challenges within the 
interdependencies of the organization, planning and reassessment become essential to 
monitor progress and reduce pitfalls. The transformation of the attitudes and behaviors 
impacts leadership styles and emotional intelligence attributes of the management team. 
Understanding the evolution of the change stages and links needed to support, the new 
approach to compliance, demands vision and hands-on knowledge. The change process 
evolves in stages as the organization learns, accepts, and matures along the 
implementation of the associated changes in policies and procedures. Finally, the new 
required level of adaptability, flexibility, and tolerance to change challenges the 
traditional authority and financial policies of the organization. 
Managing Change Resistant or Impediments 
The deliverables in this study were compliance behavior to assure medicines 
availability for patience, adaptability to handle the financial pressures, and transformation 
into a learning organization. The goal was operational compliance with FDA regulations, 
which normally in these situations, were well defined by the audits and expectations from 
the FDA. The plan to transform behavior and to address the financial pressures requires 
transformational leadership approach and tolerance to change, minimizing pitfalls and 
resistance to change while sustaining the expected CGMPs regulations from the FDA. 
In Figure 5, a concept map representing a Change Implementation Plan is 
illustrated. Cicmil (1989) developed the structure of this concept map. Cicmil suggested 
that by mapping the what, how, and why the gaps and the impediments would be 
exposed, including the vulnerable areas for implementation of the change. The what and 
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how refer to project deliverables and implementation process, respectively. The elements 
of the implementation process are the identification of the gap, the development and 
execution of the implementation of the plan, and the measuring progress. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Concept map for a complex adaptive system for the implementation of 
organizational changes. Source of Concept Map was adapted from “Implementing 
organizational change projects: Impediments and gaps” by S. Cicmil, 1999, Strategic 
Change, 8(2), page 128. Copyright © 1999 John Wiley & Sons, Ltd. 
 
Summary 
Change is an ongoing performance improvement that organizations must 
examine. There may be many different styles of change models utilized within an 
organization. The goal is to identify that there is a need for change, develop a plan for 
Project – Attain the Desired State  
WHAT – Project Deliverables 
1) Adaptability  
2) Transform to a learning organization 
 
HOW – Implementation Process  
1) Defined Gaps 
2) Develop and Implement Plan  
3) Measure Progress of Change Implementation 
Organized  
Resistance: 
 
1) Mental Models 
2) Risk of 
increased 
complexity 
3) Path of 
Dependence 
(Beinhocker, 2006)  
WHY – The NEED 
Organization Slow 
Learning Skills 
Fast Forgetting – back to 
current Mental Models 
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change, implement the plan with effective communication, and evaluate the effectiveness 
of the change implemented. The “what, how, and why” of change needs to be an ever-
rotating cycle. Although some people may not like the concept of change; for leadership, 
change in behavior is always an opportunity for improvement for long-term sustainability 
of the organization. 
Chapter 2 contained the literature search strategy that was followed. For the 
quantitative study to be performed, the independent variables, the dependent variable, and 
the FDA intervention were analyzed. Arguments were presented in which the FDA 
interventions could be considered as the cause since the FDA showed to have low 
tolerance with manufacturers in front of the impact to the supply of medicines. The 
relevance of the study and its impact on social change regarding the research gap in the 
literature were further discussed. 
The literature review on the theoretical framework addressed the theory utilized 
for this quantitative study. Critics of the theory of planned behavior presented arguments 
on the weakness of the theory.  Counter arguments were discussed from the response of 
Ajzen (2011).  An analysis of issues, trends, and concepts formalized the literature review 
for what needs to change, the how to change, and the why to change assuring an efficient 
change management process while managing resistance to change. 
In Chapter 3, the research methodology and design are presented in detail. The 
research tools to be employed are discussed, including the efforts for validity, the 
trustworthiness of the survey, and the Internet tools. Accessibility of the targeted 
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participants and the assurance of confidentiality is described. Finally, elements of 
confidentiality and data protection are enumerated.  
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Chapter 3: Research Method 
This quantitative study sought to learn to what extent, if any, management 
behaviors and financial pressures at pharmaceutical firms correlated with or predicted 
compliance with the FDA regulations avoiding interruptions in the supply of some 
essential patented or generic pharmaceutical drugs in the U.S. In Chapter 3, the research 
methodology and design were presented in detail. The research tools to be employed 
were discussed, including the efforts for validity, the trustworthiness of the survey, and 
the Internet tools. Accessibility of the targeted participants and the assurance of 
confidentiality was described. Finally, elements of confidentiality and data protection 
were enumerated. 
 The study enhanced the understanding that avoiding FDA interventions provided 
business sustainability by analyzing management behaviors. The study also accentuated 
the concept that compliance was a competitive business advantage for the pharmaceutical 
companies. The design of the research allowed the scenario of predicting the outcome of 
the dependent variable, compliance with the FDA regulations. 
Research Method and Design 
  For the study, the selected quantitative research methodology needed to correlate 
the variables and predict the outcome. The quantitative research method predicts, 
investigates relationships between variables, or assesses possible impacts on outcomes 
(Creswell, 2009). This deductive approach to confirm the correlation between the 
variables was considered adequate to address the research question and assess the 
hypotheses.  
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The quantitative study consisted of a research design including correlations and 
regression analyses. I applied this statistical tools to make a comparative analysis 
between the scenarios before and after the application of a treatment, the FDA 
intervention. The expected variability in the study and the desired to predict outcome led 
to the application of Cronbach’s alpha and regression line analyses. Also, applying 
simple t- test comparisons provided clarity to the correlation. For this study, the pre-FDA 
conditions were the scenarios that led to enforcement actions by the FDA. The 
independent variables or predictors were management behaviors and financial indicators. 
The treatment event was the application of the enforcement action by the FDA. The 
dependent variable or outcome was the level of compliance of the firms. 
The correlations between management behaviors and financial indicators on the 
compliance with the CGMP regulations defined the quality systems before and after the 
FDA intervention with the pharmaceutical companies. A multiple linear regressions 
provided the assessment between the pre-FDA conditions and the post-FDA conditions, 
before and after the FDA intervention. A regression methods were applied twice, pre-
FDA and post-FDA interventions, for comparative statistical analysis to establish patterns 
before and after the application of the treatment. 
For this study, the pre-FDA conditions were the scenarios that led to enforcement 
actions by the FDA. The pre-FDA conditions represent the situations (independent 
variables or predictors: management behaviors and financial indicators) that resulted in 
enforcement actions by the FDA. The treatment event was the application of the 
enforcement action by the FDA. The level of compliance of the firms was the dependent 
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variable or outcome. All variables were considered to be continuous at the time. The 
post-FDA condition represented the outcome after the remediation activity was 
completed, which was measured in the behavioral attitude (TPB) questionnaire 
(management “decision-making” survey), financial results [financial indicators section 
(i.e. cost of goods, investment, and revenue)], and level of compliance with the FDA 
(level of compliance responded by participants). 
Considering that there was a logical expectation that the FDA intervention was 
going to force a change in management attitudes, an impact on the regression line was 
expected, at the application of treatment, the intervention of the FDA. The analysis of the 
TPB questionnaire responses allowed to compare the relationships before and after the 
FDA intervention. Also, establishing the regression line, between the variables after the 
treatment, should assist in assessing the long-term effect on compliance, allowing for 
follow-ups and self-corrections by the firms. 
Research Questions and Hypotheses 
The focus of this quantitative dissertation research study was to determine to what 
extent, if any, management behaviors and financial indicators correlated to compliance 
with FDA regulations at the pharmaceutical firms in the United States. The conditions 
before to the FDA intervention in the pharmaceutical firms was compared to the 
conditions after the FDA intervention to predict compliance with the CGMP regulations. 
The independent variables that led to enforcement actions by the FDA are management 
behaviors of the pharmaceutical managers and the firms’ financial indicators. The 
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treatment event was the application of the enforcement action by the FDA. The level of 
compliance of the pharmaceutical company was the dependent variable. 
 Correlation between management behaviors (independent) and compliance 
(dependent): 
RQ1:  To what extent, if any, does management behaviors correlate to 
compliance with FDA regulations at the pharmaceutical firms in the United 
States? 
H1₀:  r = 0. There is no difference in management behaviors towards 
compliance at pharmaceutical firms, as a result of FDA enforcement actions in 
the United States. 
H1₁:  r ≠ 0. There are differences in management behaviors towards 
compliance at pharmaceutical firms, as a result of FDA enforcement actions in 
the United States. 
 Correlation between financial indicators (independent) and compliance   
(dependent): 
RQ2:  To what extent, if any, do financial indicators correlate to compliance 
with FDA regulations at the pharmaceutical firms in the United States? 
H2₀:  r = 0. There is no difference in compliance with FDA related to 
financial indicators at pharmaceutical firms, as a result of FDA enforcement 
actions in the United States. 
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H2₁:  r ≠ 0. There are differences in compliance with FDA related to financial 
indicators before and after the FDA enforcement actions in the United States. 
 Financial indicators (independent) impact on compliance (dependent): 
RQ3:  To what extent, if any, do financial indicators impact compliance with 
FDA regulations at the pharmaceutical firms in the United States? 
H3₀:  β₁ = β₂ = … = βk = 0. There is no impact in compliance with FDA 
related to financial indicators at pharmaceutical firms, as a result of FDA 
enforcement actions in the United States. 
H3₁:  At least one β ≠ 0. There is an impact in compliance with FDA related 
to financial indicators before and after the FDA enforcement actions in the 
United States. 
The β in Hypothesis 3 are the regression coefficients of the following multiple regression 
equation: 
 0 1 1 2 2 3 3 4 4 5 5 6 6 7 7Y X X X X X X X                  (2) 
Where,  
Y= FDA related compliance 
X1 = Cost of goods 
X2 = Investment 
X3 = Process compliance 
X4 = Change in sales 
X5 = Change in revenues 
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X6 = Change in market value of the firms 
X7 = Change in stockholders equity 
ԑ   = Error of the regression 
Pilot Study 
A pilot study was conducted to examine clarity of questions to collect feedback 
on the questionnaire’s structure and to identify essential beliefs using Likert-type scales. 
Ajzen (2002) indicated that a pre-work is required to define the behaviors of interest for 
the adequate design of the TPB survey instrument. The pilot study clarified management 
behaviors towards compliance with FDA regulations. The pilot study also collected 
feedback about financial indicators of the pharmaceutical firms. Demographics of 
participants, the degree of compliance, and the type of FDA interventions were requested 
in the next sections of the survey instrument. The pilot study confirmed the effectiveness 
and completeness of the order of the questions. 
To qualify as a participant in the pilot study, participants complied with the same 
survey population criteria that was also used for the main study. Participants were 
selected from executives and operational management levels who had the authority to 
make compliance and financial decisions within pharmaceutical firms, based on their 
self-disclosed position titles in the ISPE members’ database. The number of participants 
invited to the pilot study was 21. The response rate was 47% for 10 completed surveys. 
The 10 responses to the pilot study represented about 6% of the initially targeted usable 
responses for the main study of about 160. The pilot study participants’ selection process 
was based on convenience sampling that is different from the main study. The need to 
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ensure sufficient and reliable replies from the pilot study made it important to recruit 
participants who provided usable feedback within 14 days. 
The pilot study was conducted similarly to the same intended instrument for the 
study. The pilot study was administered through SurveyMonkey, an electronic survey 
tool chosen to collect data and facilitate analysis. Trust and desire to participate depended 
on the cover letter and personal communication by me with the pilot study’s selected 
participants. Also, the pilot study provided feedback on the effectiveness and 
completeness related to the message of confidentiality directed to ensure participation 
later on in the study questionnaire. 
Population and Qualifications 
The study population consisted of pharmaceuticals firms that had been impacted 
within the last 5-6 years by enforcement activities from the FDA in the United States, 
with a specific focus on firms that had experienced FDA interventions related to 
manufacturing CGMP violations. The FDA interventions consisted of notification of 
deviations (Form 483) with a rating of official action indicated (OAI), following the 
FDA’s escalation process as a result of the pharmaceutical firms not responding to these 
FDA communications. Audits with ratings of OAI could lead to warning letters or 
consent decrees depending on the firms’ response and follow-up actions to the FDA 
notifications. In Table 3, a total of 272 OAI audits was summarized for the 
pharmaceutical firms between 2010 and early 2015 (FDA, 2015). This number of firms 
indicated the targeted population for the main study. 
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Table 3 
FDA audits with ratings of OAI 
FDA Audit 
Year 
 
Audits with Official 
Action Indicated 
(OAI) 
 
2010 86 
2011 73 
2012 52 
2013                           47 
2014 13 
2015    1 
Total Audits  272 
 
The intended survey participants was selected from executives and operational 
management levels of the pharmaceuticals firms in the United States. ISPE members’ 
data based was used to select the participants. These participants, based on their self-
disclosed position titles, had the authority to make compliance and financial decisions for 
their firms. 
Sampling Strategy 
The sampling strategy was directed to support the main study in the 
pharmaceutical firms in the United States. The main criteria for participation were that 
the executives and senior operational management of the firms were expected to have the 
authority to make compliance and financial decisions within the firms. The participants’ 
responses were selected from the completed surveys. 
The database of potential participants was obtained from the members’ directory 
of the ISPE. Although simple random sampling as suggested by Kanupriya (2012) could 
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have been an effective sampling strategy for the study, all ISPE members that meet the 
criteria of participants were invited through SurveyMonkey to participate. The 
authorization for use of the members’ directory of the ISPE as a member is in Appendix 
D.  
For the pilot study, convenience sampling approach was the sampling strategy. 
This strategy allowed me to select participants based on my personal knowledge. The 
participants for the pilot study were considered as experts from the targeted population 
who provided the required information to finalize the study questionnaire (Frankfort-
Nachmias & Nachmias, 2008). Based on Ajzen (2002) the pilot study questionnaire 
provided a stronger selection of the construct elements for the design of the TPB 
questionnaire for the main study. 
Sampling Strategies Not Chosen 
Systematic Sampling. Systematic sampling, in which a portion of the population 
is selected (1/k), was not appropriate for the targeted hypotheses of the main study. The 
resulting sample could be impacted by the size of the each pharmaceutical firms or the 
characteristics of the FDA interventions. The financial strength of each pharmaceutical 
firms could influence the approach to change management to attain the remediation of the 
deviations from FDA regulations as noted during the FDA intervention because of the 
firms’ manufacturing processes. 
Stratified Sampling. Stratified sampling was considered as an alternate when 
considering that there could be hierarchical levels of internal authority within the 
sampling units at each firms. Nevertheless, the potential differences in the firms’ size and 
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each particular organizational structure could make it very difficult to have proportional 
sampling and understand the weight between the decision makers. When comparing 
different FDA interventions, empowerment to decision makers could depend on the 
financial resources of each pharmaceutical firms. 
Cluster Sampling. Cluster sampling intent was considered not applicable to the 
main study since the cluster approach was not aligned with the targeted participants’ 
distribution. Although the pharmaceutical industry could be considered as one 
population, the individual firms does not necessarily create a cluster scenario for 
sampling. The behavior of management was better substantiated through the approach of 
including all ISPE members that met the participants’ criteria to minimize any risk of 
biases by the individual firms’ financials. 
Sampling Size Determination 
For the sampling size determination of completed surveys, three approaches were 
followed to address the three research questions and hypotheses. For research questions 
one and two, the sampling size determination of completed surveys considered Krejcie & 
Morgan (1970) equation and Cohen’s power (1992) as the basis for calculation. The 
sample size of completed surveys for RQ3 was established by using G*Power software 
(Faul, Erdfelder, Lang, & Buchner, 2014).  
The intended study population consists of pharmaceuticals firms that had been 
impacted within the last five years by enforcement activities from the FDA in the United 
States. This population was estimated to be about 272 pharmaceutical manufacturing 
firms based on the FDA information (FDA, 2015). The sampling size of completed 
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surveys indicated by Krejcie & Morgan (1970) was to be about 160. The intended survey 
participants were selected from executives and operational management levels of the 
firms, and should have the authority to make compliance and financial decisions for their 
firms, based on their self-disclosed position titles in the ISPE members’ database. 
Also, an alternate method was utilized to estimate the sample size of completed 
surveys for research questions one and two. Cohen’s power (Cohen, 1992) was assessed 
as adequate since the population standard deviation is not known. The concept of effect 
size is based on the difference between population means. Cohen (1992) indicated that 
the effect size could be selected to be 0.5 if the difference of the means is perceived to be. 
For the main study, the effect size was not leading to the selection of a smaller effect size 
of 0.3. Calculation of the sample population with the application of Cohen’s effect size d 
was based on a power (1- β) of 0.80, and a confidence level (α) of 0.05. Assuming that 
the groups’ sizes were the same (r =1), the sample population of completed surveys 
should have been about 121 with the application of Cohen’s power.  
 For the research question and Hypothesis 3, a priori power analysis was applied 
based on the required expectation of the financial variable impact based on the FDA 
intervention in the pharmaceutical firms. The values were set for the statistical power 
(strength of the statistical test), α value (probability of the null), and the effect size 
(correlation between the variables and the predictor) to determine the sample size. The 
selected power of a statistical test represented the probability of correctly rejecting the 
null hypothesis, if applicable (Faul, Erdfelder, Lang, & Buchner, 2007). The sample size 
of completed surveys for RQ3 was established by using G*Power software (Faul, 
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Erdfelder, Lang, & Buchner, 2014). Also, the selected statistical power represented the 
probability that the selected statistical test can find a relationship between the variables. 
The G*Power software option for the linear regression study assumed a R² that is 
different from zero for two predictors in a linear regression. The sample size of 
completed surveys was determined to be about 127, based on the selected values for 
statistical power of 95%, α of 0.05, and effect size of 0.125. Appendix C presents the 
G*Power calculations for the sample determination. The power of 95% provided a 
reasonable position to avoid Type II error of not rejecting the null hypothesis when it was 
supposed to be rejected. About the effect size, the value of 0.125 was selected to test a 
reasonably low correlation between the predictors to enhance the regression model 
likeliness of projecting the outcome. 
Based on the three approaches for the sampling size determination, the potential 
sample sizes of completed surveys were 160 from the method from Krejcie & Morgan 
(1970), 121 from the Cohn’s power (1992), and 127 from the G*Power software (Faul, 
Erdfelder, Lang, & Buchner, 2014). For the study, the target sample size of completed 
surveys was about 160 to ensure that the three research questions and hypotheses were 
adequately addressed. My intent was to minimize Type I and Type II errors in the 
assessment of the three null hypotheses.  
For the intended population, computer accessibility was expected to be high, the 
typical time navigating and reading e-mails most likely be constant on a daily basis, and 
the probability of gaining the respondent attention is better than by mail or telephone 
calls. As explained by Ahern (2005), the benefits of the electronic survey are time 
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management, accessibility to sensitive/specific population, and easy and comfort to use 
(user-friendly) while minimizing the missing data. The use of an established electronic 
survey, SurveyMonkey, facilitated the data management. SurveyMonkey had a 
reasonable reputation and could add comfort to the participant, driving the overall level 
of participation. 
The SurveyMonkey was applied to estimate the optimum sample size assuming a 
normal distribution. For the initial target of 160 completed questionnaire, the 
SurveyMonkey sampling estimator indicated that the number of potential participants 
should be about 400 at a 90% confidence level and a 5% margin of error. This sample of 
400 participants projected about 162 completed surveys with a 90% probability that the 
sample of participants should reflect the attitudes of the intended population. Also, the 
margin of error of 5% intended to minimize the deviation from the true value at the 
selected confidence limit of 90%. For this scenario, the expected response rate based on 
SurveyMonkey sampling estimator implied a participation of 40.5%. 
A response rate of 40.5% was initially considered too optimistic. The expected 
response rate was set at 20% to ensure the probability of attaining the targeted 160 
completed surveys. This scenario represented about 800 participants at 20% response 
rate. The SurveyMonkey sampling estimator indicated that for 800 targeted participants 
at a 90% confidence level, the margin of error could be expected at 6%. As a precaution, 
1144 members in the directory of the ISPE with an address and meeting the participants’ 
criteria were invited to complete the main survey. 
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Description of the Survey  
The survey instrument consisted of four sections, structured as a Likert-type scale 
questionnaire. Two sections focused on the behavior of the participants and the financial 
indicators of the pharmaceutical firms in the pre-FDA and post-FDA interventions. The 
third section collected demographical information from the participants. The fourth 
section focused in the firms’ historical compliance.  
The period of the survey was an important factor. The participants were expected 
to associate personal assessment of behaviors and financial indicators for both the pre-
FDA and post-FDA interventions. The instructions in the survey instrument needed to be 
precise providing clarity to optimize the number of usable responses. 
The TPB questionnaire by Ajzen (2016) was modified for the behavioral section 
of the intended survey instrument. Ajzen (2002) suggested the essential elements for the 
construction of the survey for a TPB questionnaire. Consent to apply and modify the TPB 
questionnaire for this study was granted by Ajzen (see Appendix A). The financial 
indicators section of the planned survey instrument were based on typical indicators that 
could be impacted by the expenses needed to support remediation addressing FDA 
interventions like the cost of goods and investment in facilities or equipment. Sales, 
Revenues, and stockholders’ equity were also be part of the financial indicators. 
For the participants, computer accessibility was expected to be high; the typical 
time navigating and reading e-mails most likely be constant on a daily basis; and, the 
probability of gaining the respondent attention was better than by mail or telephone calls. 
The benefits of an electronic survey are time management, accessibility to 
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sensitive/particular populations, and being easy and comfortable to use while minimizing 
the potential for missing data (Ahern, 2005). The survey was administered through 
SurveyMonkey. SurveyMonkey has a reasonable reputation and could add comfort to the 
participant driving the overall level of participation. 
Appropriateness of the Instrument 
The questionnaire structure for assessing management behaviors was developed 
following Ajzen’s (2002) guide for constructing a theory of planned behavior 
questionnaire. Also, the sample TPB questionnaire from Ajzen (2016) was used. The 
permission to use the TPB questionnaire is in Appendix A. Two surveys from the 
literature were also used as guides. The first model considered the survey from Stone, 
Jawahar, and Kisamore (2009) in which academic misconduct was used trying to predict 
future performance as leaders. The second model was from Langham, Paulsen, and 
Härtel (2012). In this model, the target was to demonstrate that the TPB could be a 
predictor of compliance with tax regulations. In the main study, the questionnaire 
constructs considered beliefs (attitudes), normative beliefs, and perceived behavioral 
controls. 
The questionnaire based on TPB was directed to the elements of salient outcomes 
and control factors with the objective to obtain direct measurement of the attitudes 
toward the intended behavior, the perceived norm, and the perceived behavioral control 
as indicated by Ajzen (2002). The pilot study was be the source of beliefs (attitudes) and 
control factors used in the main survey instrument. Past behaviors versus current 
behaviors could depend on background changes like organizational structure and working 
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climate. A section of general questions was included to help identify future areas of study 
affecting behaviors of managers as a result of FDA interventions. 
For the financial indicators, a Likert-type scale questionnaire was developed to 
create a clear and direct tool for the participant to provide their responses. The scales 
were designed to associate in an ordinal relation with each financial indicator’s values. 
The elements included for financial indicators consisted of basic business topics like 
revenues, the cost of goods and investment in facilities or equipment. The goal was to 
provide a questionnaire structure that allowed the participants to compare periods before 
and after the FDA intervention for the financial indicators. 
The survey instrument consisted of four sections of questions to assess 
management behaviors and financial indicators of performance before pre-FDA and post-
FDA interventions. The responses to the questionnaire were expected to provide feedback 
over time while maintaining the participants’ responses aligned to both periods, before 
and after the FDA intervention. The third section of the study questionnaire asked for 
demographic information of the participants. Section four complied responses about the 
FDA experience of the firms. 
Validity of Measurements 
 Attempts to neutralize or compensate for measurement errors could be defined as 
evidence or specific conditions in support of the validity. The objective is to enhance the 
validity of the instrument about what it is intended to measure (Frankfort-Nachmias & 
Nachmias, 2008). There are three types of approaches to address measurement errors: 
content validity, empirical validity, and construct validity. 
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Content Validity 
Content validity is directed to assure that the measurement instrument covers all 
intended attributes of the study. Face validity (all questions addresses the properties of 
the variables) and sampling validity (all properties of the variables are considered) are the 
two areas that need to be considered when addressing concerns around content in the 
questions validity of a questionnaire (Frankfort-Nachmias & Nachmias, 2008). An 
important challenge is to ensure that the questionnaire addresses all significant aspects of 
behavior.  
Assessment of the feedback from the pilot study assisted in achieving a significant 
content validity. Assuming that all participants had the same level of definition of what is 
compliance was difficult to predict. Maintaining neutrality and not pre-setting responses 
on the questionnaire by me required neutrality and control over previous mental models. 
Empirical Validity  
The relationship between the measurement instrument and the actual outcomes 
requires attention. Addressing empirical validity is very difficult (Frankfort-Nachmias & 
Nachmias, 2008). Predictions via a pilot study was developed with peers in the 
pharmaceutical industry to allow comparison of initial expectations with actual measured 
results. Even establishing a reference base had its challenges, based on potential biases of 
management (participants). 
Construct Validity 
Construct validity looks for a theoretical framework that could be related to the 
intent of the measuring instrument. The TPB (Ajzen, 1991) was used to discuss the 
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outcome of the measurements. TPB presented the concepts that allowed me in the study 
to link beliefs (attitudes) with the actual behavior, subjective norms with the behavior, 
and perceived control over behavior. The correlations and linear regressions provided the 
basis to assess the data from the TPB sections of the study questionnaire. The attributes 
and assumptions of TPB could affect the study. Assessment of the survey data allowed 
defining future research in the topic. 
Questionnaire Reliability 
Cronbach’s alpha tests correlation to determine the reliability of a scale 
questionnaire (Field, 2009). Cronbach’s alpha is not a validity measure. The values for 
Cronbach’s alpha range from 0 to 1. Cronbach’s alpha provided the means to assess if the 
scale items in the study questionnaire impacted the overall total subscale reliability. 
Either eliminating or reversing the phrasing of a negative scale item were assessed to 
obtain the Cronbach’s values. All subscales of the Likert-type scale structure of the 
questionnaire were included in this assessment with the Cronbach’s alpha tests 
correlation. 
Protection of the Survey Population 
The data collected through the electronic questionnaire was protected by the terms 
provided by SurveyMonkey. An individual codification was used to protect each 
participant’s responses within SurveyMonkey. All lists of the study’s participants 
generated with the SurveyMonkey code will be destroyed by incineration for any printed 
master list after five years from the approval of the study. SurveyMonkey confidentiality 
terms will also apply in their databases. The electronic lists from my computer will be 
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stored in a bank security box for five years on a DVD and in an external memory storage 
device. Then, the data will be erased and the storage devices destroyed to assure no 
opportunity for data recovery. 
Informed Consent 
For both the pilot study and the actual survey questionnaire, consent of 
participation were sent to the intended participants as part of the electronic method 
selected following the approved by Walden University’s Institutional Research Board 
(IRB) with approval number 12-28-15-0289564 that expired on December 27, 2016. The 
participants had to confirm the consent of participation before commencing the 
questionnaire. The consent form provided an introduction of the intent of the study, 
clarity that the study was for my Ph.D. program, and informed of the confidentiality of 
the data to be provided to each participant. There were two consent forms used for this 
study: one for the pilot study and one for the study questionnaire. These consent forms 
included the invitation to participate in each survey and were the page of the e-mail 
electronic survey. Also, SurveyMonkey system provided the option to the participants to 
opt-out of the survey and any future mailing. 
As inferred by Ahern (2005), using electronic surveys have challenges in the 
areas of confidentiality and in acquiring rights and permission to quote. The use of 
established survey web pages, like SurveyMonkey, facilitated conveying the academic 
intent and privacy of the study. An opening statement regarding my academic program, 
including a reference to the IRB should have provided the opportunity for the participant 
to feel comfortable in proceeding to the questionnaire. The IRB of Walden University 
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provided the permission to apply the pilot study and the main study questionnaire. A 
copy of the study was offered to the participants that completed the main survey and 
responded to the dateline of the questionnaire. A need for reminder and follow-up were 
conducted after the IRB concurrence. The pilot study questionnaire provided insight to 
reinforce the message of confidentiality. In the consent statement, the participants were 
informed of their rights to stop their participation at any time. Also, after reading the 
instruction at the beginning of the questionnaires within SurveyMonkey, the participants 
were given a final option to stop their participation. 
Confidentiality 
For both the pilot study and the actual questionnaire, the collected data from all 
electronic questionnaires were received and tabulated with the participant using the 
SurveyMonkey code to assure confidentiality of the responses. Confidentiality follows 
the terms provided by SurveyMonkey for their database used. Any printed information or 
data regarding the names of the participants will be destroyed by incineration, including 
any printed master list. The electronic data files with names in my computer will be 
stored on a DVD and in an external memory device. The electronic devices, DVD and a 
storage memory stick, will be deposited in a bank security box for five years with the list 
of participants and codification matrix. All this data and information will then be erased, 
and the storage devices destroyed to assure no means for data recovery. 
Data Collection Plan 
Data collection is a critical stage in any research study. A data collection plan 
consists of the strategy and instrument to collect information that could dictate the 
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validity, success, and impact of the study (Frankfort-Nachmias & Nachmias, 2008). 
Research data collection should be of having in mind cost effectiveness, confidentiality, 
ethics, and accuracy. As concluded by Ahern (2005), survey applications that are well-
managed and designed through the Internet could provide the expected attributes to some 
degree. Also, effective time management in the collection and verification of sources and 
data could be achieved with the application of the Internet. 
Data collection from participants in this research study required accessibility to a 
sensitive population and assuring a high level of confidentiality. However, opportunities 
for face-to-face interviews with the intended population of pharmaceutical managers 
were very limited due to participants’ accessibility and geographic locations. Mailed 
questionnaires have advantages like reduced biases and strong protection of 
confidentiality, as listed by Frankfort-Nachmias and Nachmias (2008). The challenge was 
to grasp the interest from participants, who have multiple priorities and limited available 
time. 
Managers in this field normally have an assistant who filters the correspondence. 
As a result, the mail survey receives limited response rate. Based in today’s office 
environment in the pharmaceutical industry for the intended population, computer 
accessibility was expected to be high; the typical time navigating and reading e-mails 
most likely be constant on a daily basis; and, the probability of gaining the respondent 
attention was better than by mail or telephone calls. The survey was administered through 
SurveyMonkey. 
94 
 
 
The structure of the electronic survey is complex as explained by Ahern (2005). 
The weaknesses of using electronic surveys are mainly in the area of confidentiality and 
privacy, the authenticity of the respondent, and acquiring rights and permission to quote. 
The introduction to the survey has to be concise while projecting a clear level of 
protection and comfort to the respondent. Despite these challenges, Ahern (2005) 
summarized the benefits of the electronic survey as time management, accessibility to 
sensitive/particular population, easy and comfort to use (user-friendly), and reduces the 
missing data. 
Expected Duration 
The expected duration of the data collection activities, consisting of conducting 
the pilot study and of the actual survey process, was expected to take a total of between 
30 to 40 days. The pilot survey with the opening statement, including the confidentiality 
explanation, was delivered to 21 industry peers. This pilot survey process to gather the 
data took 12 days. The data review and formatting of the final questionnaire lasted 34 
days. The pilot process took a total of 46 days from the first mailing. 
The actual survey execution was expected to last an additional 15 to 20 days. 
Recognizing the need to send a reminder to participants might be beneficial, the projected 
timeline included reminders through SurveyMonkey every 2-3 days up to 10-12 days. 
Due to the low initial partition of the 1144 invitees, the data gathering for the main study 
took 65 days after six reminders including a required second IRB review that lasted 38 
days. The net extent of the actual data gathering process was 27 days. The total research 
lasted 111 days including the pilot study. 
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Data Acquisition 
The data acquisition instruments consisted of the behavioral attitude (TPB) 
questionnaire (management behaviors survey), the change in financial results [financial 
indicators section (i.e. cost of goods and investment in equipment and facilities)], and 
level of compliance with the FDA (compliance observations). A pre-FDA and post-FDA 
survey questionnaire was the vehicle utilized for management attitude (TPB) and 
financial indicators. An e-mail approach was employed to reach the participants. The 
design to the electronic questionnaire was analyzed to ensure an effective data acquisition 
process. The number of questionnaires that were completed, not completed, and wrongly 
completed were tabulated to summarize the actual performance of the electronic survey. 
Some statistics from the Internet survey tool were provided in the data analysis from 
SurveyMonkey. 
Data Analysis Plan 
Several steps were taken to ensure the organization, confidentiality, and meeting 
assumptions of the statistical tests to facilitate the data management process. Morrow 
(2009) suggested specifics on how to manage the data and to address shortfalls, like 
missing data and assumptions’ requirements. The first step was to develop a data 
codebook (SPSS template) to store the data for all the variables and sampling details. The 
database template was created in SPSS from the data transferred from SurveyMonkey. 
The access to my laptop was password-protected to support confidentiality protecting the 
access to the collected data and the SPSS data template. Personal references from 
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participants were cross-coded by SurveyMonkey with reference numbers to enhance 
privacy and confidentiality. 
 The second step consisted of the cleaning of the data per the steps outlined by 
Morrow (2009). Cleaning of the data refers to the process of minimizing biases and 
calculation errors generated by the quality of the obtained data. A step-by-step approach 
was followed by utilizing SPSS guides. 
1. Outliers’ scores were identified to minimize biases and not relevant 
information. Elimination of these outliers was the first task. 
2. Verifying for normality of variables enhanced the review for outliers. 
Achieving a normal distribution around the mean was an expected 
assumption.  
3. Missing data could impact the results of the analysis. The data was reviewed 
to assure that the suggested level of not more than 5% missing data was 
attained. The average of the individual responses was used to fill in the 
missing data. 
4. Transforming the data by means of reversing the Likert-Type scores provided 
alignment and proper assessment of the Cronbach’s alpha to assess the 
reliability of the scales by section or construct of the TPB. 
5. Verifying for multicollinearity was done within the SPSS regression 
application.  
6. The Pearson coefficient was used to assure that the correlations between 
variables were less than 0.8. In the event of a higher value of the correlation, 
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the variables were evaluated by either combining them or eliminating one of 
them. 
7. For homogeneity of regression, SPSS was also used.  
8. Linearity was verified by visually assessing the graphs of the data. 
9.  For the completed-usable responses, the participant had to complete over 
95% of the questions in either the pilot study or the main study including the 
demographics and FDA compliance questions at the end. 
 The application of regression analyses increased the complexity since two TPB 
scenarios pre-FDA and post-FDA interventions were assessed. Maintaining separation of 
the data for the two scenarios within the SPSS template was important. The number of 
the questions within SurveyMonkey provided the vehicle to maintain the separation of 
the data for the two TPB scenarios pre-FDA and post-FDA interventions. The application 
of SPSS for the statistical analyses and all the corresponding assumptions of regression 
analyses was utilized for both scenarios pre-FDA and post-FDA interventions. 
Hypotheses Testing Plan 
The two predictors used in this study were management behaviors and financial 
indicators. The three sets of hypotheses related to these predictors were listed below. The 
outcome variable was the level of compliance with the FDA regulations. 
 Correlations between management behaviors (independent) and compliance 
(dependent): 
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H1₀:  r = 0. There is no difference in management behaviors towards 
compliance at pharmaceutical firms, as a result of FDA enforcement actions 
in the U.S. 
H1₁:  r ≠ 0. There are differences in management behaviors towards 
compliance at pharmaceutical firms, as a result of FDA enforcement actions 
in the U.S. 
The null hypothesis, H1₀, implies that the value of the correlation coefficient is 
zero, r = 0 indicating that there is no correlation or way to predict compliance from 
management behaviors. The alternate hypothesis, H1₁, considering a two-tailed 
distribution, is r ≠ 0 or r <> 0 indicating that there is a correlation or way to predict 
compliance from management behavior. The significance level to test the hypotheses had 
a value for α of .05%. The number of unique correlations in the correlation matrix were 
based on the three constructs in the TPB questionnaire.  
 Correlations between financial indicators (independent) and compliance 
(dependent): 
H2₀:  r = 0. There is no difference in compliance with FDA related to 
financial indicators at pharmaceutical firms, as a result of FDA enforcement 
actions in the U.S. 
H2₁:  r ≠ 0. There are differences in compliance with FDA related to 
financial indicators before and after the FDA intervention. 
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The null hypothesis, H2₀, indicates the value of the correlation coefficient is zero, 
r = 0 indicating that there is no correlation or way to predict compliance from the seven 
financial indicators. The alternate hypothesis, H2₁, considering a two-tailed distribution, 
is r ≠ 0 or r <> 0 indicating that there is a correlation or way to predict compliance from 
the seven financial indicators. The significance level to test the hypotheses had a value 
for α of .05%. The number of unique correlations in the correlation matrix were based on 
the seven financial indicators.  
 Financial indicators (independent) impact on compliance (dependent): 
H3₀:  β₁ = β₂ = … = β7 = 0. There is no impact in compliance with FDA 
related to seven financial indicators at pharmaceutical firms, as a result of 
FDA enforcement actions in the United States. 
H3₁:  At least one β ≠ 0. There is an impact in compliance with FDA related 
to at least one of the seven financial indicators before and after the FDA 
enforcement actions in the United States. 
 The seven financial indicators for the test of Hypothesis 3 were the cost of goods, 
investment in facility and equipment, process compliance, sales, revenues, market value, 
and stockholder’s equity. SPSS was used to generate the models. The βs in Hypothesis 3 
were the regression coefficients of the following multiple regression equation: 
0 1 1 2 2 3 3 4 4 5 5 6 6 7 7Y X X X X X X X                        (3) 
Where,  
Y= FDA related compliance 
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X1 = Cost of goods 
X2 = Investment 
X3 = Process compliance 
X4 = Change in sales 
X5 = Change in revenues 
X6 = Change in market value of the firms 
X7 = Change in stockholders equity 
ԑ   = Error of the regression 
 For the TPB data and financial indicators in Likert-type scales, aggregate 
comparison, factor analysis and Cronbach’s alpha were utilized. For the regression 
analyses, the standard linear regression in SPSS was the approach assessing the models. 
ANOVA, t testing, Durbin-Watson statistics, and collinearity statistics were statistical 
methods that were applied through SPSS for this study. Durbin-Watson supported the 
independent assumption. Collinearity statistics provided, through variance inflation factor 
(VIF) and tolerance, the support to indicate if the assumption was met or not. 
Summary 
Chapter 3 discussed and described the research method and design. The selection 
of the quantitative methodology for the study was discussed.  The sampling plans were 
discussed for both the pilot study and the main study.  The validity and reliability of the 
survey instrument were described, and the relation to the variables of the study discussed. 
The intended population was further defined by the information from the FDA. The size 
of the sampling units (participants) determination was assessed by three mechanisms.  
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ISPE member’s database was indicated as the source of the participants meeting the 
criteria for selection. The steps to ensure confidentiality and protection of the participants 
were enumerated. Plan for data collection and data analysis to address the research 
questions were described including the statistical approach. 
Chapter 4 presents the results of the pilot and the main study. Discussion on the 
pilot study is used to facilitate key concepts to support the three construct of the TPB for 
the design of the final questionnaire. The application of three correlations between the 
three construct of the theory of planned behavior and the FDA compliance addresses 
RQ1. Analyses through correlations and linear regressions of seven financial indicators 
provide the insight to the assess RQ2 and RQ3. The findings and the resulting null testing 
are presented. 
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Chapter 4: Results  
 This quantitative study sought to learn to what extent, if any, management 
behaviors and financial pressures at pharmaceutical firms correlated with or predicted 
compliance with the FDA regulations avoiding interruptions in the supply of some 
essential patented or generic pharmaceutical drugs in the U.S. From the review of the 
literature, the gap consisted on the limited available research providing awareness and 
guidance to managers in their decision and their risk assessment process, regarding their 
FDA compliance responsibility, corporate financial mandate, and stakeholders’ 
expectations. This research was driven by the limited information on what were the 
interdependencies or correlations between the need to grow revenue and the intent to 
behave within the senior management decision process 
 The behavior by management, related to the quality of drugs to meet their 
intended quality, integrity, strength, and purity influences the level of compliance of the 
firms’ operations. The pressures of enhancing productivity, funding research, supporting 
marketing plans, and reducing the cost of goods also influences the firms’ compliance 
performance. The application of enforcement actions by the FDA on the firms was used 
as the treatment event to reestablish the expected level of compliance. A shift in the 
relationship between the variables was expected after the FDA intervention, highlighting 
the new level of compliance. 
 The independent variables that could lead to enforcement actions by the FDA 
were set as management behaviors of the pharmaceutical managers and the firms’ 
financial indicators. The treatment event was the application of the enforcement action by 
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the FDA. The level of compliance of the pharmaceutical companies was the dependent 
variable. In the study, the conditions before the FDA intervention in the pharmaceutical 
firms were compared to the post-conditions after the FDA intervention to predict 
compliance with the CGMP regulations. The research questions were formulated on three 
foci: 
 Correlations between management behaviors (independent) and compliance 
(dependent) 
 Correlations between financial indicators (independent) and compliance 
(dependent): 
 Financial indicators (independent) impact on compliance (dependent). 
 Research questions were answered based on the null hypotheses testing in 
Chapter 4. Despite the low rate of participation in the main study, the null hypotheses 
were rejected. For RQ1, the theory of planned behavior (Ajzen, 1991) was applied. The 
three behavioral constructs led to the execution of three correlations with the outcome of 
compliance with FDA regulations. For RQ2, seven correlations were conducted between 
the selected financial indicators and the outcome of compliance. For RQ3, some of the 
assumptions for the regression equations were not met avoiding any generalization from 
the models.  
 Chapter 4 contains the data collected and the results of the pilot study and the 
main study questionnaire. The pilot study elements like population, data collection, and 
feedback are presented. The outcome and impact of the pilot study on the final 
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questionnaire are discussed. Regarding the final study questionnaire, the data collection 
process, the length of the study, the IRB approvals, and the limited participation are 
presented.  
Pilot Study 
 A pilot study was conducted to examine clarity of survey questions, to collect 
feedback on the questionnaire’s structure, and to identify essential beliefs that were used 
in the Likert-type scales. Ajzen (2002) indicated that a pre-work was required to define 
the behaviors of interest for the proper design of the TPB survey instrument. Through the 
pilot study, I identified essential management behaviors towards compliance with FDA 
regulations. These management behaviors were incorporated into the Likert-type 
questions suggested by Ajzen (2016) for the main survey questionnaire. The pilot study 
also collected feedback about financial indicators of the pharmaceutical firms. 
Demographics of participants, the degree of compliance, and the type of FDA 
interventions were requested in the pilot survey instrument.  
 The pilot study questionnaire confirmed the effectiveness and completeness of the 
order of the sections. The structure of the pilot questionnaire consisted of four sections. 
The first and second sections related to the TPB initial assessment of attitudes, social 
influences, and perceived behavioral controls. This section tested the clarity of the Likert-
type questions and the open-ended questions to identify attributes of attitudes, social 
influences, and controls to finalize the main study questionnaire as indicated by Ajzen 
(2002). Also, the first two sections included a table to collect financial results of the firms 
before and after the FDA intervention or action. The intent was to identify information 
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before and after an FDA intervention in the firms. The third section consisted of the 
demographics questions. Finally, the fourth section pursued clarification on the outcome 
of any FDA interventions or actions in the firms in the past five-six years.  
 The instructions for pilot study questionnaire in SurveyMonkey included an initial 
question to allow the participant to proceed or stop their participation after reading the 
instructions to the questionnaire. This question ensured the voluntary participation of the 
person highlighting the understanding of the level of confidentiality and the positive 
social benefit if participating in the study. The instructions were part of the 
SurveyMonkey questionnaire. The number of questions in the pilot study questionnaire 
were 44. The questions consisted of Likert-type scales, open-ended questions, and tables 
to select responses. 
Pilot Study Population   
 The pilot study participants, to qualify as a participant, had to comply with the 
same participants’ criteria that applied to the main study. Participants were selected from 
executives and operational management levels who had the authority to make compliance 
and financial decisions within pharmaceutical firms. The pilot study participants’ 
selection process was based on convenience sampling from individuals known to me. The 
number of participants invited to the pilot study was 21.  
 The need to ensure sufficient and reliable replies from the pilot study required 
recruiting participants who provide useful feedback within 14 days. The pilot survey 
commenced on January 5, 2016, and was closed on January 17, 2016. 
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 From the 21 invitations sent by using SurveyMonkey, 20 of the invitations were 
opened by the intended participants and one was not opened. Of the 20 invitations that 
were opened to read the consent form, 13 participants accepted the consent form and 
proceeded to the survey. After reading the instruction, nine of the 13 participants 
accepted to proceed to the questionnaire and five did not initiate the survey. The 
participation results attained eight completed surveys and one partial-completed survey. 
The eight completed surveys provided a response rate of 38%. The eight responses to the 
pilot study represented about 5% of the initially targeted usable responses of 160 for the 
main study.  
Pilot Study Data Collection 
 The pilot study was conducted similarly to the same intended instrument for the 
main study. The pilot study was administered through SurveyMonkey, an electronic 
survey tool chosen to collect data and facilitate analysis. Trust and desire to participate 
was pursued by an initial e-mail sent to the selected 21 invitees to the pilot study. Then, a 
consent form for participation was sent via SurveyMonkey as approved by the Walden 
University’s IRB.  
 The pilot study also provided feedback on the effectiveness and completeness 
related to the message of confidentiality. Of the 21 SurveyMonkey invitations sent, 20 
invitations were opened, 13 accepted the consent from, but five participants decided not 
to participate in the survey after reading the instructions. The consent form with the 
questionnaire instructions provided adequate space for the participants to voluntarily 
decide if they would participate or not. With the 38% rate of participation in the pilot 
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study, the participation in the main study was expected to reach the initial target of 160 
completed questionnaires out of about 1144 invitations with a projected rate of 
participation of about 15%.  
Pilot Study Demographics 
 The demographics of the pilot study indicated a reasonable representation of the 
role of responsibility and area of expertise. The demographics questions where located at 
the end of the pilot study. Appendix E shows the percentage distribution of the relevant 
demographics. The decisions makers’ titles indicated the participation of directors, vice-
presidents, and one executive. The educational level included bachelors and doctorate 
degrees. The functional areas within the pharmaceutical firms represented covered 
quality, manufacturing, and others like technical services. The demographics of the pilot 
study’s participants ensured a representative source of essential management behaviors 
that were incorporated to the Likert-type scaled of the final questionnaire.  
Pilot Study Data Treatment  
 The collected data in the pilot study was initially assessed via the results review 
section through SurveyMonkey. Then, the data was transferred to an Excel template to 
facilitate the assessment of the open-ended questions to identify management behaviors 
related to decision makers through the frequency of words appearance in the responses. 
The open-ended questions led to essential concepts to support the three constructs in the 
main study regarding TPB Likert-type questions. The collected data was also transferred 
to an SPSS data table to facilitate the intended statistical assessments for correlations and 
regression analyses. 
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Pilot Study Data Analysis  
 The data analysis consisted on how to manage the data while addressing 
shortfalls, like missing data and assumptions’ requirements. The first step was to develop 
a data codebook (SPSS template) to store the data for all the variables and sampling 
details. The database template was created in SPSS from the data transferred from 
SurveyMonkey. The access to my laptop was password-protected to support 
confidentiality by protecting the access to the collected data and the SPSS data template. 
There was no need to cross-code any personal references from participants since the 
collected data from SurveyMonkey provided reference numbers to enhance privacy and 
confidentiality of the participants 
 The second step consisted of the cleaning of the data per the steps outlined by 
Morrow (2009). Cleaning of the data refers to the process of minimizing biases and 
calculation errors generated by the quality of the obtained data. A step-by-step approach 
was followed when using SPSS analysis. 
1. Outliers’ scores were initially assessed with the intent to apply Windsorizing. 
None of the Likert-type scores or financial data tables from the pilot study nor 
the main study required to apply Windsorizing approach. In the SPSS 
analysis, for just caution and only when requested a 2 sigma was applied. 
2. Verifying for normality of variables enhanced the review for outliers. SPSS 
Explore function was applied to identify if normal distribution assumption 
was met.  
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3. Transforming the data by means of reversing the Likert-Type scores provided 
alignment and proper assessment of the Cronbach’s alpha to understand the 
reliability of the scales. 
4. The data was reviewed for each variable’s Likert-type questions in the SPSS 
template to ensure that the suggested level of not more than 5% missing data 
was present. If needed for less than 5% of the data, the estimated average of 
the data was used to fill in the missing data. 
5. For completed-usable responses, the participant had to complete over 95% of 
the questions in either the pilot study or the main study including the 
demographics and FDA compliance questions at the end. 
6. For partial responses, an organized approached was implemented. This 
approach consisted in the separation of the collected data in the SPSS template 
by each of the two scenarios: pre-FDA and post-FDA interventions. This 
process allowed to consider those responses that only addressed the pre-FDA 
scenario, but the participants decided not to continue to complete the 
remainder of the questions. 
7. Transforming the data by means of reversing the Likert-Type scores provided 
alignment and proper assessment of the Cronbach’s Alpha to assess the 
reliability of the scales by section or construct of the TPB. 
8. For the correlation analyses, Pearson and Kendal coefficients were conducted. 
9. Verifying for multicollinearity was done within the SPSS application. The 
Pearson coefficient was used. In the event of a higher value than .8 of the 
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correlation values, the variables were evaluated by either combining them or 
eliminating one of them.  
10. For homogeneity of regression, SPSS was used. 
11. Linearity was initially verified by visually assessing the graphs of the data. 
 The application of regression analysis increased the complexity since two 
scenarios pre-FDA and post-FDA interventions were assessed. Maintaining separation of 
the data for the two scenarios within the SPSS template was important. The number of 
the questions within SurveyMonkey provided the vehicle to maintain the separation of 
the data for the two TPB scenarios pre-FDA and post-FDA interventions. The application 
of SPSS for the statistical analyses and all the corresponding assumptions of regression 
analyses were considered in each scenario: pre- and post-FDA intervention. 
 Open-ended questions. An assessment of the eight open-ended questions was 
conducted. All the eight responses were read and assessed for common words and time 
repeated by the respondents. The responses were tabulated in an Excel table to tabulate 
frequency and categories related to the three construct of the TPB. The responses were 
anonymous since SurveyMonkey maintained the names of the participants not linked to 
the responses, as selected by me during the formulation of the questionnaire. 
SurveyMonkey provided confirmation of the word frequency. The high frequently used 
words were similar in my tabulation and in the SurveyMonkey’s output. 
 The selected words and topics from the open-ended questions provided the pre-
work indicated by Ajzen (2002) to define the behaviors and constructs of interest for the 
suitable design of the TPB main survey instrument. By applying the words and topics to 
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the three constructs of the beliefs (attitudes), normative, and perceived behavioral control 
sections of the TPB questionnaire by Ajzen (2016), the Likert-type questions were 
modified providing the expected questionnaire structure for the main study.  
 Through the pilot study, the identified words and topics highlighted relationships, 
attitudes, and perceived controls to be asked in the main study. In the formulation of the 
Likert-type questions, I focused on management attitudes, motivation factors, peer 
influences, and behavioral controls towards compliance with FDA regulations. The 
questions were formulated to enhance the before and after scenarios regarding an FDA 
intervention or action. These constructs were incorporated into the Likert-type questions 
suggested by Ajzen (2016) for the final questionnaire. This process led to a significant 
increase in the number of Likert-type questions in the final questionnaire from 44 to 133 
questions. 
 Assessment of Likert-type questions. Likert-type scales were used to assess 
constructs of the TPB liked beliefs (attitudes), normative beliefs, and perceived 
behavioral controls. To attain an internally consistent scale, the approach to obtain the 
Discriminative Power (Frankfort-Nachmias & Nachmias, 2008) for the pilot study was 
considered. Because there were only eight questions covering the TPB constructs for the 
pilot study, the applicability of the Discriminative Power was considered not adequate to 
challenge the internal consistency of the Likert-type scales. 
The pilot study’s Likert-type scales were directed to demonstrate the adequacy of 
the TPB approach to develop the main study questionnaire. Table 4 presents the 
constructs, the variables, and the corresponding means and standard deviations 
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corresponding to pre-FDA intervention. The means are skewed towards the high side of 
the range of 1 to 7. The standards deviations could be considered homogenous except for 
q0007_0001 whose standard deviation was above 2.00 while all other values were below 
1.30. 
Table 4 
Pre-FDA Intervention 
TPB 
Constructs 
Variable Name SPSS 
Name 
Mean Standard 
Deviations 
Attitudes My compliance with CGMP regulations before the 
last FDA intervention was 
Q0002_
0001 
6.00 1.118 
  
My compliance with CGMP regulations before the 
last FDA made me feel 
 
Q0003_
0001 
 
5.89 
 
1.269 
     
Perceived  
Norms 
Most people who are important to me approve me 
being in compliance with CGMP regulations before 
the last FDA intervention 
Q0004_
0001 
6.44 0.726 
  
Most people likes me being in compliance with 
CGMP regulations before the last FDA intervention 
 
Q0005_
0001 
 
6.44 
 
0.726 
     
Perceived 
Behavioral 
Controls 
I was confident that I was in compliance with 
CGMP regulations before the last FDA intervention 
Q0006_
0001 
5.89 1.167 
 Being in compliance with CGMP regulations 
before the FDA intervention was up to me 
Q0007_
0001 
5.00 2.345 
     
Intention I intended to be in compliance with CGMP 
regulations before the last FDA intervention 
Q0008_
0001 
7.00 0.000 
     
Previous 
Behavior 
Prior to the last FDA intervention I have being in 
compliance with CGMP regulations 
Q0009_
0001 
6.33 1.000 
  
 Table 5 presents the constructs, the variables, and the corresponding means and 
standard deviations corresponding to post-FDA intervention. The means are skewed 
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towards the high side of the range of 1 to 7. All the standards deviations could be 
considered homogenous which is different from the pre-FDA intervention. 
Table 5 
Post-FDA Intervention 
TPB 
Constructs 
Variable Name SPSS 
Name 
Mean Standard 
Deviations 
Attitudes My compliance with CGMP regulations after the 
last FDA intervention was 
Q0022_
0001 
6.50 0.756 
  
My compliance with CGMP regulations after the 
last FDA made me feel 
 
Q0023_
0001 
 
6.00 
 
1.773 
     
Perceived  
Norms 
Most people who are important to me approve me 
being in compliance with CGMP regulations after 
the last FDA intervention 
Q0024_
0001 
6.25 1.165 
  
Most people likes me being in compliance with 
CGMP regulations after the last FDA intervention 
 
Q0025_
0001 
 
6.63 
 
0.744 
     
Perceived 
Behavioral 
Controls 
I was confident that I was in compliance with 
CGMP regulations after the last FDA intervention 
Q0026_
0001 
6.38 0.774 
 Being in compliance with CGMP regulations after 
the FDA intervention was up to me 
Q0027_
0001 
4.88 1.885 
     
Intention I intended to be in compliance with CGMP 
regulations after the last FDA intervention 
Q0028_
0001 
6.75 0.463 
     
Previous 
Behavior 
Prior to the last FDA intervention I have being in 
compliance with CGMP regulations 
Q0029_
0001 
6.63 0.518 
 
 Initially, Pearson’s coefficient was utilized to understand the internal consistency 
of the Likert-type scales by establishing how close the different elements of the scales are 
to each other. Also, the correlation between each subset of the construct was obtained and 
listed to establish the dependencies within each construct. Table 6 presents the Pearson 
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correlation for the TPB constructs for the pre-FDA intervention in the pilot study. The 
question q0009-0001, regarding perceived behavioral control, had non-significant 
correlations with any other variables with p values from 0.443 to 0.903. Also, question 
q0005-0001 regarding influence from or by peers was non-significant with the participant 
beliefs and attitudes (q0003-001) towards compliance with r = 0.602, p = 0.086.  
Table 6 
Pearson’s Correlation pre-FDA Intervention 
 
q0002_
0001 
q0003_
0001 
q0004_
0001 
q0005_
0001 
q0006_
0001 
q0007_
0001 
q0008_
0001 
q0009_
0001 
q0002_
0001 
Pearson Correlation 1 .881** .923** .769* .767* -.048 .c .894** 
Sig. (2-tailed)  .002 .000 .015 .016 .903 . .001 
N 9 9 9 9 9 9 9 9 
q0003_
0001 
Pearson Correlation .881** 1 .874** .602 .750* .168 .c .919** 
Sig. (2-tailed) .002  .002 .086 .020 .666 . .000 
q0004_
0001 
Pearson Correlation .923** .874** 1 .763* .803** .073 .c .975** 
Sig. (2-tailed) .000 .002  .017 .009 .851 . .000 
q0005_
0001 
Pearson Correlation .769* .602 .763* 1 .803** -.293 .c .631 
Sig. (2-tailed) .015 .086 .017  .009 .443 . .068 
q0006_
0001 
Pearson Correlation .767* .750* .803** .803** 1 .091 .c .786* 
Sig. (2-tailed) .016 .020 .009 .009  .815 . .012 
q0007_
0001 
Pearson Correlation -.048 .168 .073 -.293 .091 1 .c .213 
Sig. (2-tailed) .903 .666 .851 .443 .815  . .582 
q0008_
0001 
Pearson Correlation .c .c .c .c .c .c .c .c 
Sig. (2-tailed) . . . . . .  . 
q0009_
0001 
Pearson Correlation .894** .919** .975** .631 .786* .213 .c 1 
Sig. (2-tailed) .001 .000 .000 .068 .012 .582 .  
**. Correlation is significant at the 0.01 level (2-tailed).  
*. Correlation is significant at the 0.05 level (2-tailed). 
c. Cannot be computed because at least one of the variables is constant. 
 
 Table 7 presents the Pearson’s correlation for the TPB constructs for the post-
FDA intervention in the pilot study. The question q0027-0001, regarding perceived 
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behavioral control, had non-significant correlations with all other variables with p values 
from 0.522 to 0.909. In the post-FDA, all variables had at least one Pearson’s correlation 
that was non-significant.  
Table 7 
Pearson’s Correlation post-FDA Intervention 
 
q0022_
0001 
q0023_
0001 
q0024_
0001 
q0025
_0001 
q0026
_0001 
q0027_
0001 
q0028_
0001 
q0029_
0001 
q0022_
0001 
Pearson Correlation 1 .640 .324 .889** .889** .050 .816* .913**
Sig. (2-tailed)  .088 .433 .003 .003 .906 .013 .002
N 8 8 8 8 8 8 8 8
q0023_
0001 
Pearson Correlation .640 1 .208 .650 .542 -.171 .870** .778*
Sig. (2-tailed) .088 .622 .081 .166 .686 .005 .023
q0024_
0001 
Pearson Correlation .324 .208 1 .453 .700 -.049 .397 .178
Sig. (2-tailed) .433 .622 .259 .053 .909 .330 .674
q0025_
0001 
Pearson Correlation .889** .650 .453 1 .806* .267 .933** .696
Sig. (2-tailed) .003 .081 .259 .016 .522 .001 .055
q0026_
0001 
Pearson Correlation .889** .542 .700 .806* 1 -.064 .726* .788*
Sig. (2-tailed) .003 .166 .053 .016 .881 .041 .020
q0027_
0001 
Pearson Correlation .050 -.171 -.049 .267 -.064 1 .123 -.201
Sig. (2-tailed) .906 .686 .909 .522 .881 .772 .633
q0028_
0001 
Pearson Correlation .816* .870** .397 .933** .726* .123 1 .745*
Sig. (2-tailed) .013 .005 .330 .001 .041 .772 .034
q0029_
0001 
Pearson Correlation .913** .778* .178 .696 .788* -.201 .745* 1
Sig. (2-tailed) .002 .023 .674 .055 .020 .633 .034 
**. Correlation is significant at the 0.01 level (2-tailed).    *. Correlation is significant at the 0.05 level 
(2-tailed). 
 
 Considering the small number of participants, skewness and kurtosis were used to 
assess the distribution of the variables. In the scenario of pre-FDA intervention, the 
skewness results were all negative indicating that there was a cluster at the higher end of 
the scales (Field, 2009). Kurtosis was used to measure the degree to which scores cluster 
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in the tails of a frequency distribution. Kurtosis’ values were both positive and negative. 
Positive kurtosis values indicate that the distribution tends to peak at the tails due to the 
high number of scores in the tail. Negative kurtosis values signal few scores in the tails 
and a flat distribution (Field, 2009). In the scenario of post-FDA intervention, the 
skewness results were also all negative indicating that there was a cluster at the higher 
end of the scales (Field, 2009). The kurtosis’ values were also both positive and negative. 
 The non-normal distribution in six out of seven distributions was significant as 
confirmed by using Kolmogorov-Smirnov and Shapiro-Wilk in SPSS. Table 8 shows the 
results of the Kolmogorov-Smirnov and Shapiro-Wilk tests for the pre-FDA intervention. 
For the post-FDA intervention in Table 9, the results for Kolmogorov-Smirnov and 
Shapiro-Wilk tests are illustrated. In a similar manner, the non-normality is confirmed 
with seven of eight variables being significant. 
Table 8 
Test of Normalityb pre-FDA Intervention 
 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
q0002_0001 .259 9 .083 .844 9 .065 
q0003_0001 .313 9 .011 .795 9 .018 
q0004_0001 .333 9 .005 .763 9 .008 
q0005_0001 .333 9 .005 .763 9 .008 
q0006_0001 .316 9 .010 .792 9 .017 
q0007_0001 .248 9 .119 .827 9 .042 
q0009_0001 .303 9 .017 .710 9 .002 
a. Lilliefors Significance Correction        b. q0008_0001 is constant. It has been omitted. 
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Table 9 
Test of Normality post-FDA Intervention 
 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
q0022_0001 .371 8 .002 .724 8 .004 
q0023_0001 .339 8 .007 .668 8 .001 
q0024_0001 .365 8 .002 .724 8 .004 
q0025_0001 .443 8 .000 .601 8 .000 
q0026_0001 .300 8 .033 .798 8 .027 
q0027_0001 .225 8 .200* .908 8 .343 
q0028_0001 .455 8 .000 .566 8 .000 
q0029_0001 .391 8 .001 .641 8 .000 
*. This is a lower bound of the true significance. a. Lilliefors Significance Correction 
 
The distribution of the scores was skewed or non-normal in most cases. The 
results of Kolmogorov-Smirnov and Shapiro-Wilk tests indicated the non-normality of 
the data. Kendall’s correlation coefficient, τ, was used to understand the correlation 
between the variables. Kendall’s Tau is a non-parametric measure that also applies to a 
small number of scores that rank in a similar manner.  
 Despite the non-normal characteristics of the variables, Kendall Tau correlation 
results confirmed the observation from the Pearson’s correlation coefficients for the pre-
FDA intervention. Question q0007-0001, regarding perceived behavioral control, had 
non-significant correlations with any other variables with p values from 0.456 to 0.906. 
However, the correlations were all negative when compared to the Pearson’ coefficients. 
All other Kendall’s Tau correlations were significant including participant believes and 
attitudes (q0005-001) for the pre-FDA intervention. In the case of the post-FDA scenario, 
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Kendall’s Tau correlations maintained the same direction of the Pearson correlation and 
also signaled q0027-0001 with non-significant correlations with all other variables. Table 
10 and Table 11 present Kendall’s correlation coefficient, τ, for both the pre-FDA and 
post-FDA interventions, respectively. 
Table 10 
Kendall’s Correlation pre-FDA Intervention 
                         Kendall's tau 
q0002_
0001 
q0003
_0001 
q0004_
0001 
q0005_
0001 
q0006
_0001 
q0007_
0001 
q0008
_0001 
q0009
_0001 
q0002_
0001 
 
Correlation Coefficient 1.000 .837** .867** .749* .593 -.105 . .867** 
Sig. (2-tailed) . .006 .006 .018 .056 .726 . .006 
N 9 9 9 9 9 9 9 9 
q0003_
0001 
Correlation Coefficient .837** 1.000 .762* .682* .453 -.107 . .762* 
Sig. (2-tailed) .006 . .017 .032 .149 .724 . .017 
q0004_
0001 
Correlation Coefficient .867** .762* 1.000 .826* .736* -.039 . 1.000** 
Sig. (2-tailed) .006 .017 . .012 .023 .901 . . 
q0005_
0001 
Correlation Coefficient .749* .682* .826* 1.000 .736* -.232 . .826* 
Sig. (2-tailed) .018 .032 .012 . .023 .456 . .012 
q0006_
0001 
Correlation Coefficient .593 .453 .736* .736* 1.000 -.036 . .736* 
Sig. (2-tailed) .056 .149 .023 .023 . .906 . .023 
q0007_
0001 
Correlation Coefficient -.105 -.107 -.039 -.232 -.036 1.000 . -.039 
Sig. (2-tailed) .726 .724 .901 .456 .906 . . .901 
q0008_
0001 
Correlation Coefficient . . . . . . . . 
Sig. (2-tailed) . . . . . . . . 
q0009_
0001 
Correlation Coefficient .867** .762* 1.000** .826* .736* -.039 . 1.000 
Sig. (2-tailed) .006 .017 . .012 .023 .901 . . 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
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Table 11 
Kendall’s correlation post-FDA Intervention 
                              Kendall's tau                         
q0022
_0001 
q0023
_0001 
q0024
_0001 
q0025
_0001 
q0026
_0001 
q0027
_0001 
q0028
_0001 
q0029
_0001 
 q0022_
0001 
Correlation Coefficient 1.000 .857* .400 .807* .835* -.049 .770* .939** 
Sig. (2-tailed) . .013 .244 .022 .017 .883 .034 .010 
N 8 8 8 8 8 8 8 8 
q0023_
0001 
Correlation Coefficient .857* 1.000 .333 .719* .703* -.094 .816* .913* 
Sig. (2-tailed) .013 . .322 .038 .040 .770 .022 .010 
q0024_
0001 
Correlation Coefficient .400 .333 1.000 .588 .703* .047 .544 .304 
Sig. (2-tailed) .244 .322 . .089 .040 .884 .127 .393 
q0025_
0001 
Correlation Coefficient .807* .719* .588 1.000 .700* .222 .961** .716 
Sig. (2-tailed) .022 .038 .089 . .047 .503 .009 .051 
q0026_
0001 
Correlation Coefficient .835* .703* .703* .700* 1.000 -.092 .662 .770* 
Sig. (2-tailed) .017 .040 .040 .047 . .779 .068 .034 
q0027_
0001 
Correlation Coefficient -.049 -.094 .047 .222 -.092 1.000 .173 -.155 
Sig. (2-tailed) .883 .770 .884 .503 .779 . .611 .649 
q0028_
0001 
Correlation Coefficient .770* .816* .544 .961** .662 .173 1.000 .745* 
Sig. (2-tailed) .034 .022 .127 .009 .068 .611 . .049 
q0029_
0001 
Correlation Coefficient .939** .913* .304 .716 .770* -.155 .745* 1.000 
Sig. (2-tailed) .010 .010 .393 .051 .034 .649 .049 . 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
 Analysis of Cronbach's alpha to determine the reliability of the scales from the 
pilot study questionnaire was conducted for both scenarios: pre-FDA and post-FDA 
interventions. The data was analyzed by applying SPSS and by using Field (2009) as a 
reference. Cronbach's alpha is not a validity measure. The values for Cronbach’s alpha 
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range from 0 to 1. Cronbach’s alpha provides the means to assess if a given scale item 
impacts the overall total subscale reliability. Reversing the phrasing of a negative scale 
item improved the Cronbach’s values. For the pre-FDA scenario in Table 12, the 
Cronbach’s alpha was .800 which infers good reliability. For the post-FDA intervention, 
Table 13 presented a Cronbach’s alpha with a value of .726. 
Table 12 
Cronbach’s alpha pre-FDA Intervention 
Cronbach's alpha 
Cronbach's alpha Based on 
Standardized Items N of Items 
.800 .909 7 
 
Table 13 
Cronbach’s alpha pre-FDA Intervention 
Cronbach's alpha 
Cronbach's alpha Based on 
Standardized Items N of Items 
.726 .887 8 
  
 Table 14 presented the SPSS function to identify the effect of the Cronbach’s 
alpha if a given item was deleted for the pre-FDA scenario. The values in the last column 
in Table 14 have a range from .714 to .953. The question q0007_0001, if removed, could 
have a significant favorable impact in the overall Cronbach’s alpha from .800 to .953. 
Also, in Table 14, all values for Corrected Item-Total Correlation represented the 
correlations between each item and the total score. These correlation values need to be at 
or above 0.3, as per Field (2009). In this subscale, all values are over 0.3 except for 
q0007_0001. In the event of any value below 0.3, the item should be assessed, including 
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being eliminated. Item q0007_0001 represented the concept that the person has no 
perceived control in complying with the FDA regulations in the pre-FDA intervention.  
Table 14 
Cronbach’s Adjustments pre-FDA Intervention 
 
Scale Mean if 
Item Deleted 
Scale Variance if 
Item Deleted 
Corrected Item-
Total Correlation 
Squared Multiple 
Correlation 
Cronbach's alpha 
if Item Deleted 
q0002_
0001 
36.0000 27.250 .771 .904 .736 
q0003_
0001 
36.1111 25.111 .847 .957 .714 
q0004_
0001 
35.5556 30.028 .872 .998 .750 
q0005_
0001 
35.5556 32.528 .536 .982 .785 
q0006_
0001 
36.1111 26.861 .767 .939 .735 
q0007_
0001 
37.0000 30.500 .058 .500 .953 
q0009_
0001 
35.6667 27.000 .914 .998 .721 
 
 Table 15 presented the SPSS function to identify the effect of the Cronbach’s 
alpha if a given item was deleted for the post-FDA scenario. The values in the last 
column in Table 15 have a range from .649 to .859. The question q0027_0001, if 
removed, could have a significant favorable impact in the overall Cronbach’s alpha from 
.726 to .859. Also in Table 15, all values for Corrected Item-Total Correlation 
represented the correlations between each item and the total score. These correlation 
values need to be at or above 0.3, as per Field (2009). In this subscale, all values are over 
0.3 except for q0027_0001. In the event of any value below 0.3, the item should be 
assessed, including being eliminated. Item q0027_0001 represented the concept that the 
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person has no perceived control in complying with the FDA regulations in the post-FDA 
intervention. 
Table 15 
Cronbach’s adjustments post-FDA Intervention 
 
Scale Mean if Item 
Deleted 
Scale Variance if 
Item Deleted 
Corrected Item-Total 
Correlation 
Cronbach's alpha if 
Item Deleted 
q0022_0
001 
43.5000 21.714 .811 .649 
q0023_0
001 
44.0000 17.429 .502 .693 
q0024_0
001 
43.7500 22.786 .347 .713 
q0025_0
001 
43.3750 21.125 .924 .633 
q0026_0
001 
43.6250 21.982 .783 .654 
q0027_0
001 
45.1250 25.268 -.043 .859 
q0028_0
001 
43.2500 23.643 .920 .673 
q0029_0
001 
43.3750 24.268 .679 .688 
 
 Financial Indicators. The pilot study collected information regarding the 
financial indicators of the firms. For comparison, the indicators prior and after the FDA 
intervention or action were requested to the best recollection of the participants. The 
requested information focused on the elements of decreased, no change, and increased. 
The tables in the pilot study requesting the financial information scaled the responses to 
ensure clarity on the responses. 
 The responses were collected from seven participants. The overall averages were 
calculated to allow initial assessment of the clarity of the tables. Table 16 and Table 17 
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below presents the averages of the responses. The averages projected the trend between 
the prior and after the FDA intervention and actions. 
Table 16 
Before FDA: Financial Indicators 
FNANCIAL OPERATING INDICATORS Decreased No change Increased 
COGS 14.3% 28.6% 57.1% 
Investment (Facility & Equipment) 42.9% 28.6% 28.6% 
Process compliance 28.6% 14.3% 57.1% 
Sales 14.3% 42.9% 57.1% 
Revenues 14.3% 28.6% 57.1% 
Averages 22.9% 28.6% 51.4% 
 
FINANCIAL INDICATORS Decreased No change Increased 
Actual sales (end of year prior to FDA) 0.0% 28.6% 57.1% 
Actual revenues (end of year prior to FDA) 0.0% 28.6% 57.1% 
Market values (end of year prior to FDA) 0.0% 28.6% 42.9% 
Stockholder's equity (end of year prior to FDA) 0.0% 28.6% 57.1% 
Averages 0.0% 28.6% 53.6% 
 
Table 17 
After FDA: Financial Indicators 
FINANCIAL OPERATING INDICATORS Decreased No change Increased 
COGS 14.3% 28.6% 57.1% 
Investment (Facility & Equipment) 0.0% 0.0% 85.7% 
Process compliance 0.0% 0.0% 85.7% 
Sales 14.3% 28.6% 57.1% 
Revenues 14.3% 28.6% 57.1% 
Averages 8.6% 17.1% 68.6% 
 
FINANCIAL INDICATORS   Decreased   No change      Increased 
Actual sales (end of year after to FDA) 0.0% 42.9% 57.1% 
Actual revenues (end of after prior to FDA) 0.0% 28.6% 71.4% 
Market values (end of year after to FDA) 0.0% 42.9% 57.1% 
Stockholder's equity (end of year after to FDA) 0.0% 42.9% 57.1% 
Averages 0.0% 39.3% 60.7% 
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 Reputation of the Firms and Management Changes. The last two questions in 
the financial sections of the pilot study questionnaire requested the participants to provide 
their opinion regarding two potential outcomes from the FDA interventions or actions. 
These responses projected the impact on the firms’ reputation and the change 
management process resulting from the FDA’s intervention or actions. Comparing results 
in Table 18 and Table 19 allowed to conduct the assessment. 
Table 18 
Before FDA: Reputation and Management Change 
Answer Options Decrease 
of -50% 
Decrease 
of -5% to -
49%% 
No 
Change 
Increase of 
+5% to 
+49%% 
Increase of -
+50% 
Response 
Count 
Reputation of the 
Firm 
0 1 5 1 0 7 
Management 
change 
0 0 4 5 0 7 
answered question 7 
skipped question 2 
 
Table 19 
After FDA: Reputation and Management Change 
Answer Options Decrease 
of -50% 
Decrease 
of -5% to -
49%% 
No 
Change 
Increase of 
+5% to 
+49%% 
Increase of -
+50% 
Response 
Count 
Reputation of the 
Firms 
0 2 2 3 0 7 
Management 
change 
0 0 5 2 0 7 
answered question 7 
skipped question 2 
 
 FDA Experience. For the FDA experience of the firms, only six of the eight 
completed questionnaires addressed the last six questions out of 44 total questions. This 
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questions collected information regarding the firms experience with the FDA in the past 
six years from 2010 through 2015. The six responders indicated that their firms had FDA 
audits. The responses were assumed to be based on the best recollection of each of the 
participants. In all years, the FDA issued 483 observations. In two events, the outcome of 
the FDA intervention were audits with Official Action Indicated. On one occasion, the 
FDA intervention consisted of a Warning Letter. To assess the overall result of the 
responses, in the last two question the participants were asked to compare the firms’ 
compliance position with the FDA’s CGMP regulations before and after the FDA’s 
interventions. The overall average reflected a favorable increase from 5.67 to 5.83 for a 
favorable 2.8% increase in compliance with the FDA regulations. 
 Regression Analysis. Regression analyses were conducted to understand the 
relationship between the financial indicators with the firms’ compliance position with the 
FDA CGMP regulations. The financial indicators data were transformed within SPSS to 
facilitate the linear equation. Seven financial indicators were included in the assessment. 
Each indicator was considered as separate predictor model within SPSS analysis. 
 The assessment of the regression analysis was limited to 7 responses that made 
difficult the analysis of the assumptions. For both scenarios, pre-FDA and post-FDA 
interventions, multi-collinearity was the only assumption that could be confirmed as met. 
None of the results for the F- ratio, t- test or ANOVA were significant indicating that 
limited effectiveness of the model to predict the impact of the financial indicators in the 
compliance of the firms. The lack of significance in the above tests could be used to 
indicate that the model could not be used to generalize the outcome. The limited data 
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could not be used to establish the heteroscedasticity assumption. The normal probability 
plots indicated the non-normal distribution of variances for the pilot data.  
Outcome from Pilot Study 
 The main outcome of the pilot study could be summarized in five points. First, the 
concept of comparing the pre-FDA and post-FDA interventions was possible and 
understood by the participants. Second, the open-ended questions provided important 
elements to support the constructs of the TPB Likert-type questionnaire. The third point 
referred to the effectiveness of the table approach to collect the financial indicators. The 
table format was effective and led to the execution of the intended regression analysis 
between these indicators and the dependent variable, compliance with the FDA 
regulations. Regarding the fourth point, the pilot study data could not be used to finalize a 
predicting model for the relation between compliance of the firms and the financial 
indicators. Finally, the time to execute the pilot study was as planned and following the 
IRB guidance including the approved consent form. 
Final Study  
 The final study questionnaire consisted of four sections. The structure of the final 
questionnaire although not identical followed the concepts of the pilot study. The first 
sections related to the TPB initial assessment of attitudes, social influences, and 
perceived behavioral controls prior to the FDA intervention in the pharmaceutical firms. 
The first section also included a table to collect financial results of the firms before the 
FDA intervention or action. The second section related to the TPB initial assessment of 
attitudes, social influences, and perceived behavioral controls after the FDA intervention 
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in the pharmaceutical firms including a table to collect financial results of the firms after 
the FDA intervention or action. The intent of sections one and two was to identify 
information before and after any FDA intervention in the firms. The third section 
consisted of the demographics questions. Finally, the fourth section pursued clarification 
on the experience with any FDA interventions or actions in the firms in the past five-six 
years.  
 The instructions for the final study questionnaire in SurveyMonkey included an 
initial question to allow the participant to proceed or stop their participation after reading 
the instructions to the questionnaire. This question ensured the voluntary participation of 
the person highlighting the understanding of the level of confidentiality and the positive 
social benefit if participating in the study. The instructions were part of the 
SurveyMonkey questionnaire. The number of questions in the main study questionnaire 
were 133. The questions consisted of Likert-type scales and tables to select responses. 
The numbers of questions in the final questionnaire were about three times more than in 
the pilot questionnaire. The increase in the number of Likert-Type questions was driven 
by the feedback from the open-ended questions from the pilot participants and the final 
structure recommended by Ajzen (2016). Table 20 presents the questions distribution in 
the final questionnaire. 
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Table 20 
Questions Final Questionnaire 
Section  Scenario                 Number of Questions 
First  
Before the FDA 
  
61  
Second  
Before the FDA 
  
61  
Third  Demographics   6  
Fourth  Experience with FDA   5  
    Total 133  
 
 The length of the final questionnaire turned out to be one of two major limiting 
factors in the completeness of the questionnaires that were attempted by the participants 
that decided to provide their information. Of the 45 participants that initiated the final 
survey, only 21 completed the sections to the end. Feedback from several of these 
participants was that the number of questions were too many. In some cases, the pre-FDA 
and post-FDA scenarios were considered repeatable despite that it was indicated in the 
instructions that this was part of the questionnaire structure to allow the comparison of 
the pre-FDA and post-FDA scenarios. This concern of repeatability was highlighted by 
one out of eight participants of the pilot study and was considered a threat by me. 
Emphasis to highlight the confidentiality and the intended repeatability of questions in 
the instruction did not prove to be effective in managing this factor regarding the survey 
length. 
 The rate of participation in the final study based on 21 completed surveys was 
1.9% from the original 1144 participants selected from the ISPE database following the 
criteria of participants. If only the 79 participants that accepted to commence the survey 
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are considered, the rate of initiating the survey on 21 completed surveys was 27.8%. The 
low initiation rate of the survey was identified as the second major limiting factor for the 
completeness of the final study where the target was to obtain about 160 versus 21 
completed questionnaires for a performance of 13.1%. Although the pilot plant 
participation was 38%, the final low participation in the final study was not expected.  
 The low participation and initiation rate impacted the data analysis and the basis 
for judging the test of the hypotheses and the corresponding decisions regarding the null 
statements. The data collected is presented and the potential null assessment was based 
on the low rate of participation. Despite the consent form indicating the steps to protect 
the confidentiality of the participants, I had no evidence to explain or conclude the low 
participation and initiation rate at the stage of analyzing the data.  
Population 
The intended study population consisted of the pharmaceuticals firms that have 
been impacted within the last five-six years by enforcement activities from the FDA in 
the United States. The initial target were firms that had experienced FDA interventions 
related to manufacturing CGMP violations. Since the data collection was directed to the 
participants, the criteria for the pharmaceuticals firms also consisted in that they had 
operations and that the firms were public companies. 
The main criteria for the selection of participation was that the executives and 
senior operational management of the pharmaceutical firms were expected to have the 
authority to make compliance and financial decisions within the firms. The database of 
potential participants was obtained from the members’ directory of the International 
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Society of Pharmaceutical Engineers (ISPE). Sampling strategy targeted all ISPE 
members that meet the criteria of participation. The self-disclosed title listed by the 
members in the ISPE database was used for the determination of executives and 
operational management.  
Participants were selected by pharmaceutical firms, states, and alphabetical order 
to create the participants’ Excel database. The participants’ e-mails as listed in the ISPE 
database by the participants themselves were included in the Excel database. A total of 
1144 participants were identified in the pharmaceutical firms within the USA. Finally, all 
the pharmaceutical firms were confirmed to be public corporations by their participation 
in a financial board disclosing stock market price to investors. 
The survey for the final study commenced on February 12, 2016, and was closed 
on April 19, 2016. Several reminders were sent in the first two weeks and after a second 
review of the narratives by the IRB. The IRB second review lasted 38 days or half of the 
time of the final study. Table 21 lists the message history of the final study regarding the 
communication with the participants. A total of 5238 messages were sent requesting 
participation and clarifying the need to have repeatable questions to cover the pre-FDA 
and post-FDA interventions or actions. 
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Table 21 
Messages to Participants 
Messages Sent Date Number of e-mails 
Initial Invitation  2/12/2016 1144 
First Reminder                   2/15/2016 1052 
Follow-up to Partials                        2/17/2016 17 
Second Reminder                                                     2/20/2016 1022 
Third Reminder                                                 3/31/2016 987 
Closure Note                                                        4/13/2016 962 
Closure note to Partials                                     4/16/2016   54 
 Total 5238 
 
 From the original 1144 invitations sent by using SurveyMonkey, 58 e-mails 
bounced indicating that these e-mails were never received. An additional 50 participants 
opted not to participate after reading the consent form. 608 of the invitations were opened 
by the intended participants and no action was taken regarding their options to participate 
or not to participate. 428 of the invitations were never opened by the recipients. Of the 
608 invitations that were opened to read the consent form, 90 participants accepted the 
consent form and proceeded to the survey. After reading the instruction, 79 of the 90 
participants accepted to proceed to the questionnaire and 11 did not initiate the survey. Of 
the 79 participants that moved to the first question of section one, only 45 initiated this 
question. From the 45 participants that initiated the survey and after conducting the 
missing data assessment, the participation results attained 21 completed surveys and 24 
partial-completed survey. The 21 completed surveys provided a response rate of about 
1.9% versus the original 1144 invitations. If the 79 participants are only considered, the 
rate of participation was 27.8%. 
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Data Collection 
 The final study was conducted following the same instrument of the pilot study. 
The final study was administered through SurveyMonkey, an electronic survey tool 
chosen to collect data and facilitate analysis. A consent form for participation was sent 
via SurveyMonkey as approved by the Walden University’s IRB. Trust and desire to 
participate was pursued through the narrative presented in the consent form including 
access by the participant to Walden’s IRB office. 
 Of the 1144 SurveyMonkey invitations sent, 608 invitations were opened and 536 
were either not recognized, e-mail bounced back, or the participant opted out of the 
survey. Only 90 invitations accepted the consent from, but eleven participants decided 
not to participate in the survey after reading the instructions. In addition, of the 79 
participants that proceeded to read the first survey questions, only 45 initiated the 
questions and 21 completed the survey’s 133 questions. The consent form with the 
questionnaire instructions provided adequate space for the participants to voluntarily 
decide if they would participate or not. With the 38% rate of participation in the pilot 
study, the participation in the main study was expected to reach the initial target of 160 
completed questionnaires out of about 1144 invitations with a projected rate of 
participation of about 15%. The actual participation was 1.9% of the 1144 participants 
selected form the ISPE database meeting the criteria of participants. Of the expected 160 
completed surveys, only 21 surveys were completed with an additional 24 partially 
completed surveys. 
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 The data was collected and initially read through the SurveyMonkey analysis 
section. I did not conduct any specific statistical analysis within the SurveyMonkey data 
presentation. This data section was used to track the participation along the survey 
period. The collected data was exported to SPCC for the data analysis of this final study. 
The internal codification of SurveyMonkey was used to maintain and protect the 
confidentiality of the participants. 
Demographics 
 The demographics of the final study indicated a reasonable representation of the 
role of responsibility and area of expertise within the selected participants. The 
demographics questions where located on the third section of the final study. Appendix F 
shows the percentage distribution of the relevant demographics. The decisions makers’ 
titles indicated the participation of managers, directors, vice-presidents, and one 
executive. The educational level included high school diploma, bachelors, masters, MBA, 
and doctorate degrees. The functional areas within the pharmaceutical firms represented 
covered quality, manufacturing, engineering, and others like regulatory. The 
demographics of the final study’s 21 participants ensured a representative source of 
essential management behaviors that were incorporated to the Likert-type scaled of the 
final questionnaire while recognizing the overall limited participation. 
Data Treatment  
 The collected data in the final study was initially assessed via the results review 
section through SurveyMonkey. The collected data was transferred to an SPSS data table 
to facilitate the statistical assessments from correlations and regression analyses. The 
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assessment within SurveyMonkey consisted mainly in tracking responses and the rate of 
participation during the survey period. The SPSS database allowed to organize the 
responses for the correlations analysis and the execution of the regression analyses of the 
data for both the pre-FDA and post-FDA interventions and actions. 
Data Analysis  
 The data analysis initial steps consisted on how to manage the data while 
addressing shortfalls, like missing data and assumptions’ requirements. The low level of 
completed responses limited the overall analysis. The first step was to develop a data 
codebook (SPSS template) to store the data for all the variables and sampling details. The 
database template was created in SPSS from the data transferred from SurveyMonkey. 
The access to my laptop, it was password-protected to support confidentiality protecting 
the access to the collected data and the SPSS data template. There was no need to cross-
code any personal references from participants since the collected data from 
SurveyMonkey provided reference numbers to enhance privacy and confidentiality of 
participants. 
 The second step consisted of the cleaning of the data per the steps outlined by 
Morrow (2009). Cleaning of the data refers to the process of minimizing biases and 
calculation errors generated by the quality of the obtained data. A step-by-step approach 
was followed for the SPSS analysis. 
1. For the 45 original surveys that were initiated by participants, 24 surveys were 
removed from the database since significant number of questions were not 
completed by the participants.  
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2. For the remaining 21 surveys that answered questions in all the four sections of 
the questionnaire, some questions were not answered by each participant. 
Through SPSS, all missing data in the Likert-type scales were completed with the 
corresponding average of each question. For the questions related to financial 
indicators, any missing data was replaced with the response of “no change.”  The 
data was reviewed for each variable’s Likert-type questions in the SPSS template 
to ensure that the suggested level of not more than 5% missing data was present 
for each participant in each of the two Likert-type sections of the survey. 
3. The Outliers’ scores were initially assessed with the intent to apply Windsorizing. 
None of the Likert-type scores or financial data tables from the main study 
required to apply the Windsorizing approach. In the SPSS analysis, for just 
caution and only when requested a 2 sigma was applied.  
4. The data was reviewed for each variable’s Likert-type questions in the SPSS 
template to ensure that the suggested level of not more than 5% missing data was 
present. If needed for less than 5% of the data, the estimated average of the data 
was used to fill in the missing data. In the case of more than 5% missing data for a 
given variable, the data for that participant was not included in the analysis. 
5. For completed-usable responses, the participant had to complete over 95% of the 
questions in either the pilot study or the main study including the demographics 
and FDA compliance questions at the end. 
6. For partial responses, an organized approached was implemented. This approach 
consisted in the separation of the collected data in the SPSS template by each of 
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the two scenarios: pre-FDA and post-FDA interventions. This process allowed to 
consider those responses that only addressed the pre- scenario, but the participants 
decided not to continue to complete the remainder of the questions. 
7. Transforming the data by means of reversing the Likert-Type scores provided 
alignment and proper assessment of the Cronbach’s alpha to assess the reliability 
of the scales by section or construct of the TPB. 
8. Linearity was verified by visually assessing the graphs of the data. 
9. Verifying for multicollinearity was done within the SPSS application.  
10.  For homogeneity of regression, SPSS was used. 
11.  Linearity was initially verified by visually assessing the graphs of the data. 
 The application of regression analysis increased the complexity since two 
scenarios pre-FDA and post-FDA interventions were assessed. Maintaining separation of 
the data for the two scenarios within the SPSS template was important. The number of 
the questions within SurveyMonkey provided the vehicle to maintain the separation of 
the data for the two scenarios pre-FDA and post-FDA interventions. The application of 
SPSS for the correlations analysis and all the corresponding assumptions of regression 
analysis were considered in both scenarios: pre-FDA and post-FDA interventions. 
 Research Question 1 (RQ1). To what extent, if any, does management behaviors 
(independent) correlate to compliance (dependent) with FDA regulations at the 
pharmaceutical firms in the United States? 
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 H1₀: r = 0. There is no difference in management behaviors towards 
compliance at pharmaceutical firms, as a result of FDA enforcement actions in 
the U.S. 
 H1₁: r ≠ 0. There are differences in management behaviors towards 
compliance at pharmaceutical firms, as a result of FDA enforcement actions in 
the U.S. 
 One method of assessing the predictability of behaviors is by applying the theory 
of planned behavior. Ajzen (1991) developed TPB to provide a model of measuring 
attitudes and dispositions to predict behavior. TPB infers the existence of a direct 
relationship between intention and actual behavior. Also, attitudes and norms can explain 
any behavior following the principles of TPB. The study applied TPB to understand and 
predict the intention of pharmaceutical management to comply with the FDA regulations. 
 According to TPB, three types of beliefs direct and influence human behavior: 
salient beliefs or attitudes (b), normative beliefs (n), and perceived behavioral control (c) 
(Ajzen, 2002). The interrelations between these beliefs influence the intention towards a 
given behavior. Intentions are the predecessors of behaviors (Ajzen, 1991). The relation 
between intention and behavior depends on the strength of the attitude from behavioral 
beliefs, the social pressures leading to subjective beliefs, and the level of perceived 
control that the person has in front of the decision process. Actual behavioral control 
results from the limitations or obstacles performing the intention. If adequate control 
exists, an individual’s intention predicts the actual behavior, as a direct outcome. These 
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constructs were incorporated into the Likert-type questions suggested by Fishbein and 
Ajzen (2010) for the main survey questionnaire.  
 All Likert-type scales were selected by me to be unipolar (1 to 7) to avoid 
potential biases by having a negative implication with ratings in a -3 to +3 scale. The first 
section of the questionnaire was to assess the overall expected outcome regarding the 
expected compliance with the FDA regulations pre-FDA and post-FDA interventions. A 
total of 61 questions were included in this section for each scenario. Table 22 presents the 
average and standard deviations for these Likert-Type questions for each participant. All 
averages were skewed to the high side of the 1 to 7 Likert-type scales. 
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Table 22 
Outcome pre-FDA and post-FDA intervention 
     pre-FDA  intervention  post-FDA  intervention 
Participants Ave. outcome SD 
 Ave. 
Outcome SD 
1 6.7 1.94  7.0 0.00 
2 5.6 0.97  6.6 0.97 
3 5.0 1.41  5.5 0.97 
4 6.9 0.32  6.7 0.48 
5 6.4 1.07  4.1 0.88 
6 6.4 1.90  6.7 0.95 
7 6.8 0.42  6.7 0.95 
8 6.2 0.92  5.9 1.10 
9 6.6 0.85  6.7 0.84 
10 6.5 0.96  6.4 1.26 
11 6.3 1.25  6.2 1.87 
12 5.7 1.42  6.9 0.32 
13 6.3 1.06  6.6 0.97 
14 6.4 1.90  6.9 0.17 
15 5.6 0.70  5.7 0.67 
16 6.7 0.48  6.4 0.70 
17 5.5 0.71  5.9 0.32 
18 6.0 0.82  6.0 0.82 
19 5.8 0.63  5.9 0.74 
20 6.4 0.70  6.1 1.45 
21 5.5 0.53  6.6 0.52 
 
 The overall attitude regarding the beliefs was defined as the sum of the products 
of the individual beliefs, b, and the corresponding strength, e (Fishbein and Ajzen, 2010). 
The projected relation was based on A = Ʃ bᵢ * eᵢ. Letter A corresponds to the overall 
attitude towards the given behavior. In the study, the overall behavior towards 
compliance with the FDA regulations was the target. Tables 23 and 24 present the 
calculation for the overall attitude A for both pre-FDA and post-FDA interventions. 
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Table 23 
Overall Attitude pre-FDA 
Beliefs  Ave. b SD Ave. e SD Ave. be SD Max Min 
Cheaper 3.80 2.04 6.57 1.12 24.98 14.76 49 1 
Reliable 6.10 0.94 5.38 1.07 33.26 9.86 49 1 
Product quality 6.50 0.97 6.24 1.00 40.64 9.34 49 1 
Supply 6.38 1.07 6.57 1.33 42.24 11.73 49 1 
Competitive 6.00 1.34 6.81 0.51 41.10 10.05 49 1 
Accomplishment 6.29 0.96 6.62 0.59 41.76 8.14 49 1 
Effective 6.19 0.81 6.95 0.22 43.10 6.15 49 1 
Information 6.33 1.02 5.76 0.94 36.67 9.06 49 1 
Tension 4.30 2.08 6.67 0.58 29.15 14.98 49 1 
Overworked 3.48 2.04 5.95 1.02 20.67 12.34 49 1 
    Attitude = 353.56  490  
         
Table 24 
Overall Attitude post-FDA 
Beliefs  Ave. b SD Ave. e SD Ave. be SD Max Min 
Cheaper 3.80 1.89 6.76 0.70 25.31 12.59 49 1 
Reliable 5.62 1.53 5.71 0.85 32.48 11.15 49 1 
Product 6.05 1.43 6.86 0.36 41.71 10.86 49 1 
Supply 6.14 1.20 3.95 2.13 23.67 13.27 49 1 
Competitive 5.95 1.40 6.52 0.75 39.43 11.70 49 1 
Accomplishment 6.19 0.98 6.62 0.59 41.19 8.45 49 1 
Effective 6.00 0.95 6.81 0.51 41.05 8.04 49 1 
Information 5.86 1.20 5.95 0.92 35.05 9.98 49 1 
Tension 4.35 1.71 6.71 0.64 29.26 12.16 49 1 
Overworked 3.45 1.86 5.86 1.06 20.39 12.01 49 1 
    Attitude = 329.53  490  
         
 The overall normative beliefs, N, was defined as the sum of the products of the 
individual normative beliefs, n, and the corresponding strength, m (Fishbein and Ajzen. 
2010). The projected relationship based on summarized N = Ʃ nᵢ * mᵢ. Letter N 
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corresponds to the overall attitude towards the given normative belief towards a behavior. 
In the study, the overall behavior towards compliance with the FDA regulations was the 
target. Table 25 and Table 26 present the calculation for the overall normative beliefs N 
for both pre-FDA and post-FDA interventions. 
Table 25 
Overall Normative Belief pre-FDA 
Normative  Ave. B SD Ave. e SD 
Ave. 
Be SD 
Ma
x 
Mi
n 
SR MGT 7.00 0.00 6.86 0.48 48.00 3.35 49 1 
PEERS 6.81 0.40 5.71 1.62 38.86 11.19 49 1 
BUSS ASSOC 6.76 0.62 5.81 1.25 39.33 9.33 49 1 
DIRECT/MAN 6.81 0.51 6.86 0.48 46.86 5.60 49 1 
SUP 6.86 0.36 6.86 0.48 47.14 5.03 49 1 
PARENTS 4.10 2.41 5.48 2.06 25.14 17.80 49 1 
FRIENDS 3.95 2.33 5.71 1.62 24.19 16.58 49 1 
SR MGT 6.95 0.22 6.86 0.48 47.76 4.35 49 1 
BUSS ASSOC 6.67 0.66 5.81 1.25 39.10 10.33 49 1 
BUSS ASSOC 6.14 1.56 5.81 1.25 35.86 12.41 49 1 
    Normative = 392.24  490  
 
Table 26 
Overall Normative Belief post-FDA 
Normative  Ave. n SD Ave. m SD Ave. nm SD Max Min 
SR MGT 6.48 0.68 6.71 0.72 43.62 7.12 49 1 
PEERS 6.71 0.46 5.90 1.04 39.82 8.56 49 1 
BUSS ASSOC 6.48 1.21 5.43 1.54 35.19 12.40 49 1 
DIRECT/MAN 6.71 0.56 6.71 0.72 45.19 6.74 49 1 
SUP 6.81 0.40 6.71 0.72 45.86 6.36 49 1 
PARENTS 3.81 2.66 4.48 2.44 21.95 19.59 49 1 
FRIENDS 4.15 2.22 5.90 1.04 25.09 14.96 49 1 
SR MGT 6.95 0.22 6.71 0.72 46.75 5.68 49 1 
BUSS ASSOC 6.32 0.78 5.43 1.54 34.74 12.42 49 1 
BUSS ASSOC 5.53 1.91 5.43 1.54 30.18 15.06 49 1 
    Normative = 368.39  490  
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 The overall perceived control behaviors, PBC, was defined as the sum of the 
products of the individual perceived control beliefs, p, and the corresponding strength, c 
(Fishbein & Ajzen, 2010). The projected relationship was based on PBC = Ʃ pᵢ * cᵢ. 
Letters PBC correspond to the overall attitude towards the given perceived behavioral 
control towards a behavior. In the study, the overall behavior towards compliance with 
the FDA regulations was the target. Table 27 and Table 28 present the calculation for the 
overall perceived behavioral control PBC for both pre-FDA and post-FDA interventions. 
Table 27 
Overall PBC pre-FDA 
Control Ave. p SD Ave. c SD Ave. pc SD Max Min 
KNOWLEDGE 3.14 2.22 3.65 2.17 9.75 8.81 49 1 
KNOWLEDGE 6.90 0.30 3.65 2.17 25.12 15.09 49 1 
EVENTS 3.29 1.59 6.33 0.86 21.43 11.83 49 1 
FEEL 5.50 1.47 6.38 0.97 35.93 12.41 49 1 
FAMILY 4.80 1.81 6.29 0.96 31.03 13.51 49 1 
GOALS 4.65 1.53 6.05 1.40 27.45 10.55 49 1 
BUDGET 4.24 2.14 6.00 1.30 26.10 15.14 49 1 
DATELINES 3.29 2.19 6.00 1.30 18.67 13.10 49 1 
    Attitude = 195.47 392   
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Table 28 
Overall PBC post-FDA 
Control Ave. p SD Ave. c SD Ave. pc SD Max Min 
KNOWLEDGE 3.95 2.13 3.48 2.16 12.24 9.37 49 1 
KNOWLEDGE 6.71 0.64 3.48 2.16 23.24 14.90 49 1 
EVENTS 3.81 1.50 5.62 1.86 22.29 12.02 49 1 
FEEL 5.40 1.43 5.75 1.61 31.91 13.52 49 1 
FAMILY 5.10 1.73 5.75 1.64 30.10 14.60 49 1 
GOALS 3.55 1.77 5.75 1.51 19.07 9.59 49 1 
GOALS 4.79 1.75 5.50 1.88 27.09 14.77 49 1 
DATELINES 3.19 2.04 5.50 1.88 16.45 11.80 49 1 
    Control = 182.38  392  
 
 On Table 29, the summary of the results was listed for both the pre-FDA and 
post-FDA interventions. The maximum value for each construct was included. Also, the 
percent of the maximum attained by each construct was listed. Although the average 
outcome tended to be slightly higher towards compliance from 88% to 90%, the TPB 
constructs tended to be 3-5% lower for the post-FDA intervention versus the maximum 
points to be attained in each scale.  
Table 29 
Overall Results for TPB constructs 
 
 Outcome A N PBC 
Pre-FDA 6.16 353.56 392.24 195.47 
Post-FDA 6.27 329.53 368.39 182.38 
Max 7 490 490 392 
Pre-FDA 88% 72% 80% 50% 
Post-FDA 90% 67% 75% 47% 
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 This data indicated that the probable effect of the FDA intervention in the 
participants’ behavior was inversed. While the expected outcome of compliance was 
improved, the impact on the behavioral constructs were negative. Although the 
participants’ beliefs of being in compliance was reduced after the FDA intervention, the 
lost in influence from peers’ opinions and the reduction on the influence of perceived 
controls provided a final favorable impact on the outcome of enhanced compliance with 
FDA regulations. These trends allowed for a better compliance expectation after the FDA 
intervention. 
 An attempt to assess if a prediction could be obtained from the three constructs of 
behavior regarding the responses to the outcome of compliance by the participants, 
correlation analyses were conducted for both scenarios, pre-FDA and post-FDA 
interventions. Also, following the TPB, a linear regression analysis was performed using 
SPSS to generate and assess if prediction models could be applied to compare both 
scenarios. For the regression analysis, the SPSS forced entry approach was used to 
present the contribution to the model. The order of the constructs followed the TPB order 
of beliefs (attitudes), normative beliefs, and perceived behavior controls (PBC). 
 Considering the small number of participants, skewness and kurtosis were used to 
assess the distribution of the variables. In the scenario of pre-FDA intervention, the 
skewness results were negative indicating that there was a cluster at the higher end of the 
scales (Field, 2009). Kurtosis was used to measure the degree to which scores cluster in 
the tails of a frequency distribution. For the pre-FDA, the kurtosis’ values were positive 
and negative. Positive kurtosis values indicated that the distribution tended to peak at the 
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tails due to the high number of scores in the tail. Negative kurtosis values signaled few 
scores in the tails and a flat distribution (Field, 2009). In the scenario of post-FDA 
intervention, the skewness results were also negative indicating that there was a cluster at 
the higher end of the scales (Field, 2009). The kurtosis’ values were also positive and 
negative. 
 The four variables were also assessed for their characteristics as a normal or non-
normal distribution. Kolmogorov-Smirnov and Shapiro-Wilk results were obtained in 
SPSS. The results of the Kolmogorov-Smirnov and Shapiro-Wilk tests for the pre-FDA 
intervention were all non-significant implying that the distribution of the four variables 
were normal. See Table 30.  
Table 30 
Tests of Normality pre-FDA 
 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Outcome_pre .180 21 .073 .936 21 .181 
Beliefs_pre .096 21 .200* .984 21 .972 
Normative_pre .176 21 .089 .922 21 .096 
Control_pre .123 21 .200* .976 21 .860 
* This is a lower bound of the true significance. 
a. Lilliefors Significance Correction 
 
 For the post-FDA intervention in Table 31, the results for Kolmogorov-Smirnov 
and Shapiro-Wilk tests are illustrated. Results were non-significant indicating a tendency 
to normal distribution for three independent variables: beliefs (attitude), normative 
beliefs, and perceived behavioral control. For the dependent variable outcome of 
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compliance, the Shapiro-Wilk tests indicated a significant correlation indicating a non-
normal distribution different from the pre-FDA scenario.  
Table 31 
Tests of Normality post-FDA 
 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Outcome_post .173 21 .099 .830 21 .002 
Beliefs_post .124 21 .200* .971 21 .758 
Normative_post .155 21 .200* .933 21 .160 
Control_post .107 21 .200* .973 21 .800 
* This is a lower bound of the true significance. 
a. Lilliefors Significance Correction 
 Pearson’s coefficient correlation was utilized to understand the internal 
consistency of the Likert-type scales by establishing how close the different elements of 
the scales are to each other. Also, the correlation between each subset of the construct 
was obtained and listed to establish the dependencies within each construct. Table 32 
presents the Pearson correlation for the pre-FDA intervention. The construct of beliefs 
(attitudes) had the highest correlation with the outcome of compliance with a value of r = 
0.633, p < 0.01. The other two construct, normative beliefs and perceived behavioral 
control had non-significant correlations with r values of r = 0.328 and r = 0.183, 
respectively.  
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Table 32 
Pre-FDA Correlations 
 Outcome_pre Beliefs_pre Normative_pre Control_pre 
Outcome_pre Pearson 
Correlation 
1 .633** .328 .183 
Sig. (1-tailed)  .001 .073 .213 
N 21 21 21 21 
Beliefs_pre Pearson 
Correlation 
.633** 1 .328 .243 
Sig. (1-tailed) .001  .074 .144 
Normative_pre Pearson 
Correlation 
.328 .328 1 -.127 
Sig. (1-tailed) .073 .074  .292 
Control_pre Pearson 
Correlation 
.183 .243 -.127 1 
Sig. (1-tailed) .213 .144 .292  
**. Correlation is significant at the 0.01 level (1-tailed). 
 
 Table 33 presents the Pearson’s correlation for the post-FDA intervention. The 
construct of beliefs (attitudes) also had the highest correlation with the outcome of 
compliance with a value of r = 0.693, p < 0.01. The other two construct, normative 
beliefs and perceived behavioral control had non-significant correlations with r values of 
0.294 and 0.303, respectively. Also, the construct of behavioral beliefs had a significant 
correlation with the construct of perceived behavioral control with r = 0.376, p < 0.05. 
This last significant correlation differed from the pre-FDA intervention where the 
correlation was non-significant between these two constructs.  
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Table 33 
Post-FDA Correlations 
 Outcome_post Beliefs_post 
Normative_pos
t Control_post 
Outcome_post Pearson 
Correlation 
1 .693** .294 .303 
Sig. (1-tailed)  .000 .098 .091 
N 21 21 21 21 
Beliefs_post Pearson 
Correlation 
.693** 1 .332 .376* 
Sig. (1-tailed) .000  .071 .046 
Normative_post Pearson 
Correlation 
.294 .332 1 -.268 
Sig. (1-tailed) .098 .071  .120 
Control_post Pearson 
Correlation 
.303 .376* -.268 1 
Sig. (1-tailed) .091 .046 .120  
**. Correlation is significant at the 0.01 level (1-tailed). 
*. Correlation is significant at the 0.05 level (1-tailed). 
 
 The correlation data indicated a favorable change in correlation between the 
outcome of compliance and beliefs (attitude) for before and after the FDA intervention of 
about 9.5%. The value of r increased from 0.633 to 0.693 for the construct of beliefs 
(attitude) towards compliance by the participants with significances of p < 0.01. The 
other two independent constructs had non-significant correlations. The perceived 
behavioral control non-significant correlation with the outcome of compliance also 
increased by about 65% from the pre-FDA (r = 0.183) to the post-FDA scenario (r = 
0.303). From the limited population that participated in the study, the null hypothesis was 
rejected for RQ1. 
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 A regression analysis was conducted to establish a model with the TPB constructs 
as predictors of the outcome of compliance of the firms with the FDA regulations. The 
regression analyses were performed using SPSS for both scenarios: pre-FDA and post-
FDA. All assumptions were assessed to understand the robustness of the models. 
 For regression analysis, there were several assumptions that needed to be met 
(Field, 2009). Meeting the assumptions allowed assessing if the conclusions were true for 
a wider population. For a regression model to generalize beyond the sample population, 
assumptions have to be met. The assumptions were assessed for each scenario: pre-FDA 
and post-FDA interventions. The assessment was as follows: 
1. Variable types: All predictor variables were quantitative or categorical (with 
two categories), and the outcome variable was quantitative: continuous and 
unbounded. 
2. Non-zero variance: The predictors should had variation in value. They did not 
have variances of 0. 
3. Sample Size: The ratio of predictors to cases was expected to be significant 
because of its impact on the value of R. This assumption was not met. 
4. No perfect multicollinearity: There was no perfect linear relationship between 
two or more of the predictors. The predictor variables did not highly 
correlated. 
5. Predictors are not correlated with external variables: External variables could 
be present. In the model, not all contribution that could significantly influence 
the outcome was identified. This assumption was not met.  
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6. Homoscedasticity: At each level of the predictor variable(s), the variance of 
the residual terms were constant. The SPSS graphs supported this assumption. 
7. Independent errors: For any two observations the residual terms should be 
independent. This assumption tested whether adjacent residuals are correlated. 
The test statistic was allowed to vary between 0 and 4 with a value of 2 
meaning that the residuals were uncorrelated. 
8. Normally distributed errors: This assumption indicates that the differences 
between the model and the observed data are most frequently zero or very 
close to zero. The SPSS graphs did not support this assumption.  
9. Independence: All of the values of the dependent variable were independent 
of each other. 
10. Linearity: The mean values of the dependent variable were represented in a 
reasonable spread indicating a straight line. Assumption met. 
 The dependent variable was the outcome of compliance as indicated in the main 
survey by the participants in the Likert-type scales for the TPB section. The values of the 
behavioral construct variables were the values of the beliefs with the influence of the 
corresponding strengths. For beliefs (attitude), the average product of b*e was used. For 
normative beliefs, the average product of n*m was used. For perceived behavioral control 
(control), the average product of p*c was used. This approached allowed to have a direct 
relation in the model with the beliefs in each of the three constructs. The values of the 
variables are presented in Table 34 for the pre-FDA scenario and post-FDA scenario. 
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Table 34 
Pre-FDA and Post-FDA scenario 
 pre-FDA behavioral constructs  post-FDA behavioral constructs 
Participants Ave. O Ave. be Ave. nm Ave. pc  Ave. O Ave. be Ave. nm Ave. pc 
1 6.7 36.1 40.8 32.9  7.0 36.8 27.4 25.9 
2 5.6 37.1 30.7 24.0  6.6 32.4 32.0 15.8 
3 5.0 22.0 22.4 19.4  5.5 21.4 22.1 23.9 
4 6.9 37.3 45.2 24.8  6.7 34.9 44.5 21.3 
5 6.4 34.9 33.2 9.6  4.1 24.4 27.7 15.5 
6 6.4 42.7 42.5 34.0  6.7 35.2 33.1 26.3 
7 6.8 44.1 30.5 39.3  6.7 42.0 24.7 29.4 
8 6.2 36.9 44.6 15.1  5.9 23.6 34.4 23.4 
9 6.6 41.4 49.0 18.8  6.7 38.2 45.5 21.9 
10 6.5 33.3 45.2 28.5  6.4 34.4 44.8 30.0 
11 6.3 30.5 36.0 20.3  6.2 29.8 32.5 26.3 
12 5.7 34.5 41.5 29.6  6.9 32.3 37.8 26.0 
13 6.3 31.9 40.0 25.0  6.6 35.8 38.6 24.5 
14 6.4 45.5 41.4 20.3  6.9 44.8 40.6 22.8 
15 5.6 25.0 33.3 34.1  5.7 25.6 24.6 25.5 
16 6.7 31.9 39.3 20.9  6.4 33.7 41.3 20.6 
17 5.5 27.7 46.5 12.8  5.9 26.7 48.3 12.8 
18 6.0 38.6 42.6 32.5  6.0 40.6 41.7 32.6 
19 5.8 28.6 40.1 25.1  5.9 29.8 41.0 17.6 
20 6.4 35.5 46.5 21.9  6.1 35.0 44.2 20.9 
21 5.5 33.5 47.7 20.9  6.6 34.6 46.9 16.0 
  
 In the next step, the possible predicting models were evaluated for both FDA 
scenarios. A model in a forced order was developed in SPSS for each scenario. Table 35 
presents the model for the pre-FDA scenario. The correlation R between the variables and 
the prediction R2 of how much of the dependent variable is contributed by each predictor 
were obtained. Also, the assumption of independent errors was verified with the Durbin–
Watson statistic. The value of 2.21 was obtained, indicating that the assumption of 
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independent errors could be considered as met. About the external variables, the R2 
values of model 1 indicated that the predictors accounted for about 42% contribution to 
the outcome variable, indicating that there were other external variables not included, 
violating this assumption.  
Table 35 
Pre-FDA Model b 
Model 
 
R 
R 
Square 
Adjusted 
R Square 
Std. Error 
of the 
Estimate 
Change Statistics 
Durbin-
Watson 
R Square 
Change 
F 
Change df1 df2 
Sig. F 
Change 
1 .649a .421 .318 .42625 .421 4.115 3 17 .023 2.210 
a. Predictors: (Constant), Control_pre, Normative_pre, Beliefs_pre 
b. Dependent Variable: Outcome_pre 
 
 The adjusted R2 provided a way to understand how well the model could 
generalize the scenario under review. The smallest the difference of the adjustment the 
better the possibility for the model to represent the population, not just the sample. In 
model 1, the value of R2 was 00.421 and was adjusted to about 32% for the contribution 
of the three constructs. The F- ratio indicated the significance of the change with p < 
0.05. 
 For the post-FDA scenario, the three TPB constructs were introduced in a forced 
order as developed in SPSS. Table 36 presents the model for the post-FDA scenario. 
Also, the assumption of independent errors was verified with the Durbin–Watson 
statistic. The value of 2.066 was obtained, indicating that the assumption of independent 
errors could be considered as met. About the “external variables,” the R2 values of model 
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1 indicated that the predictors accounted for about 49% contribution to the outcome 
variable, indicating that there are other external variables not included, violating this 
assumption.  
Table 36 
Model b Summary post-FDA 
Mode
l R 
R 
Square 
Adjusted 
R 
Square 
Std. Error 
of the 
Estimate 
Change Statistics 
Durbin-Watson 
R 
Square 
Change 
F 
Change df1 df2 
Sig. F 
Change 
1 .701
a 
.492 .402 .50620 .492 5.481 3 17 .008 2.066 
a. Predictors: (Constant), Control_post, Normative_post, Beliefs_post 
b. Dependent Variable: Outcome_post 
 
  The adjusted R2 provided a way to understand how well the model could 
generalize the scenario under review. The smallest the difference of the adjustment the 
better the possibility for the model to represent the population, not just the sample. In 
model 1, the R2 = 0.492 was adjusted to 40.2% representing the adjustment to the overall 
contribution of the three variables. The F-ratio provided the significance of the change, p 
< 0.01. 
 The ANOVA challenged whether the models were better predictors of the 
outcome than the guess based on the average means. The F-ratio indicated the ratio of the 
accuracy of the model versus the means (Field, 2009). All values of F were lower above 
one signaling that the model’s fits were good predictors than the guess from the means. 
The models for both scenarios (pre-FDA and post-FDA) had an F-ratio that were 
significant (p < 0.05) indicating that the outcome could unlikely happen by chance.  
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 The model parameters were then obtained by SPSS. Table 37 presents the slope 
values, B, for each predictor (TPB constructs). Only beliefs had a significant value of p < 
0.05. None of the other construct had a significant (p < 0.05) indicating a weak 
contribution to the outcome. The smallest the significance of the B values the stronger the 
contribution of the prediction to the outcome (Field, 2009). Regarding the standardized 
beta (labeled as Beta, β), beliefs (β = 0.568), had the largest impact on the standard 
deviation of the outcome of behavior towards compliance. The other two standardized 
beta (labeled as Beta, β) were normative beliefs (β = 0.150) and PBC (β = 0.065). 
Table 37 
Models’ Parameters a pre-FDA 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
1 (Constant) 3.903 .742  5.259 .000 
Beliefs_pre .049 .018 .568 2.769 .013 
Normative_pre .012 .015 .150 .750 .463 
Control_pre .004 .013 .065 .331 .745 
 
 To assess how close is the B value of the sample to the B value of the population, 
a level of confidence of 95% was selected. See Table 38. Only one of the constructs 
(beliefs) had a spread between the upper and lower boundaries of the confidence limit not 
crossing the value of zero implying that the construct was strong for the prediction of the 
outcome of the model. Regarding the Collinearity Statistics, VIF values were all close to 
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1.0 and tolerances were below 1.0. These results indicated that the models met the 
assumption of collinearity. 
Table 38 
Models’ Parameters a pre-FDA 
Model t Sig. 
95.0% 
Confidence 
Interval for B Correlations 
Collinearity 
Statistics 
Lower 
Bound 
Upper 
Bound 
Zero-
order Partial Part Tolerance VIF 
1 (Constant) 5.259 .000 2.337 5.469      
Beliefs_pre 2.769 .013 .012 .086 .633 .558 .511 .810 1.234 
Normative_
pre 
.750 .463 -.021 .044 .328 .179 .139 .847 1.180 
Control_pre .331 .745 -.024 .032 .183 .080 .061 .893 1.119 
 
 For the post-FDA scenario, Table 39 presents the slope values, B, for each 
predictor (TPB constructs). Only beliefs had a significant value of p < 0.05. None of the 
other construct had a significant (p < 0.05) indicating a weak contribution to the outcome. 
The smallest the significance value, the stronger the contribution of the prediction to the 
outcome (Field, 2009). Regarding the standardized beta (labeled as Beta, β), beliefs (β = 
0.614), had the largest impact on the standard deviation of the outcome of behavior 
towards compliance. The other two standardized beta (labeled as Beta, β) were normative 
beliefs (β = 0.118) and PBC (β = 0.104). 
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Table 39 
Model Parameters a post-FDA 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
1 (Constant) 3.456 .858  4.031 .001 
Beliefs_post .065 .023 .614 2.877 .010 
Normative_post .010 .017 .118 .576 .572 
Control_post .013 .026 .104 .499 .624 
 
To assess how close is the B value of the sample to the B value of the population, 
a level of confidence of 95% was selected. See Table 40. Only one of the constructs 
(beliefs) had a spread between the upper and lower boundaries of the confidence limit not 
crossing the value of zero implying that the construct was strong for the prediction of the 
outcome of the model. Regarding the Collinearity Statistics, VIF values were all close to 
1.0 and tolerances were below 1.0. These results indicated that the models met the 
assumption of collinearity. 
Table 40 
Model Parameters a post-FDA 
Model 
Sig. 
95.0% Confidence 
Interval for B Correlations 
Collinearity 
Statistics 
  
Lower 
Bound 
Upper 
Bound 
Zero-
order Partial Part Tolerance VIF 
1 (Constant) 4.031 .001 1.647 5.266      
Beliefs_post 2.877 .010 .017 .113 .693 .572 .498 .657 1.523 
Normative_p
ost 
.576 .572 -.025 .045 .294 .138 .100 .710 1.409 
Control_post .499 .624 -.043 .069 .303 .120 .086 .685 1.460 
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 To further assess the assumption of collinearity, a diagnostic was performed by 
SPSS for both scenarios: pre-FDA and post-FDA. In both scenarios, all Eigenvalue were 
below one. Only Eigenvalues below 1 were considered for the assessment of collinearity. 
For the pre-FDA, the three constructs had their highest values in different dimensions for 
the test of Variance Proportions. For the post-FDA, the three constructs also had their 
highest values in different dimension also meeting the assumption of no multicollinearity. 
 The next step was to assess if any case had a significant influence or should be 
considered as an outlier. Using SPSS, the case summary analysis was applied to both 
scenarios: pre-FDA and post-FDA. The Mahalanobis Distance values did not show any 
case to be of concerned. The Cook’s number expect for one (case 5) were below 1.0. But, 
the Centered Leverage Values were all within the three times the expected value of 0.57. 
None of the cases were excluded from the Cook’s numbers and DFBeta calculations by 
SPSS indicating no undue influence from any of the cases in the model. In the post-FDA 
scenario, all cases were included with values of Cook of +/-1.  
 All the values of DFBeta except case 5 and case 17 in the post-FDA were beyond 
+/-1 but less than two implying that all other cases could be considering not having undue 
influence in the regression models. For case 5 (post-FDA) and case 17 (post-FDA), the 
Centered Leverage Values were within expectation leading to accept both cases as not 
having undue influence in the model. Regarding the covariance ration, CVR, the limits of 
1.57 and -0.42. All cases were within or not significantly apart from these values. Case 8 
had a value of 2.0 but its Cook’s and Centered Value were well within expectations. No 
case was found to have an undue influence in the model. 
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 For the assumptions of linearity and homoscedasticity, the plots assessed under 
SPSS could be considered as supporting these assumptions. For the residual normality, 
the graphs for both scenario had a subtle separation form the straight line implying lack 
of normality. Since not all assumptions were met, the regression model for TPB cannot 
be used to generalize beyond the sample of the study in either the pre-FDA or the post-
FDA intervention. 
 Research Question 2 (RQ2). To what extent, if any, do financial indicators 
(independent) correlate to compliance (dependent) with FDA regulations at the 
pharmaceutical firms in the United States? 
 H2₀:  r = 0. There is no difference in compliance with FDA related to financial 
indicators at pharmaceutical firms, as a result of FDA enforcement actions in 
the U.S. 
 H2₁:  r ≠ 0. There are differences in compliance with FDA related to financial 
indicators, as a result of FDA enforcement actions in the U.S. 
 Seven correlations were performed with the seven financial indicators to 
understand the possible correlations between these indicators and the dependent variable 
outcome of compliance for each scenario: pre-FDA and post-FDA interventions. The 
seven financial indicators for the test of Hypothesis 3 were the cost of goods, investment 
in facility and equipment, process compliance, actual sales, actual revenues, market 
value, and stockholder’s equity. The basis of the correlations was the firms’ level of 
compliance as indicated by the participants both before and after the FDA intervention. 
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 The main study collected information regarding the financial indicators of the 
firms. For comparison, the indicators prior and after the FDA intervention or action were 
requested to the best recollection of the participants. The requested information focused 
on the elements of decreased, no change, and increased. The tables in the study 
requesting the financial information scaled the responses to ensure clarity on the 
responses. 
 The financial responses were collected from the 21 participants. The overall 
averages were calculated to allow initial assessment of the clarity of the tables. Table 41 
below presents the averages of the responses for the pre-FDA scenario.  
Table 41 
Pre-FDA: Financial Indicators 
FINANCIAL OPERATING INDICATORS Decreased No change Increased 
COGS 14.3% 61.9% 23.8% 
Investment (Facility & Equipment)    4.8% 28.6% 66.7% 
Process compliance 42.9% 47.6%    9.5% 
Averages 20.7% 46.0%   33.3% 
 
FINANCIAL INDICATORS Decreased No change Increased 
Actual sales (end of year prior to FDA) 47.6% 47.6%  4.8% 
Actual revenues (end of year prior to FDA) 42.8% 52.4%  4.8% 
 
Market values (end of year prior to FDA)   4.8% 42.9% 52.4% 
Stockholder's equity (end of year prior to FDA)   14.3% 47.6% 38.1% 
   27.4% 47.6% 25.0% 
 
 
 Table 42 presents the responses for the post-FDA scenario. The average response 
of the participants indicated that the financial indicators increased from the pre-FDA to 
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the post-FDA intervention. The results showed that the financial operating indicators 
“increased” from pre-FDA 33.3% to post-FDA 54.1%. The participants also indicated 
that the financial indicators “increased” from pre-FDA 25 to post-FDA 38%. The 
averages projected an increasing trend for financial indicators between the prior and after 
the FDA intervention and action. 
Table 42 
Post-FDA: Financial Indicators 
FINANCIAL OPERATING INDICATORS Decreased No change Increased 
COGS 14.3% 52.4% 33.3% 
Investment (Facility & Equipment) 9.5% 28.6% 61.9% 
Process compliance 0.0% 42.9% 67.1% 
Averages  7.9% 41.3% 54.1% 
 
FINANCIAL INDICATORS Decreased   No change      Increased 
Actual sales (end of year after to FDA)  4.8% 47.6% 47.7% 
Actual revenues (end of after prior to FDA)  4.8% 47.6% 47.7% 
Market values (end of year after to FDA) 14.3% 53.4% 33.3% 
Stockholder's equity (end of year after to FDA) 19.0% 57.1% 23.8% 
Averages 10.7% 51.4% 38.12% 
 
 To understand the distribution of the financial data, within the SPSS calculation, 
the skewness and the kurtosis were obtained. In both scenarios of pre-FDA and post-FDA 
interventions, the skewness results were all positive indicating that there was a cluster at 
the left end of the scales (Field, 2009). Kurtosis was used to measure the degree to which 
scores cluster in the tails of a frequency distribution. Kurtosis’ values were positive for 
all the financial indicators on both scenarios. Positive kurtosis values indicates that the 
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distribution tends to peaked at the tails due to the high number of scores in the tail. 
Negative kurtosis values signals few scores in the tails and a flat distribution (Field, 
2009). 
 The non-normal distribution in all the financial indicators were significant as 
confirmed by indicated by the calculations for Kolmogorov-Smirnov and Shapiro-Wilk in 
SPSS. All values for both scenarios were significant [(K-S): p < 0.001 and (S-W): p < 
0.005] confirming that none of the financial indicators had a normal distribution. Table 
43 shows the results of the Kolmogorov-Smirnov and Shapiro-Wilk tests for the pre-FDA 
intervention. For the post-FDA intervention in Table 44, the results for Kolmogorov-
Smirnov and Shapiro-Wilk tests were illustrated. 
Table 43 
Test of Normality pre-FDA Intervention 
 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
COGS_pre .322 21 .000 .779 21 .000 
Investment_fac_equip_pre .288 21 .000 .856 21 .005 
Compliance_pre .273 21 .000 .774 21 .000 
Sales_pre .325 21 .000 .749 21 .000 
Revenues_pre .325 21 .000 .749 21 .000 
Act_sales_pre .307 21 .000 .739 21 .000 
Act_revenues_pre .312 21 .000 .742 21 .000 
Market_value_pre .282 21 .000 .827 21 .002 
Stockholders_pre .252 21 .001 .796 21 .001 
a. Lilliefors Significance Correction 
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Table 44 
Test of Normality post-FDA Intervention 
 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
COGS_post .277 21 .000 .797 21 .001 
Investment_fac_equip_post .377 21 .000 .697 21 .000 
Compliance_post .372 21 .000 .633 21 .000 
Act_sales_post .282 21 .000 .827 21 .002 
Act_revenues_post .282 21 .000 .827 21 .002 
Market_value_post .277 21 .000 .797 21 .001 
Stockholders_post .290 21 .000 .800 21 .001 
a. Lilliefors Significance Correction 
 
 Despite the non-normal distribution, the Pearson Correlation was performed to 
understand the possible correlation between the financial indicators for each scenario: 
pre-FDA and post-FDA interventions. The basis of the correlations was the firms’ level 
of compliance as indicated by the participants both before and after the FDA intervention. 
The intent was to establish if there was a correlation between any of the financial 
indicators with the level of compliance of the firms on both scenarios. 
 Of the seven financial indicators, the compliance of the firms prior to the FDA 
intervention had a significant correlation at p < 0.05 with three of them considering a 
one-tailed assumption due to the skewness of the data in the responses. Investment in 
facility and equipment (r = |-0.468|, p < 0.05), compliance expenses (r = |-0.558|, p < 
0.05), and stockholders’ equity (r = 0.392, p < 0.05) were significantly correlated to 
compliance. In addition, facility and equipment and compliance expenses were 
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significantly correlated to actual sales, actual revenues, and market value at p < 0.01. 
Table 45 and 46 present the Pearson Correlation information for the pre-FDA and post-
FDA scenario, respectively.  
Table 45 
Pearson Correlations (pre-FDA) 
 
q0133
_00
01 
COGS
_pre 
Investment
_fac_equip
_pre 
compli
ance_p
re 
Act_sales
_pre 
Act_re
venues
_pre 
Marke
t_valu
e_pre 
Stock
holde
rs_pr
e 
q0133_000
1 
Pearson 
Correlation 
1 -.259 -.468* -.558** -.061 -.199 -.184 .392* 
Sig. (1-tailed)  .129 .016 .004 .397 .194 .212 .039 
N 21 21 21 21 21 21 21 21 
COGS_pre Pearson 
Correlation 
-.259 1 .258 .324 -.019 .103 .112 .174 
Sig. (1-tailed) .129  .130 .076 .467 .328 .314 .225 
Investment
_fac_equip
__pre 
Pearson 
Correlation 
-.468* .258 1 .824** .311 .452* .346 -.261 
Sig. (1-tailed) .016 .130  .000 .085 .020 .062 .127 
complianc
e__pre 
Pearson 
Correlation 
-.558** .324 .824** 1 .508** .687** .522** -.036 
Sig. (1-tailed) .004 .076 .000  .009 .000 .008 .438 
Act_sales_
pre 
Pearson 
Correlation 
-.061 -.019 .311 .508** 1 .933** .703** .375* 
Sig. (1-tailed) .397 .467 .085 .009  .000 .000 .047 
Act_reven
ues_pre 
Pearson 
Correlation 
-.199 .103 .452* .687** .933** 1 .772** .352 
Sig. (1-tailed) .194 .328 .020 .000 .000  .000 .059 
Market_va
lue_pre 
Pearson 
Correlation 
-.184 .112 .346 .522** .703** .772** 1 .565** 
Sig. (1-tailed) .212 .314 .062 .008 .000 .000  .004 
Stockholde
rs_pre 
Pearson 
Correlation 
.392* .174 -.261 -.036 .375* .352 .565** 1 
Sig. (1-tailed) .039 .225 .127 .438 .047 .059 .004  
*. Correlation is significant at the 0.05 level (1-tailed). 
**. Correlation is significant at the 0.01 level (1-tailed). 
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Table 46 
Pearson Correlations (post-FDA) 
 
q0134
_0001 
COG
S_pos
t 
Investmen
t_fac_equi
p_post 
Complian
ce_post 
Act_sale
s_post 
Act_revenu
es_post 
Market
_value
_post 
Stock
holder
s_post 
q013
4_00
01 
Pearson Corr. 1 -.024 -.190 -.263 -.059 -.059 .101 .374* 
Sig. (1-
tailed) 
 
.459 .205 .125 .399 .399 .332 .047 
N 21 21 21 21 21 21 21 21 
COG
S_po
st 
Pearson Corr. -.024 1 .206 .249 .010 .010 -.082 .089 
Sig. (1-
tailed) 
.459 
 
.185 .138 .482 .482 .361 .351 
Inves
tmen
t_fac
_equi
p_po
st 
Pearson Corr. -.190 .206 1 .829** .732** .732** .423* .272 
Sig. (1-
tailed) 
.205 .185 
 
.000 .000 .000 .028 .116 
Com
plian
ce_p
ost 
Pearson Corr. -.263 .249 .829** 1 .767** .767** .394* .211 
Sig. (1-
tailed) 
.125 .138 .000 
 
.000 .000 .039 .180 
Act_
sales
_post 
Pearson Corr. -.059 .010 .732** .767** 1 1.000** .552** .387* 
Sig. (1-
tailed) 
.399 .482 .000 .000 
 
.000 .005 .041 
Act_
reven
ues_
post 
Pearson Corr. -.059 .010 .732** .767** 1.000** 1 .552** .387* 
Sig. (1-
tailed) 
.399 .482 .000 .000 .000 
 
.005 .041 
Mark
et_va
lue_p
ost 
Pearson Corr. .101 -.082 .423* .394* .552** .552** 1 .749** 
Sig. (1-
tailed) 
.332 .361 .028 .039 .005 .005 
 
.000 
Stoc
khol
ders_
post 
Pearson Corr. .374* .089 .272 .211 .387* .387* .749** 1 
Sig. (1-
tailed) 
.047 .351 .116 .180 .041 .041 .000 
 
*. Correlation is significant at the 0.05 level (1-tailed). 
**. Correlation is significant at the 0.01 level (1-tailed). 
 
165 
 
 
 The compliance of the firms after the FDA intervention only had a significant 
correlation with stockholders’ equity (r = 0.374, p < 0.05) considering a one-tailed 
assumption due to the skewness of the data in the responses. Similar to the pre-FDA 
scenario, investment in facility and equipment and compliance expenses were 
significantly correlated to actual sales, actual revenues, and market value at p < 0.01. 
Compliance expenses was significantly correlated to all other indicators except for COGS 
and stockholders’ equity implying the importance of compliance expense between the 
indicators in both scenarios.  
 Since the distribution of the scores was skewed or non-normal as supported by the 
results of Kolmogorov-Smirnov and Shapiro-Wilk tests, Kendall’s Tau correlation 
coefficient, τ, was used to understand the correlation between the variables. Kendall’s 
Tau is a non-parametric measure that applies to a small number of scores that also rank in 
a similar manner (Field, 2009). The limited number of completed surveys of 21 also 
signaled the use of Kendall’s correlation coefficient, τ. 
 Of the seven financial indicators and following Kendall’s correlation coefficient, 
τ, the compliance of the firms prior to the FDA intervention had a significant correlation 
at p < 0.05 with two of them considering a one-tailed assumption due to the skewness of 
the data in the responses. Investment in facility and equipment (r = |-0.432|, p < 0.05) and 
compliance expenses (r = |-0.497|, p < 0.01) were significantly correlated to compliance 
of the firms. Also, facility and equipment and compliance expenses were significantly 
correlated to actual sales, actual revenues, and market value at p < 0.01. Table 47 
presents Kendall’s correlation coefficient, τ for the pre-FDA intervention.  
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Table 47 
Kendall’s correlation coefficient, τ (pre-FDA) 
 
q0133_
0001 
COGS
_pre 
Investmen
t_fac_equi
p__pre 
complianc
e__pre 
Act_sales
_pre 
Act_rev
enues_p
re 
Marke
t_valu
e_pre 
Stock
holde
rs_pr
e 
q0133
_0001 
Corr. Coeff. 1.000 -.253 -.432* -.497** -.061 -.201 -.193 .338 
Sig. (1-tailed) . .110 .017 .008 .386 .170 .176 .051 
N 21 21 21 21 21 21 21 21 
COGS
_pre 
Corr. Coeff. -.253 1.000 .235 .308 -.067 .067 .081 .158 
Sig. (1-tailed) .110 . .123 .069 .375 .375 .348 .220 
Invest
ment_f
ac_equ
ip__pr
e 
Corr. Coeff. -.432* .235 1.000 .816** .367* .501** .406* -.111 
Sig. (1-tailed) .017 .123 . .000 .038 .008 .023 .292 
compli
ance__
pre 
Corr. Coeff. -.497** .308 .816** 1.000 .565** .713** .568** .107 
Sig. (1-tailed) .008 .069 .000 . .004 .000 .003 .302 
Act_sa
les_pre 
Corr. Coeff. -.061 -.067 .367* .565** 1.000 .921** .731** .418* 
Sig. (1-tailed) .386 .375 .038 .004 . .000 .000 .023 
Act_re
venues
_pre 
Corr. Coeff. -.201 .067 .501** .713** .921** 1.000 .815** .388* 
Sig. (1-tailed) .170 .375 .008 .000 .000 . .000 .032 
Market
_value
_pre 
Corr. Coeff. -.193 .081 .406* .568** .731** .815** 1.000 .570*
* 
Sig. (1-tailed) .176 .348 .023 .003 .000 .000 . .003 
Stockh
olders_
pre 
Corr. Coeff. .338 .158 -.111 .107 .418* .388* .570** 1.000 
Sig. (1-tailed) .051 .220 .292 .302 .023 .032 .003 . 
*. Correlation is significant at the 0.05 level (1-tailed). 
**. Correlation is significant at the 0.01 level (1-tailed). 
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 The compliance of the firms after the FDA intervention had no significant 
correlation with any of the financial indicators considering a one-tailed assumption due to 
the skewness of the data in the responses. Similar to the pre-FDA scenario, investment in 
facility and equipment and compliance expenses were significantly correlated to actual 
sales, actual revenues, and market value at p < 0.01. Compliance expenses was 
significantly correlated to all other indicators except for COGS and stockholders’ equity. 
Table 48 presents Kendall’s correlation coefficient, τ.  
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Table 48 
Kendall’s correlation coefficient, τ (post-FDA) 
 
q0134
_0001 
COGS
_post 
Investmen
t_fac_equi
p_post 
Complianc
e_post 
Act_sales
_post 
Act_revenue
s_post 
Marke
t_valu
e_post 
Stock
holde
rs_po
st 
q0134
_0001 
Corr. Coeff. 1.000 -.033 -.212 -.248 -.059 -.059 .067 .329 
Sig. (1-
tailed) 
. .436 .154 .125 .388 .388 .373 .055 
N 21 21 21 21 21 21 21 21 
COGS
_post 
Corr. Coeff. -.033 1.000 .227 .269 .015 .015 -.046 .085 
Sig. (1-
tailed) 
.436 . .136 .104 .470 .470 .412 .339 
Invest
ment_f
ac_equ
ip_pos
t 
Correlation 
Coefficient 
-.212 .227 1.000 .858** .728** .728** .422* .246 
Sig. (1-
tailed) 
.154 .136 . .000 .000 .000 .021 .117 
Compl
iance_
post 
Corr. Coeff. -.248 .269 .858** 1.000 .779** .779** .420* .213 
Sig. (1-
tailed) 
.125 .104 .000 . .000 .000 .025 .160 
Act_sa
les_po
st 
Corr. Coeff. -.059 .015 .728** .779** 1.000 1.000** .546** .327 
Sig. (1-
tailed) 
.388 .470 .000 .000 . . .004 .056 
Act_re
venues
_post 
Corr. Coeff. -.059 .015 .728** .779** 1.000** 1.000 .546** .327 
Sig. (1-
tailed) 
.388 .470 .000 .000 . . .004 .056 
Market
_value
_post 
Corr. Coeff. .067 -.046 .422* .420* .546** .546** 1.000 .734*
* 
Sig. (1-
tailed) 
.373 .412 .021 .025 .004 .004 . .000 
Stockh
olders
_post 
Corr. Coeff. .329 .085 .246 .213 .327 .327 .734** 1.000 
Sig. (1-
tailed) 
.055 .339 .117 .160 .056 .056 .000   . 
**. Correlation is significant at the 0.01 level (1-tailed). 
*. Correlation is significant at the 0.05 level (1-tailed). 
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The null hypothesis, H2₀, was rejected for RQ2 in the pre-FDA intervention since several 
correlations were proven to be significant to at least p < 0.05. The Kendall’s correlation 
coefficient, τ indicated that prior to the FDA intervention there were two financial 
indicators that influence the compliance of the firms with the FDA regulations. 
Investment in facility and equipment and compliance expenses were significantly 
correlated to the level of compliance. Also, investment in facility and equipment, as well 
as compliance expenses, correlated significantly with sales, revenues, and market value 
with p < 0.01.  
The test for the null hypothesis, H2₀, for RQ2 was difficult to be assessed for the 
post-FDA scenario. The limited number of participants was also a factor not allowing a 
definite result. The Pearson correlation indicated that the compliance of the firms had a 
significant correlation with stockholders’ equity (p < 0.05). For the Kendall’s correlation 
coefficient, τ, the compliance of the firms had no significant correlation with any of the 
financial indicators. The stockholders’ equity had a p significance value equal to 0.055. 
The Kendall’s correlation coefficient indicated that investment in facility and equipment 
and compliance expenses had significant correlations with actual sales, actual revenues, 
and market value at p < 0.01. If the interdependencies between the indicators were used 
to imply that complince expenses impact actual sales and actual revenues, the null 
hypothesis could be rejected. 
 Research Question 3 (RQ3). To what extent, if any, do financial indicators 
(independent) impact compliance (dependent) with FDA regulations at the 
pharmaceutical firms in the United States? 
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 H3₀:  β₁ = β₂ = … = β7 = 0. There is no impact in compliance with FDA 
related to seven financial indicators at pharmaceutical firms, as a result of 
FDA enforcement actions in the United States. 
 H3₁:  At least one β ≠ 0. There is an impact in compliance with FDA related 
to at least one of the seven financial indicators before and after the FDA 
enforcement actions in the United States. 
 To address RQ3 and the null test, regression analyses were conducted to establish 
a model with the financial indicators as predictors of level of compliance of the firms 
with the FDA regulations. The regression analyses were performed using SPSS for both 
scenarios: pre-FDA and post-FDA. All assumptions were assessed to understand the 
robustness of the models. 
 Assumptions for Multiple Regression Analysis. For regression analysis, there 
were several assumptions that needed to be met. Meeting the assumptions allowed 
assessing if the conclusions were true for a wider population. For a regression model to 
generalize beyond the sample population, assumptions have to be met (Field, 2009). The 
assumptions were assessed for both scenarios: pre-FDA and post-FDA interventions. The 
assessment of the assumptions was: 
1) Variable types:  All predictor variables were quantitative and the outcome 
variable was quantitative: continuous and unbounded. 
2) Non-zero variance:  The predictors should had variation in value. They did not 
have variances of 0. 
171 
 
 
3) Sample Size:  The ratio of predictors to cases was expected to be significant 
because of its impact on the value of R. These assumption was not met. 
4) No perfect multicollinearity:  There was no perfect linear relationship between 
two or more of the predictors in the pre-FDA scenario. The predictor variables did 
not highly correlated. For the post-FDA, actual sales and actual revenues were 
perfect correlated, SPSS removed actual revenues in the post-FDA model. 
5) Predictors are not correlated with external variables:  External variables could 
be present. In the model, not all contribution that could significantly influence the 
outcome was identified. This assumption was not met.  
6) Homoscedasticity:  At each level of the predictor variable(s), the variance of 
the residual terms were constant. The SPSS graphs supported this assumption. 
7) Independent errors:  For any two observations the residual terms should be 
independent. This assumption tested whether adjacent residuals are correlated. 
The test statistic was allow to vary between 0 and 4 with a value of 2 meaning 
that the residuals were uncorrelated. 
8) Normally distributed errors:  This assumption indicates that the differences 
between the model and the observed data are most frequently zero or very close to 
zero. The SPSS graphs did not support this assumption.  
9) Independence:  All of the values of the dependent variable were independent of 
each other. 
10) Linearity:  The mean values of the dependent variable were represented in a 
reasonable spread indicating a straight line. Assumption met. 
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 The dependent variable was the level of compliance as indicated in the main 
survey. All 21 participants indicated that their firms had at least one FDA intervention in 
the last 5-6 years. The FDA interventions consisted of No Action Indicated, Voluntary 
Action Indicated, and Official Action indicated. The predictors or independent variables 
were seven. Similar to the pilot study, in the main survey, the participants provided to 
their best recollection the tendencies for the financial indicators regarding the FDA 
interventions. As indicated in the Data Treatment section, missing values from the 
participants were noted as no change to avoid influencing the tendencies of the 
independent variables. The variables were listed in Table 49 and Table 50. 
Table 49 
Variables and Descriptive Statistics 
 Mean Std. Deviation N 
Level of Compliance pre-FDA 5.9524 .58959 21 
COGS_pre .0952 .62488 21 
Investment_fac_equip_pre .7619 .76842 21 
compliance_pre .6667 .65828 21 
Act_sales_pre .5714 .59761 21 
Act_revenues_pre .6190 .58959 21 
Market_value_pre .5238 .67964 21 
Stockholders_pre .2381 .70034 21 
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Table 50 
Variables and Descriptive Statistics 
 Mean Std. Deviation N 
Level of Compliance post-FDA 6.0476 .58959 21 
COGS_post .1905 .67964 21 
Investment_fac_equip_post .5238 .67964 21 
Compliance_post .5714 .50709 21 
Act_sales_post .4762 .67964 21 
Act_revenues_post .4762 .67964 21 
Market_value_post .1905 .67964 21 
Stockholders_post .0476 .66904 21 
  
 The descriptive statistics generated by SPSS provided a correlation matrix for 
each FDA scenario. The matrix provided three elements: Pearson correlation between the 
variables, the significance of the correlation, and the number of cases included in the 
assessment. In Table 51, the correlation matrix lists the results for the pre-FDA scenario 
of the 21 cases or completed questionnaires. The three variables with a high correlation 
with the level of compliance of the firms were investment in facility and equipment (r = |-
0.468|, p < 0.05), compliance expenses (r = |-0.558|, p < 0.01) and stockholders’ equity (r 
= 0.392, p < 0.05). 
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Table 51 
Variables and Descriptive Statistics 
 
q0133
_0001 
COG
S_pre 
Investmen
t_fac_equi
p__pre 
complianc
e__pre 
Act_sale
s_pre 
Act_reven
ues_pre 
Marke
t_valu
e_pre 
Stoc
khol
ders_
pre 
Pearson 
Correlat
ion 
q0133_0001 1.000 -.259 -.468 -.558 -.061 -.199 -.184 .392 
COGS_pre -.259 1.000 .258 .324 -.019 .103 .112 .174 
Investment_fa
c_equip__pre 
-.468 .258 1.000 .824 .311 .452 .346 -.261 
compliance__p
re 
-.558 .324 .824 1.000 .508 .687 .522 -.036 
Act_sales_pre -.061 -.019 .311 .508 1.000 .933 .703 .375 
Act_revenues_
pre 
-.199 .103 .452 .687 .933 1.000 .772 .352 
Market_value_
pre 
-.184 .112 .346 .522 .703 .772 1.000 .565 
Stockholders_
pre 
 
.392 .174 -.261 -.036 .375 .352 .565 1.00 
Sig. (1-
tailed) 
q0133_0001 . .129 .016 .004 .397 .194 .212 .039 
COGS_pre .129 . .130 .076 .467 .328 .314 .225 
Investment_fa
c_equip__pre 
.016 .130 . .000 .085 .020 .062 .127 
compliance__p
re 
.004 .076 .000 . .009 .000 .008 .438 
Act_sales_pre .397 .467 .085 .009 . .000 .000 .047 
Act_revenues_
pre 
.194 .328 .020 .000 .000 . .000 .059 
Market_value_
pre 
.212 .314 .062 .008 .000 .000 . .004 
Stockholders_
pre 
.039 .225 .127 .438 .047 .059 .004 . 
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 As indicated in the assessment of the financial indicators, the compliance of the 
firms before the FDA intervention had a significant correlation at p < 0.05 with three of 
the indicators considering a one-tailed assumption due to the skewness of the data in the 
responses. Investment in facility and equipment, compliance expenses, and stockholders 
equity were significantly correlated to compliance (p < 0.05). Also, compliance expenses 
were significantly correlated to facility and equipment, actual sales, actual revenues, and 
market value at p < 0.01. Since none of the correlation between different variables was 
high (r = 0.9), the possibility of multicollinearity was considered low (Field, 2009). 
 In Table 52, the correlation matrix lists the results for the post-FDA scenario of 
the 21 cases or completed questionnaires. Two variables with a high correlation with the 
level of compliance of the firms were compliance expenses (r = |-0.263|, p = 0.125) and 
stockholders’ equity (r = 0.374, p < 0.05). The compliance of the firms after the FDA 
intervention only had a significant correlation with stockholders’ equity (p < 0.05) 
considering a one-tailed assumption due to the skewness of the data in the responses. 
Compliance expenses were significantly correlated to facility and equipment, actual sales, 
actual revenues, and market value at p < 0.05. In the case of the post-FDA scenario, two 
variables had a correlation of r = 1.0 generating the possibility of multicollinearity (Field, 
2009). As a result, SPSS removed the financial indicator labeled as actual revenues to 
compensate and improving the possibility of complying with the assumption of 
multicollinearity. 
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Table 52 
Variables and Descriptive Statistics 
 
q0134_
0001 
COGS
_post 
Investment
_fac_equip
_post 
Complia
nce_post 
Act_sales
_post 
Act_rev
enues_p
ost 
Market
_value
_post 
Stock
holde
rs_po
st 
Pearson 
Correla
tion 
q0134_0001 1.000 -.024 -.190 -.263 -.059 -.059 .101 .374 
COGS_pos -.024 1.000 .206 .249 .010 .010 -.082 .089 
Investment_f
ac_equip_pos
t 
-.190 .206 1.000 .829 .732 .732 .423 .272 
Compliance_
post 
-.263 .249 .829 1.000 .767 .767 .394 .211 
Act_sales_po
st 
-.059 .010 .732 .767 1.000 1.000 .552 .387 
Act_revenues
_post 
-.059 .010 .732 .767 1.000 1.000 .552 .387 
Market_valu
e_post 
.101 -.082 .423 .394 .552 .552 1.000 .749 
Stockholders
_post 
.374 .089 .272 .211 .387 .387 .749 1.00 
Sig. (1-
tailed) 
q0134_0001 . .459 .205 .125 .399 .399 .332 .047 
COGS_post .459 . .185 .138 .482 .482 .361 .351 
Investment_f
ac_equip_pos
t 
.205 .185 . .000 .000 .000 .028 .116 
Compliance_
post 
.125 .138 .000 . .000 .000 .039 .180 
Act_sales_po
st 
.399 .482 .000 .000 . .000 .005 .041 
Act_revenues
_post 
.399 .482 .000 .000 .000 . .005 .041 
Market_valu
e_post 
.332 .361 .028 .039 .005 .005 . .000 
Stockholders
_post 
.047 .351 .116 .180 .041 .041 .000 . 
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 In the next step, following the hierarchical method of assessing the independent 
variables, the predicting model was evaluated for both FDA scenarios. For the seven 
financial indicators, a total of seven models in a hierarchical order were developed in 
SPSS. Table 53 presented the model for the pre-FDA scenario. The correlation R 
between the variables and the prediction R2 of how much of the dependent variable is 
contributed by each predictor were obtained. Also, the assumption of independent errors 
was verified with the Durbin–Watson statistic. The value of 1.53 was obtained, indicating 
that the assumption of independent errors could be considered as met. In relation to 
external variables, the R2 values of model 7 indicated that the predictors accounted for 
60.7% contribution to the outcome variable, indicating that there are other external 
variables not included, violating this assumption.  
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Table 53 
Model Summary h pre-FDA 
Model R 
R 
Square 
Adjusted R 
Square 
Std. Error of 
the Estimate 
Change Statistics 
Durbin-
Watson 
R Square 
Change F Change df1 df2 
Sig. F 
Change 
1 .259a .067 .018 .58435 .067 1.361 1 19 .258  
2 .489
b 
.239 .155 .54211 .172 4.076 1 18 .059 
 
3 .564c .319 .198 .52789 .079 1.982 1 17 .177  
4 .617
d 
.381 .226 .51858 .063 1.616 1 16 .222 
 
5 .619e .383 .178 .53457 .002 .057 1 15 .815  
6 .622f .386 .124 .55198 .003 .069 1 14 .797  
7 .779
g 
.607 .395 .45868 .220 7.275 1 13 .018 1.528 
a. Predictors: (Constant), COGS_pre 
b. Predictors: (Constant), COGS_pre, Investment_fac_equip__pre 
c. Predictors: (Constant), COGS_pre, Investment_fac_equip__pre, compliance__pre 
d. Predictors: (Constant), COGS_pre, Investment_fac_equip__pre, compliance__pre, Act_sales_pre 
e. Predictors: (Constant), COGS_pre, Investment_fac_equip__pre, compliance__pre, Act_sales_pre, 
Act_revenues_pre 
f. Predictors: (Constant), COGS_pre, Investment_fac_equip__pre, compliance__pre, Act_sales_pre, 
Act_revenues_pre, Market_value_pre 
g. Predictors: (Constant), COGS_pre, Investment_fac_equip__pre, compliance__pre, Act_sales_pre, 
Act_revenues_pre, Market_value_pre, Stockholders_pre 
h. Dependent Variable: q0133_0001 
 
 The adjusted R2 provided a way to understand how well the model could 
generalize the scenario under review. The smallest the difference of the adjustment the 
better the possibility for the model to represent the population, not just the sample. In 
model 7, the R2 = 0.607 was adjusted to 0.395 or 39.5% representing a reduction of 0.212 
or 21.2% of the overall contribution of the seven variables. The stockholder’s equity 
added almost 32.1% in contribution in comparison to the previous six predictors. 
Investment in facilities and equipment was the second largest contributor with 13.7%. 
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These two predictors contributed 45.8% of the total 60.7% of all the financial indicators. 
The F- ratio provided the significance of the change. Only model 7 had a significant F- 
ratio of 7.28, p < 0.05. For model 2, COGS and investment on facilities and equipment 
had a significance at p < 0.59, but still above the expectations. 
 For the post-FDA scenario, the hierarchical method of assessing the independent 
variables was also followed. For the seven financial indicators, a total of seven models in 
a hierarchical order were developed in SPSS. Table 54 presents the model for the post-
FDA scenario. The correlation R between the variables and the prediction R2 of how 
much of the dependent variable is contributed by each predictor were obtained. Also, the 
assumption of independent errors was verified with the Durbin–Watson statistic. The 
value of 2.18 was obtained, indicating that the assumption of independent errors could be 
considered as met. In relation to external variables, the R2 values of model 6 indicated 
that the predictors accounted for about 30% contribution to the outcome variable, 
indicating that there are other external variables not included, violating this assumption.  
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Table 54 
Model Summary g post-FDA 
Model R 
R 
Square 
Adjusted 
R 
Square 
Std. 
Error of 
the 
Estimate 
Change Statistics 
Durbin-
Watson 
R Square 
Change 
F 
Change df1 df2 
Sig. F 
Change 
1 .024a .001 -.052 .60474 .001 .011 1 19 .919  
2 .191b .036 -.071 .61007 .036 .669 1 18 .424  
3 .271c .073 -.090 .61560 .037 .678 1 17 .422  
4 .362d .131 -.086 .61448 .058 1.062 1 16 .318  
5 .394e .155 -.126 .62573 .024 .430 1 15 .522  
6 .547f .299 -.001 .58987 .144 2.879 1 14 .112 2.175 
a. Predictors: (Constant), COGS_post 
b. Predictors: (Constant), COGS_post, Investment_fac_equip_post 
c. Predictors: (Constant), COGS_post, Investment_fac_equip_post, Compliance_post 
d. Predictors: (Constant), COGS_post, Investment_fac_equip_post, Compliance_post, Act_sales_post 
e. Predictors: (Constant), COGS_post, Investment_fac_equip_post, Compliance_post, 
Act_sales_post, Market_value_post 
f. Predictors: (Constant), COGS_post, Investment_fac_equip_post, Compliance_post, 
Act_sales_post, Market_value_post, Stockholders_post 
g. Dependent Variable: q0134_0001 
 
 The adjusted R2 provided a way to understand how well the model could 
generalize the scenario under review. The smallest the difference of the adjustment the 
better the possibility for the model to represent the population, not just the sample. In 
Model 6, the R2 = 0.299 was adjusted to -0.001 representing a very significant adjustment 
to the overall contribution of the seven variables. This adjustment implied that the model 
did not generalized beyond the sample. The stockholder’s equity contributed with 14.4% 
in comparison to the 15.5% of the previous five predictors. Actual sales were the second 
largest contributor with 5.8%. These two predictors contributed 20.2% of the total 29.9% 
of the financial indicators for the post-FDA scenario. The F-ratio provided the 
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significance of the change. None of the post-FDA models had a significance value less 
than 0.05 affecting the robustness of the models. 
The next test performed in SPSS was the calculation of the ANOVA for the seven 
models. The ANOVA challenged whether the models were better predictors of the 
outcome than the guess based on the average of the means. The F-ratio indicated the ratio 
of the accuracy of the model versus the means (Field, 2009). For the pre-FDA scenario, 
all values of F were above one signaling that the model’s fits are better predictors than 
the guess from the means. In Table 55, only model 7 has an F-ratio that was significant to 
p < 0.048 indicating the low probability of the outcome could happen by chance. Models 
2, 3, and 4 had F-ratios that were non-significance at less than 0.09.  
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Table 55 
ANOVA a pre-FDA 
Model Sum of Squares df Mean Square F Sig. 
1 Regression .465 1 .465 1.361 .258b 
Residual 6.488 19 .341   
Total 6.952 20    
2 Regression 1.663 2 .831 2.829 .085c 
Residual 5.290 18 .294   
Total 6.952 20    
3 Regression 2.215 3 .738 2.650 .082d 
Residual 4.737 17 .279   
Total 6.952 20    
4 Regression 2.650 4 .662 2.463 .087e 
Residual 4.303 16 .269   
Total 6.952 20    
5 Regression 2.666 5 .533 1.866 .160f 
Residual 4.287 15 .286   
Total 6.952 20    
6 Regression 2.687 6 .448 1.470 .258g 
Residual 4.266 14 .305   
Total 6.952 20    
7 Regression 4.217 7 .602 2.864 .048h 
Residual 2.735 13 .210   
Total 6.952 20    
a. Dependent Variable: q0133_0001 
b. Predictors: (Constant), COGS_pre 
c. Predictors: (Constant), COGS_pre, Investment_fac_equip__pre 
d. Predictors: (Constant), COGS_pre, Investment_fac_equip__pre, compliance__pre 
e. Predictors: (Constant), COGS_pre, Investment_fac_equip__pre, compliance__pre, Act_sales_pre 
f. Predictors: (Constant), COGS_pre, Investment_fac_equip__pre, compliance__pre, Act_sales_pre, 
Act_revenues_pre 
 
The ANOVA for the six models for the post-FDA intervention are presented in 
Table 56. The ANOVA challenged whether the models were better predictors of the 
outcome than the guess based on the average means. The F-ratio indicated the ratio of the 
accuracy of the model versus the means (Field, 2009). For the post-FDA scenario, all 
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values of F are below one signaling that the model’s fits are not good predictors than the 
guess from the means. None of the models in the post-FDA scenario had an F-ratio that 
was significant indicating that the outcome could happen by chance.  
Table 56 
ANOVA a post-FDA 
Model Sum of Squares df Mean Square F Sig. 
1 Regression .004 1 .004 .011 .919b 
Residual 6.948 19 .366   
Total 6.952 20    
2 Regression .253 2 .127 .340 .716c 
Residual 6.699 18 .372   
Total 6.952 20    
3 Regression .510 3 .170 .449 .721d 
Residual 6.442 17 .379   
Total 6.952 20    
4 Regression .911 4 .228 .603 .666e 
Residual 6.041 16 .378   
Total 6.952 20    
5 Regression 1.079 5 .216 .551 .735f 
Residual 5.873 15 .392   
Total 6.952 20    
6 Regression 2.081 6 .347 .997 .465g 
Residual 4.871 14 .348   
Total 6.952 20    
a. Dependent Variable: q0134_0001 
b. Predictors: (Constant), COGS_post 
c. Predictors: (Constant), COGS_post, Investment_fac_equip_post 
d. Predictors: (Constant), COGS_post, Investment_fac_equip_post, Compliance_post 
e. Predictors: (Constant), COGS_post, Investment_fac_equip_post, Compliance_post, Act_sales_post 
f. Predictors: (Constant), COGS_post, Investment_fac_equip_post, Compliance_post, Act_sales_post, 
Market_value_post 
g. Predictors: (Constant), COGS_post, Investment_fac_equip_post, Compliance_post, Act_sales_post, 
Market_value_post, Stockholders_post 
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The model parameters were then obtained by SPSS. For the pre-FDA scenario, 
the model discussion was focused on model 7 since this model was the only one with 
significance F-ratio in the ANOVA assessment. Table 57 presents the slope values, B, 
for each predictor (financial indicator). Stockholders’ equity was the only B value that 
was significant (p < 0.05) indicating a strong contribution to the outcome. The smallest 
the significance of the B values the stronger the contribution of the prediction to the 
outcome (Field, 2009). Regarding the standardized beta (labeled as Beta, β), 
Stockholders equity (β = 0.760), compliance expense (β = |-0.754|), and market value (β 
= |-0.624|) have the largest impact on the standard deviation of the outcome, the level of 
compliance of the firms. 
Table 57 
Model 7 Parameters a pre-FDA 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
7 (Constant) 6.065 .166  36.466 .000 
COGS_pre -.218 .193 -.231 -1.127 .280 
Investment_fac_equip__pre .365 .269 .476 1.356 .198 
compliance__pre -.676 .393 -.754 -1.718 .110 
Act_sales_pre .029 .566 .029 .051 .960 
Act_revenues_pre .316 .733 .316 .431 .674 
Market_value_pre -.541 .295 -.624 -1.834 .090 
Stockholders_pre .640 .237 .760 2.697 .018 
Dependent Variable: q0133_0001 
185 
 
 
To assess how close is the B value of the sample to the B value of the population, a 
level of confidence of 95% was selected as shown in Table 58. In model 7, only 
stockholders’ equity had a small spread between the upper and lower boundaries of the 
confidence limit and not crossing the value of zero. Having only one indicator with these 
characteristics implied that the model was not strong for the prediction of the outcome of 
the model. Regarding the Collinearity Statistics, actual revenues had a VIF value 
significantly above 10 (17.732) with a tolerance below 0.2 (0.056). For actual sales, the 
VIF value was slightly above 10 (10.872) with a tolerance below 0.1 (0.092). These 
results highlighted a potential problem in meeting the assumption of collinearity. 
Table 58 
pre-FDA Confidence and Collinearity 
Model 
95.0% Confidence 
Interval for B Correlations 
Collinearity 
Statistics 
Lower 
Bound 
Upper 
Bound Zero-order 
Partia
l Part Tolerance VIF 
7 (Constant) 5.705 6.424      
COGS_pre -.636 .200 -.259 -.298 -.196 .720 1.389 
Investment_fac_equip_
_pre 
-.216 .947 -.468 .352 .236 .246 4.068 
compliance__pre -1.526 .174 -.558 -.430 -.299 .157 6.376 
Act_sales_pre -1.194 1.252 -.061 .014 .009 .092 10.872 
Act_revenues_pre -1.267 1.898 -.199 .119 .075 .056 17.732 
Market_value_pre -1.178 .096 -.184 -.453 -.319 .262 3.820 
Stockholders_pre .127 1.152 .392 .599 .469 .381 2.622 
Dependent Variable: q0133_0001 
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Table 59 presents the slope values, B, for each predictor (financial indicator). 
None of the B values had a significance (p < 0.05) indicating that none of the B values 
had a strong contribution to the outcome. The smallest the significance of the B values 
was for the stockholders’ equity (p = 0.112). The smallest the significance value, the 
stronger the contribution of the prediction to the outcome (Field, 2009). Regarding the 
standardized beta (labeled as Beta, β), stockholders’ equity (β = 0.611) had the largest 
impact on the standard deviation of the outcome, the level of compliance of the firms. 
Table 59 
Model 6 Parameters a post-FDA 
Model 
Unstandardized 
Coefficients 
Standardize
d 
Coefficients 
t Sig. B Std. Error Beta 
6 (Constant) 6.266 .202  31.00
0 
.000 
COGS_post .004 .222 .004 .016 .988 
Investment_fac_eq
uip_post 
-.066 .363 -.076 -.182 .858 
Compliance_post -.433 .546 -.372 -.792 .441 
Act_sales_post .178 .356 .205 .500 .625 
Market_value_post -.252 .339 -.291 -.743 .470 
Stockholders_post .538 .317 .611 1.697 .112 
 
To assess how close is the B value of the sample to the B value of the population, 
a level of confidence of 95% was selected as shown in Table 60. In model 6, none of the 
Dependent Variable: q0134_0001a 
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predictors had a spread between the boundaries not crossing the value of zero. Having no 
indicator with these characteristics implied that the model was not strong for the 
prediction of the outcome of the model. Regarding the Collinearity Statistics, none of the 
VIF value was significantly above 10, and all tolerances were above 0.1 with a tolerance 
below 0.2. These results implied that there should not be a concern of not meeting the 
assumption of collinearity for the post-FDA scenario after excluding actual revenues 
from the predictors. 
Table 60 
post-FDA Confidence and Collinearity 
Model 
95.0% Confidence 
Interval for B Correlations 
Collinearity 
Statistics 
Lower 
Bound 
Upper 
Bound 
Zero-
order Partial Part Tolerance VIF 
6 (Constant) 5.833 6.700      
COGS_post -.473 .480 -.024 .004 .004 .762 1.312 
Investment_fac_equi
p_post 
-.845 .713 -.190 -.049 -.041 .286 3.501 
Compliance_post -1.605 .739 -.263 -.207 -.177 .227 4.412 
Act_sales_post -.585 .942 -.059 .133 .112 .297 3.365 
Market_value_post -.980 .476 .101 -.195 -.166 .327 3.060 
Stockholders_post -.142 1.219 .374 .413 .380 .386 2.591 
 
To further assess the assumption of collinearity, a diagnostic was performed by 
SPSS for both scenarios: pre-FDA and post-FDA. In both scenarios, the Eigenvalue for 
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COGS was higher than one. Only Eigenvalues below one were considered for the 
assessment of Variance Proportions. For the pre-FDA in Table 61, several indicators had 
their highest value in dimension 8 implying that the model did not meet the assumption 
of no multicollinearity. For the post-FDA in Table 62, investment in facility and 
equipment and actual sales had their highest value in dimension 6 implying a challenge 
to the assumption of no multicollinearity. 
Table 61 
Collinearity a pre-FDA 
Dimensio
n 
Eigenvalu
e 
Conditio
n Index 
Variance Proportions 
(Constan
t) 
COG
S_pre 
Investme
nt_fac_eq
uip__pre 
complian
ce__pre 
Act_ 
sales
_pre 
Act_     
reven
ues_p
re 
Mark
et_val
ue_pr
e 
Stock
holde
rs_pr
e 
1 5.090 1.000 .01 .00 .00 .00 .00 .00 .00 .00 
2 1.125 2.127 .00 .01 .02 .01 .00 .00 .01 .17 
3 .995 2.261 .01 .62 .00 .00 .00 .00 .00 .02 
4 .376 3.678 .74 .00 .00 .00 .01 .00 .03 .04 
5 .219 4.826 .02 .18 .10 .01 .07 .02 .12 .11 
6 .112 6.747 .18 .15 .06 .09 .00 .00 .74 .62 
7 .067 8.691 .05 .02 .73 .52 .07 .01 .01 .03 
8 .016 17.662 .00 .01 .08 .36 .85 .97 .08 .00 
a. Dependent Variable: q0133_0001 
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Table 62 
Collinearity a post-FDA 
Dimensio
n 
Eigenvalu
e 
Conditi
on 
Index 
Variance Proportions 
(Constan
t) 
COG
S_pos
t 
Investmen
t_fac_equi
p_post 
Complian
ce_post 
Act_ 
sales
_post 
Market
_value
_ post 
Stockholder
s_post 
1 3.871 1.000 .01 .01 .01 .01 .01 .01 .01 
2 1.424 1.649 .03 .06 .00 .00 .00 .06 .11 
3 .881 2.096 .01 .63 .00 .00 .01 .00 .05 
4 .415 3.054 .67 .01 .06 .00 .05 .00 .04 
5 .190 4.508 .01 .09 .00 .00 .07 .90 .67 
6 .149 5.097 .00 .12 .55 .00 .63 .01 .05 
7 .069 7.470 .27 .09 .37 .99 .22 .02   .07 
a. Dependent Variable: q0134_0001 
 The next step was to assess if any case had a significant influence or should be 
considered as an outlier. Using SPSS, the case summary analysis was applied to both 
scenarios: pre-FDA and post-FDA. In the pre-FDA scenario for two cases, 5 and 18, the 
Mahalanobis Distance values were 19.05 but the corresponding Centered Leverage Value 
were within the expected value of 0.36. The two cases were excluded from the Cook’s 
and DFBeta calculations by SPSS indicating the over influence of these two cases in the 
model. In the post-FDA scenario, all cases were included with values of Cook at or below 
+/-1 and values of DFBeta in expectations implying that all cases could be considering 
not having undue influence in the regression model for the post-FDA scenario.  
 For the assumptions of linearity and homoscedasticity, some of the plots assessed 
under SPSS could be considered as supporting these assumptions. For the residual 
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normality, the graphs for both scenario divert from the straight line implying lack of 
normality. Since not all assumptions were met, the regression models for the financial 
indicators cannot be used to generalize beyond the sample of the study in either the pre-
FDA or the post-FDA intervention. 
Reputation of the Firms and Management Changes. 
 The last two questions in the financial sections of the main study questionnaire 
requested the participants to provide their opinion regarding the potential outcomes from 
the FDA interventions or actions. These responses projected the impact on the firms’ 
reputation and the change management process resulting from the FDA’s intervention or 
actions. Comparing results in Table 63 and Table 64 allowed to conduct the assessment. 
Table 63 
Before FDA: Reputation and Management Change 
Answer 
Options 
 Decrease 
of -50% 
Decrease 
of -5% to 
-49%% 
No 
Change 
Increase of 
+5% to 
+49%% 
Increase of 
-+50% 
Response 
Count 
Reputation 
of the Firm 
 0 1 12 6 2 21 
Management 
change 
 0 1 9 8 3 21 
 answered question                 21 
 skipped question 0 
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Table 64 
After FDA: Reputation and Management Change 
Answer 
Options 
 Decrease 
of -50% 
Decrease 
of -5% to 
-49%% 
No 
Change 
Increase of 
+5% to 
+49%% 
Increase of 
-+50% 
Response 
Count 
Reputation of 
the Firms 
 0 2 10 6 0 18 
Management 
change 
 0 3 8 6 2 18 
 answered question 18 
 skipped question 3 
 
FDA Experience.  
 For the FDA experience of the firms, only the 21 completed questionnaires 
addressed the last six questions out of 133 total questions. This questions collected 
information regarding the firms experience with the FDA in the past six years from 2010 
through 2015. The 21 responders indicated that their firms had FDA audits. The 
responses were assumed to be based on the best recollection of each of the participants. 
In all years, the FDA issued 483 observations. In five occasions, the outcome of the FDA 
intervention were audits with Official Action Indicated. None of the 21 participants 
reported warning letters nor consent decrees. To assess the overall result of the responses, 
in the last two question the participants were asked to compare the firms’ compliance 
position with the FDA’s CGMP regulations before and after the FDA’s interventions. 
The overall average of firm’s compliance reflected a favorable increase of 1.7% from 
5.95 to 6.05 in a scale of a maximum value of 7. 
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 A dependent-means t-test was applied to the two scenarios’ means: pre-FDA and 
post-FDA considering that the same participants took part in both scenarios. Through 
SPSS, a paired-samples t-test was conducted. The Pearson coefficient for the two 
scenarios was large at r = 0.870, p < 0.01 implying that the same population was used for 
the comparison. In Table 65, the results of the paired sample test are shown.  
Table 65 
Paired Sample Test 
 
Paired Differences 
t df 
Sig. 
(2-
tailed)       Mean 
Std.   
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 q0133_0001 - 
q0134_0001 
-.09524 .30079 .06564 -.23216 .04168 -1.451 20 .162 
 
 The sign of the Mean was negative indicating that the mean of the compliance of 
the firms after the FDA intervention was larger than before the FDA intervention. The 
standard error was small at 0.066 with a negative t- test confirming that the mean of the 
post-FDA was larger than the pre-FDA scenario. The level of compliance increased after 
the FDA intervention as indicated by the means of the participants. Since the expected 
compliance trend was to increase in value, the two-tailed significance was divided by two 
to obtained a one-tailed non-significance value of p = 0.081. The value of p represented 
the probability that the value of t of -1.451 could be experienced if the null hypothesis 
could not be rejected (no difference between these means). The prediction of this test 
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indicated that the compliance of the firms should increase by the FDA intervention, at 
t(20) = -1.451, p = 0.081. 
 The 95% confidence interval of the differences for this t- test indicated the frame 
within which the true mean difference could be found (Field, 2009). This test’s true mean 
difference lied between -0.232 and + 0.042. The problem with this interval was that it 
contained zero between the two boundaries implying that the true value of the differences 
could be zero at 95% confidence limit. I calculated with SPSS at what confident interval 
limit the true value of the mean difference could be considered as not being zero. At 80% 
confident interval, the mean differences could be considered as unlikely to be equal to 
zero. 
Inconsistencies Applied to Data Analysis 
 In the statistical analyses for research questions one and two, the data analysis 
was consistent with the pilot study. For the financial indicators analysis, the approach 
was similar for both scenarios: before and after the FDA intervention. No inconsistencies 
were noted or applied to these analyses. In the case of assumptions, any non-compliance 
with the regression assumptions was discussed in the data analysis section. 
Reliability Analysis of Questionnaire 
 Analysis of Cronbach's alpha to determine the reliability of the scales from the 
main study questionnaire was conducted for both scenarios: pre-FDA and post-FDA 
interventions. The data was analyzed by applying SPSS and by using Field (2009) as a 
reference. Cronbach's alpha is not a validity measure. The values for Cronbach’s alpha 
range from 0 to 1. Cronbach’s alpha provides the means to assess if a given scale item 
194 
 
 
impacts the overall total subscale reliability. Reversing the phrasing of a negative scale 
item improved the Cronbach’s values.  
 The main questionnaire was divided into four section for conducting the 
reliability assessment with the Cronbach’s alpha in SPSS. This approach allowed to focus 
in each major section of the questionnaire depending on the scenario that was under 
review. The four section were the pre-FDA Likert-type scales, the pre-FDA financial 
indicators, the post-FDA Likert-type scales, and the post-FDA financial indicators. The 
four Cronbach’s alpha values were above .8. An assessment of the Corrected Item-Total 
Correlation as well as the Cronbach's alpha if Item Deleted for the four subscales did not 
provide a substantial improvement to the overall Cronbach's alpha values. Table 66 
presents the four subscales and the corresponding Cronbach's alphas. 
Table 66 
Cronbach's alpha values for the Sub-scales 
 
 Cronbach's alpha 
Cronbach's alpha 
Based on 
Standardized Items N of Items 
Pre-FDA Likert-type (TPB) .828 .929 57 
Post-FDA Likert-type (TPB) .855 .939 58 
Pre-FDA Financial  
Post-FDA Financial                         
.874 
.901 
.879 
.904 
9 
9 
 
Research Questions 
 The two group of predictors used in the study were management behaviors and 
financial indicators in the two scenarios: pre-FDA and post-FDA interventions. The three 
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sets of hypotheses related to these predictors were listed below. The dependent variable 
was the level of compliance with the FDA regulations. 
Research Question 1 
 To what extent, if any, does management behaviors (independent) correlate to 
compliance (dependent) with FDA regulations at the pharmaceutical firms in the 
United States? 
 H1₀:  r = 0. There is no difference in management behaviors towards 
compliance at pharmaceutical firms, as a result of FDA enforcement actions in 
the U.S. 
 H1₁:  r ≠ 0. There are differences in management behaviors towards 
compliance at pharmaceutical firms, as a result of FDA enforcement actions in 
the U.S. 
 According to TPB, three types of beliefs direct and influence human behavior: 
beliefs (b), normative beliefs (n), and perceived behavioral control (c) (Ajzen, 2002). The 
interrelations between these beliefs influence the intention towards a given behavior. 
Three correlations between the outcome of compliance and the three constructs of the 
TPB were performed instead of the original strategy of only one correlation. The null 
hypothesis, H1₀, was rejected for RQ1 in the pre-FDA and post-FDA interventions for the 
three constructs of the TPB. Correlations were found not equal to zero (r ≠ 0). The 
significance of the correlations varied and not all met the expectation, p < 0.05. 
196 
 
 
 In the Pearson correlation for the pre-FDA intervention, the construct of beliefs 
(attitudes) had the highest correlation with the outcome of compliance with a value of r = 
0.633, p < 0.01. The other two construct, normative beliefs and perceived behavioral 
control had non-significant correlations with r values of r = 0.328 and r = 0.183, 
respectively. For the post-FDA intervention, the construct of beliefs (attitudes) also had 
the highest correlation with the outcome of compliance with a value of r = 0.693, p < 
0.01. The other two construct, normative beliefs and perceived behavioral control had 
non-significant correlations with r values of 0.294 and 0.303, respectively. Also, the 
construct of behavioral beliefs had a significant correlation with the construct of 
perceived behavioral control with r = 0.376, p < 0.05. This last significant correlation 
differed from the pre-FDA intervention where the correlation was non-significant 
between these two constructs.  
 The correlation data indicated a favorable change in correlation between the 
outcome of compliance and behavioral beliefs (attitude) for before and after the FDA 
intervention of about 9.5%. The value of r increased from 0.633 to 0.693 for the construct 
of beliefs (attitude) towards compliance by the participants with significances of p < 0.01. 
The other two independent constructs had non-significant correlations. The perceived 
behavioral control non-significant correlation with the outcome of compliance also 
increased by about 65% from the pre-FDA (r = 0.183) to the post-FDA scenario (r = 
0.303). From the limited population that participated in the study, the null hypothesis was 
rejected for RQ1. 
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 A regression analysis was also conducted to establish if there was a linear model 
of the three TPB constructs as predictors of the outcome of compliance of the firms with 
the FDA regulations. For the pre-FDA scenario, the R2 = 0.421 and was adjusted to about 
32% for the contribution of the three constructs. The F- ratio indicated the significance of 
the change with p < 0.05. For the post-FDA scenario, the R2 = 0.492 was adjusted to 
40.2% representing the adjustment to the overall contribution of the three independent 
variables. The F-ratio provided the significance of the change, p < 0.01.   
Research Question 2 
To what extent, if any, do financial indicators (independent) correlate to 
compliance (dependent) with FDA regulations at the pharmaceutical firms in the 
United States? 
 H2₀:  r = 0. There is no difference in compliance with FDA related to financial 
indicators at pharmaceutical firms, as a result of FDA enforcement actions in 
the U.S. 
 H2₁:  r ≠ 0. There are differences in compliance with FDA related to financial 
indicators, as a result of FDA enforcement actions in the U.S. 
 Seven Pearson Correlations were performed with the seven financial indicators to 
understand the possible correlations between these indicators and the dependent variable 
outcome of compliance for each scenario: pre-FDA and post-FDA interventions. The 
basis of the correlations was the firms’ level of compliance as indicated by the 
participants both before and after the FDA intervention. The null hypothesis, H2₀, was 
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rejected for RQ2 in the pre-FDA and post-FDA interventions. Correlations were found 
that were not equal to zero (r ≠ 0). The significance of the correlations varied and not all 
met the expectation, p < 0.05. 
 Pre-FDA Intervention. Of the seven financial indicators, the compliance of the 
firms prior to the FDA intervention had a significant Pearson correlation at p < 0.05 with 
three of them considering a one-tailed assumption due to the skewness of the data in the 
responses. Investment in facility and equipment (r = |-0.468|, p < 0.05), compliance 
expenses (r = |-0.558|, p < 0.05), and stockholders’ equity (r = 0.392, p < 0.05) were 
significantly correlated to compliance. In addition, facility and equipment and 
compliance expenses were significantly correlated to actual sales, actual revenues, and 
market value at p < 0.01.  
  Since the distribution of the scores was skewed or non-normal as supported by 
the results of Kolmogorov-Smirnov and Shapiro-Wilk tests, Kendall’s Tau correlation 
coefficient, τ, was used to understand the correlation between the variables. Of the seven 
financial indicators and following Kendall’s correlation coefficient, τ, the compliance of 
the firms prior to the FDA intervention had a significant correlation at p < 0.05 with two 
of them considering a one-tailed assumption due to the skewness of the data in the 
responses. Investment in facility and equipment (r = |-0.432|, p <0.05) and compliance 
expenses (r = |-0.497|, p < 0.01) were significantly correlated to compliance of the firms. 
Also, facility and equipment and compliance expenses were significantly correlated to 
actual sales, actual revenues, and market value at p < 0.01. The null hypothesis, H2₀, was 
rejected for RQ2 in the pre-FDA intervention.  
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 Post-FDA Intervention. The compliance of the firms after the FDA intervention 
only had a significant Pearson correlation with stockholders’ equity (r = 0.374, p < 0.05) 
considering a one-tailed assumption due to the skewness of the data in the responses. 
Similar to the pre-FDA scenario, investment in facility and equipment and compliance 
expenses were significantly correlated to actual sales, actual revenues, and market value 
at p < 0.01. Compliance expenses was significantly correlated to all other indicators 
except for COGS and stockholders’ equity implying the importance of compliance 
expense between the indicators. 
From the Kendall’s coefficient, τ, the compliance of the firms had no significant 
correlation with any of the financial indicators in the post-FDA scenario. The 
stockholders’ equity had a significance value equal to 0.055. The Kendall’s correlation 
coefficient indicated that investment in facility and equipment and compliance expenses 
had significant correlations with actual sales, actual revenues, and market value at p < 
0.01. Since the interdependencies between the indicators also indicated that significant 
correlations between compliance expenses with actual sales and actual revenues, the 
rejection of the null hypothesis was supported for the RQ2 for the post-FDA intervention. 
Research Question 3 
To what extent, if any, do financial indicators (independent) impact compliance 
(dependent) with FDA regulations at the pharmaceutical firms in the United 
States? 
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 H3₀:  β₁ = β₂ = … = β7 = 0. There is no impact in compliance with FDA 
related to seven financial indicators at pharmaceutical firms, as a result of 
FDA enforcement actions in the United States. 
 H3₁:  At least one β ≠ 0. There is an impact in compliance with FDA related 
to at least one of the seven financial indicators before and after the FDA 
enforcement actions in the United States. 
 The seven financial indicators for the test of Hypothesis 3 were the cost of goods, 
investment in facility and equipment, process compliance, actual sales, actual revenues, 
market value, and stockholder’s equity. The regression analyses were directed to test H3₀ 
for pre-FDA and post-FDA. The βs in Hypothesis 3 were the regression coefficients of 
the following multiple regression equation: 
0 1 1 2 2 3 3 4 4 5 5 6 6 7 7Y X X X X X X X                  (4) 
Where,  
Y= FDA related compliance 
X1 = Cost of goods 
X2 = Investment 
X3 = Process compliance 
X4 = Change in sales 
X5 = Change in revenues 
X6 = Change in market value of the firms 
X7 = Change in stockholders equity 
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ԑ    = Error of the regression 
 The null hypothesis, H3₀, was rejected for the pre-FDA and post-FDA scenarios. 
All indicators had a β value indicating a slope not equal to zero. Since not all assumptions 
were met, the regression models for the financial indicators cannot be used to generalize 
beyond the sample of the study in the pre-FDA and post-FDA interventions. 
 Pre-FDA Intervention. The null hypothesis, H3₀, was rejected for the pre-FDA 
intervention scenario. All indicators had a β value indicating a slope not equal to zero. 
The R2 = 0.607 was adjusted to 0.395 or 39.5% representing a reduction of 0.212 or 
21.2% of the overall contribution of the seven variables. The stockholder’s equity added 
almost 32.1% in contribution in comparison to the previous six predictors. Investment in 
facilities and equipment was the second largest contributor with 13.7%. The 
stockholder’s equity and investment in facilities and equipment contributed about 45.8% 
of the total 60.7% of all the financial indicators. 
 For the ANOVA assessment, all values of F-ratio were above one signaling that 
the model’s fits are better predictors than the guess from the means. Also, the model had 
an F-ratio that was significant to p < 0.048 indicating the low probability of the outcome 
could happen by chance. Since not all assumptions were met, the regression model for the 
financial indicators cannot be used to generalize beyond the sample of the study in the 
pre-FDA intervention. 
 Post-FDA Intervention. The null hypothesis, H3₀, was rejected for the post-FDA 
intervention scenario. All indicators had a β value indicating a slope not equal to zero. 
The stockholders’ equity contributed with 14.4% in comparison to the 15.5% of the 
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previous five predictors. Actual sales were the second largest contributor with 5.8%. 
These two predictors contributed 21.2% of the total 29.9% of the financial indicators for 
the post-FDA scenario.  
 For the ANOVA assessment, all values of F-ratio were below one signaling that 
the model’s fits were not better predictors than the guess from the means. None of the 
models in the post-FDA scenario had an F-ratio that was significant indicating that the 
outcome could happen by chance. Since not all assumptions were met, the regression 
model for the financial indicators cannot be used to generalize beyond the sample of the 
study in the pre-FDA intervention.  
 Regarding the comparison between the pre-FDA and post-FDA scenarios, the 
contribution of the seven indicators diminished from 60.7% to 29.9%. Other contributors 
not considered in the initial model impacted the post-FDA scenario like inventory, cost of 
supplies, and capacity. These potential other financial contributors could have become 
evident to the participants lowering the model effectiveness after the FDA intervention. 
Summary 
 In Chapter 4, the pilot study, the data collection, the data analysis were discussed. 
The limited level of participation in the main study was presented with the corresponding 
demographics. Despite the limited participation, decisions were presented for the three 
tests of the null hypotheses.  
 RQ1 considered the three constructs of the theory of plan behavior. The limited 
participation with 21 completed questionnaires impacted the analysis by limiting the 
depth of the trends. Considering the correlations of the three constructs of the TPB with 
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the outcome of compliance, the null hypothesis, H1₀, of RQ1 was rejected. Based on the 
correlation found between the financial indicators with the level of compliance of the 
firms, the null hypothesis, H2₀, for research questions two was rejected for both 
scenarios: pre-FDA and post-FDA. The slopes in the regression models for RQ3 rejected 
the null hypothesis, H3₀. Both regression models cannot be used to generalize beyond the 
sample of the study. 
 Chapter 5 presents the conclusion and potential interdependencies between the 
different data analyses that were conducted in Chapter 4. Limitations that were found and 
potential areas for future studies were discussed. The conclusion of the study was 
presented. 
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Chapter 5: Discussion, Conclusions, and Recommendations 
  This quantitative study sought to learn to what extent, if any, management 
behaviors and financial pressures at pharmaceutical firms correlated with or predicted 
compliance with the FDA regulations avoiding interruptions in the supply of some 
essential patented or generic pharmaceutical drugs in the U. S. In Chapter 4, the pilot 
study, the data collection, and the data analysis were discussed. The limited level of 
participation in the main study was presented with the corresponding demographics. 
Despite the limited participation, decisions were presented for the three tests of the null 
hypotheses. RQ1 focused on the concepts of the theory of plan behavior (Ajzen, 1991). 
With the available and limited data, the null hypothesis, H1₀, of RQ1 was rejected. Based 
on the correlation found between the seven financial indicators and the level of 
compliance of the firms, the null hypothesis, H2₀, for RQ2 was rejected for both 
scenarios: pre-FDA and post-FDA. The slopes in the regression models for RQ3 rejected 
the null hypothesis, H3₀. Both regression models cannot be used to generalize beyond the 
sample of the study. 
 The nature of the study intended to address the research questions to raise 
management’s awareness avoiding interruptions in the supply of some essential patented 
or generic pharmaceutical drugs. The study highlighted that (a) avoiding FDA actions 
provides business sustainability and (b) compliance is a competitive advantage for 
pharmaceutical companies. The design of the research sought to predict the outcome of 
the dependent variable, that is, compliance with FDA regulations. 
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 The behavior by management, related to the quality of drugs to meet their 
intended quality, integrity, strength, and purity influenced the level of compliance of the 
firm’s operations. Also, the pressures of enhancing productivity, funding research, 
supporting marketing plans, and reducing the cost of goods impacted the firm’s 
compliance performance. The application of enforcement actions by the FDA on the 
firms was used as the treatment event reinforcing the expected level of compliance. A 
shift in the relationship between the variables was observed in the correlations and the 
linear regressions after the FDA intervention, highlighting the new level of compliance. 
 The independent variables that could lead to enforcement actions by the FDA 
were set as management behaviors of the pharmaceutical managers and the firms’ 
financial indicators. The treatment event was the application of the enforcement action by 
the FDA. The level of compliance of the pharmaceutical company was the dependent 
variable. In the study, the conditions before the FDA intervention in the pharmaceutical 
firms were compared to the conditions after the FDA intervention to predict compliance 
with the CGMP regulations. The research questions were formulated on three focus: 
 Correlations between management behaviors (independent) and compliance 
(dependent) 
 Correlations between financial indicators (independent) and compliance 
(dependent): 
 Financial indicators (independent) impact on compliance (dependent). 
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Interpretation of the Findings 
The specific problem addressed in this study related to shortfalls in compliance 
performance and product quality leading to medicine shortages that affected patients’ 
treatment and health. Pollack (2013) expressed that shortfall in investment decisions for 
enhancing quality systems and the limited manufacturing capacity were the drivers 
causing medicine shortages. Price competition to attain market share, financial benefits 
on market value, and management incentives skewed against investing in plant 
improvements drove pharmaceutical manufacturing leaders’ decisions and behaviors 
away from compliance (Asotra, Cossin, & Yacobi, 2012). Senior leaders’ attitude 
towards the lack of compliance and focus in quality systems seems to prevail in their 
management decision-making process. Shortfalls in quality systems resulted from 
extreme control over the cost of goods and a commitment to strong marketing programs. 
Mehta (2013) suggested that implementing principles and guidelines as developed by the 
International Conference on Harmonization could be a significant step in facilitating 
senior leaders’ understanding of the compliance expectations. Correcting CGMP 
violations by the pharmaceutical manufacturing leaders implies that productivity-
financial indicators need assessment and that management behaviors require 
modification. Change management practices as described in chapter two could support 
the change process, continuous improvement efforts, and deal with potential resistance to 
change. 
The findings despite the limited participation in the study supported the 
arguments presented in the literature. Behaviors and financial indicators correlated with 
207 
 
 
compliance with the FDA regulations. The application of the TPB, as well as the 
correlations and regression analyses between financial indicators and compliance, 
allowed me to reject the null hypotheses two and three to support the arguments in the 
literature. Behaviors and approach to financial decisions were different between the pre-
FDA and post-FDA interventions. Changes in the trend of the reputation of the firms and 
changes in management also supported the findings. 
TPB developed by Ajzen (1991) was utilized to assess behaviors of the 
pharmaceutical managers. The central point of TPB is that there is a direct relationship 
between intention and actual behavior. TPB highlights that any behavior could be 
explained and that behaviors are not difficult to predict. For this study, the intention of 
the pharmaceutical industry management to comply with the regulations of the FDA, as 
well as managing the financial limitations and complexity, was an excellent scenario to 
assess with TPB. 
 According to Langham, Paulsen, and Härtel (2012), TPB proposes a direct 
relationship between intention and actual behavior. This relationship is essential to the 
understanding of the willingness to comply and of the actual action of non-compliance. 
Consequently, predicting intention to comply is as important as predicting the actual 
compliance behavior. TPB also evaluates the topic of behavioral control, including the 
concepts of perceived behavioral control and actual control. Perceived behavioral control 
consists of the individual’s ability to control behavior and willingness to apply the 
required behavior. Actual control is essential for investigating behaviors that require the 
individual to overcome performance hurdles. Attitudes and values are specific elements 
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in this approach. Despite the limited participation, understanding the findings that lead to 
the unwillingness to comply or drive to ignore compliance facilitated the assessment of 
probable prevention measures accompanying any FDA intervention. By applying linear 
regression to research questions one, TPB approach provided models to understand how 
to predict behavior and reinforce the intention that could modify future compliance of the 
firms. 
The correlation of the financial indicators with compliance with the FDA 
regulations prior to the FDA intervention in RQ2 provided insight on the levels of 
interdependencies including the significance of the findings. Investment in facility and 
equipment and compliance expenses demonstrated a significant correlation to compliance 
with the FDA regulations. For the post-FDA scenario, the correlation coefficient 
indicated that investment in facility and equipment and compliance expenses had 
significant correlations with actual sales, actual revenues, and market value at p < 0.01. If 
the interdependencies between the indicators were used to imply that compliance 
expenses impact actual sales and actual revenues, the null hypothesis could be rejected in 
the post-FDA scenario for RQ2. 
 The predictors for RQ3  were the seven financial indicators. The outcome variable 
was the level of compliance with the FDA regulations. The null hypothesis, H3₀, was 
rejected for both FDA intervention scenarios. All indicators had a B value indicating a 
slope not equal to zero. Of the seven predictors for the pre-FDA intervention, 
stockholders’ equity had an ANOVA value with significance to p < 0.05. The influence 
of all participants (cases) in the regression model for the pre-FDA scenario was verified, 
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and two were found to be outside the expectation based on the Mahalanobis Distance 
values. For the post-FDA scenario, the influence of all cases of the regression model was 
found to be within expectation.  
 For the assumptions of residual normality, linearity, and homoscedasticity, plots 
assessed under SPSS could be considered supporting these assumptions in both FDA 
scenarios. The lack of significance on the characteristics of the regression models 
indicated that the models were not robust. The findings cannot be generalized and used 
beyond the sample population since not all assumptions for the two linear regressions 
were met. The low level of participation limited the precision on the assessment of the 
assumptions of the regression model. 
Research Question 1 
To what extent, if any, does management behaviors (independent) correlate to 
compliance (dependent) with FDA regulations at the pharmaceutical firms in the 
United States? 
 H1₀:  r = 0. There is no difference in management behaviors towards 
compliance at pharmaceutical firms, as a result of FDA enforcement actions in 
the U.S. 
 H1₁:  r ≠ 0. There are differences in management behaviors towards 
compliance at pharmaceutical firms, as a result of FDA enforcement actions in 
the U.S. 
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 The null hypothesis, H1₀, was rejected for RQ1 in the pre-FDA and post-FDA 
interventions. Correlations were found that were not equal to zero (r ≠ 0). The 
significance of the correlations varied and not all correlations met the expectation, p < 
0.05. 
 In the Pearson correlation for the pre-FDA intervention, the construct of 
behavioral beliefs (attitudes) had the highest correlation with the outcome of compliance 
with a value of r = 0.633, p < 0.01. The other two construct, normative beliefs and 
perceived behavioral control, had non-significant correlations with values of r = 0.328 
and r = 0.183, respectively. For the post-FDA intervention, the construct of behavioral 
beliefs (attitudes) also had the highest correlation with the outcome of compliance with a 
value of r = 0.693, p < 0.01. The other two construct, normative beliefs and perceived 
behavioral control, had non-significant correlations with values of r = 0.294 and r = 
0.303, respectively. Also, the construct of behavioral beliefs had a significant correlation 
with the construct of perceived behavioral control with r = 0.376, p < 0.05. This last 
significant correlation differed from the pre-FDA intervention where the correlation was 
non-significant between these two constructs. This fact implied the influence on 
individual beliefs and their own perception of controlling behaviors after the FDA 
intervention. 
 The correlation data indicated a favorable change in correlation between the 
outcome of compliance and behavioral beliefs (attitude) for before and after the FDA 
interventions of about 9.5%. The value of r increased from 0.633 to 0.693 for the 
construct of beliefs (attitude) towards compliance by the participants with significances 
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of p < 0.01. The other two independent constructs had non-significant correlations. The 
perceived behavioral control non-significant correlation with the outcome of compliance 
also increased by about 65% from the pre-FDA (r = 0.183) to the post-FDA scenario (r = 
0.303). The change in the r value for the perceived behavioral control construct led to the 
change in significance with the outcome of compliance after the FDA intervention. From 
the limited population that participated in the study, the null hypothesis was rejected for 
RQ1. 
 A regression analysis was also conducted to establish if there was a linear model 
of the three TPB constructs as predictors of the outcome of compliance of the firms with 
the FDA regulations. For the pre-FDA scenario, the R2 = 0.421 and was adjusted to about 
32% for the contribution of the three constructs. The F- ratio indicated the significance of 
the change with p < 0.05. For the post-FDA scenario, the R2 = 0.492 was adjusted to 
40.2% representing the adjustment to the overall contribution of the three independent 
variables. The F-ratio provided the significance of the change, p < 0.01. For the ANOVA 
assessment, the models for both scenarios (pre-FDA and post-FDA) had an F-ratio that 
were significant (p < 0.05) indicating that the outcome could unlikely happen by chance.  
 For the comparison before and after the FDA intervention, the contribution of the 
three constructs of the TPB increased from 42.1% to 49.2%. This increased in 
contribution after the FDA intervention represented an overall 16.9% favorable impact on 
the compliance of the firms with FDA regulations. For the participants of the study, the 
FDA intervention influenced their behaviors towards compliance with the FDA 
regulations in the United States. Since not all assumptions were met, the regression 
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model for TPB cannot be used to generalize beyond the sample of the study in either the 
pre-FDA or the post-FDA interventions. 
 Research Question 2 
To what extent, if any, do financial indicators (independent) correlate to 
compliance (dependent) with FDA regulations at the pharmaceutical firms in the 
United States? 
 H2₀:  r = 0. There is no difference in compliance with FDA related to financial 
indicators at pharmaceutical firms, as a result of FDA enforcement actions in 
the U.S. 
  H2₁:  r ≠ 0. There are differences in compliance with FDA related to financial 
indicators, as a result of FDA enforcement actions in the U.S. 
 The null hypothesis, H2₀, was rejected for RQ2 in the pre-FDA and post-FDA 
interventions. Correlations were found that were not equal to zero (r ≠ 0). The 
significance of the correlations varied and not all met the expectation, p < 0.05. 
Pre-FDA Intervention 
 The null hypothesis, H2₀, was rejected for RQ2 in the pre-FDA intervention. Of 
the seven financial indicators, the compliance of the firms prior to the FDA intervention 
had a significant Pearson correlation at p < 0.05 with three of them considering a one-
tailed assumption due to the skewness of the data in the responses. Investment in facility 
and equipment (r = |-0.468|, p < 0.05), compliance expenses (r = |-0.558, p < 0.05), and 
stockholders’ equity (r = 0.392, p < 0.05) were significantly correlated to compliance. 
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Also, facility and equipment and compliance expenses were significantly correlated to 
actual sales, actual revenues, and market value at p < 0.01.  
  Since the distribution of the scores was skewed or non-normal as supported by 
the results of Kolmogorov-Smirnov and Shapiro-Wilk tests, Kendall’s Tau correlation 
coefficient, τ, was also used to understand the correlation between the variables. Of the 
seven financial indicators and following Kendall’s correlation coefficient, τ, the 
compliance of the firms prior to the FDA intervention had a significant correlation at p < 
0.05 with two of them considering a one-tailed assumption due to the skewness of the 
data in the responses. Investment in facility and equipment (r = |-0.432|, p <0.05) and 
compliance expenses (r = |-0.497|, p < 0.01) were significantly correlated to compliance 
of the firms. Also, facility and equipment and compliance expenses were significantly 
correlated to actual sales, actual revenues, and market value at p < 0.01. 
Post-FDA Intervention 
The null hypothesis, H2₀, was also rejected for RQ2 in the post-FDA intervention. 
The compliance of the firms after the FDA intervention only had a significant Pearson 
correlation with stockholders’ equity (r = 0.374, p < 0.05) considering a one-tailed 
assumption due to the skewness of the data in the responses. Similar to the pre-FDA 
scenario, investment in facility and equipment and compliance expenses were 
significantly correlated to actual sales, actual revenues, and market value at p < 0.01. 
Compliance expenses were significantly correlated to all other indicators except for 
COGS and stockholders’ equity implying the importance of compliance expense between 
the indicators. 
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From the Kendall’s correlation coefficient, τ, the compliance of the firms had no 
significant correlation with any of the financial indicators in the post-FDA scenario. The 
stockholders’ equity had a p significance value equal to 0.055. The Kendall’s correlation 
coefficient indicated that investment in facility and equipment and compliance expenses 
had significant correlations with actual sales, actual revenues, and market value at p < 
0.01. Since the interdependencies between the indicators investment in facility and 
equipment and compliance expenses indicated significant correlations with actual sales, 
actual revenues, and market value, the rejection of the null hypothesis was supported for 
the RQ2 for the post-FDA intervention. 
Research Question 3 
To what extent, if any, do financial indicators (independent) impact compliance 
(dependent) with FDA regulations at the pharmaceutical firms in the United 
States? 
 H3₀:  β₁ = β₂ = … = β7 = 0. There is no impact in compliance with FDA 
related to seven financial indicators at pharmaceutical firms, as a result of 
FDA enforcement actions in the United States. 
 H3₁:  At least one β ≠ 0. There is an impact in compliance with FDA related 
to at least one of the seven financial indicators before and after the FDA 
enforcement actions in the United States. 
 The seven financial indicators for the test of Hypothesis 3 were the cost of goods, 
investment in facility and equipment, process compliance, actual sales, actual revenues, 
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market value, and stockholder’s equity. The regression analyses were directed to test H3₀ 
for pre-FDA and post-FDA. The βs in Hypothesis 3 were the regression coefficients of 
the following regression equation: 
0 1 1 2 2 3 3 4 4 5 5 6 6 7 7Y X X X X X X X                  (5) 
Where,  
Y= FDA related compliance 
X1 = Cost of goods 
X2 = Investment 
X3 = Process compliance 
X4 = Change in sales 
X5 = Change in revenues 
X6 = Change in market value of the firms 
X7 = Change in stockholders equity 
ԑ    = Error of the regression 
 The null hypothesis, H3₀, was rejected for the pre-FDA and post-FDA scenarios. 
All indicators had a β value indicating a slope not equal to zero. Since not all assumptions 
were met, the regression models for the financial indicators cannot be used to generalize 
beyond the sample of the study in the pre-FDA and post-FDA interventions. 
Pre-FDA Intervention 
 The null hypothesis, H3₀, was rejected for the pre-FDA intervention scenario. All 
indicators had a β value indicating a slope not equal to zero. The R2 = 0.607 was adjusted 
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to 0.395 or 39.5% representing a reduction of 0.212 or 21.2% of the overall contribution 
of the seven variables. The stockholder’s equity and investment in facilities and 
equipment contributed about 30% of the total 39.5% of all the financial indicators. For 
the ANOVA assessment, all values of F-ratio were above one signaling that the model’s 
fits were better predictors than the guess from the means. Also, the model had an F-ratio 
that was significant to p < 0.048 indicating the low probability of the outcome could 
happen by chance. Since not all assumptions were met, the regression model for the 
financial indicators cannot be used to generalize beyond the sample of the study in the 
pre-FDA intervention. 
Post-FDA Intervention 
 The null hypothesis, H3₀, was rejected for the post-FDA intervention scenario. All 
indicators had a β value indicating a slope not equal to zero. The R2 = 0.299 was adjusted 
to -0.001 representing a very significant adjustment to the overall contribution of the six 
variables. The stockholder’s equity contributed almost 15% in comparison to the 14% of 
the other five predictors. Actual sales were the second largest contributor with about 6%. 
These two predictors contribute about 21% of the total 29.8% of the financial indicators 
in the post-FDA scenario.  
 For the ANOVA assessment, all values of F-ratio were below one signaling that 
the model’s fits were not better predictors than the guess from the means. None of the 
models in the post-FDA scenario had an F-ratio that was significant indicating that the 
outcome could happen by chance. Since not all assumptions were met, the regression 
model for the financial indicators cannot be used to generalize beyond the sample of the 
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study in the pre-FDA intervention. Comparing the two scenarios, the contribution of the 
financial indicators decreased from 60.7%  to 29.9% indicating that other factors were 
also perceived as contributing to the compliance model of the post-FDA model that were 
not part of the initial pre-FDA model.  
Limitations of the Study 
The length of the main study proved to be a major limitation. The pilot study had 
about 40 questions. The main study had 133 questions. The number of participants that 
initiated the survey was about 90 of which 45 progressed through the questions. Only 21 
participants provided completed surveys for the study. The participation rate of 1.9% was 
a major impact to the completeness of the study. The assumptions for the linear 
regressions in RQ3 were not met. The predicting models could not be generalized beyond 
the participants. 
The low level of participation limited the study depth and significance of the 
findings. The rationale for the low participation could have been the sensitivity of the 
topic in the pharmaceutical industry for the shortages of quality product to the patients. 
Also, the participants could had concerns on the confidentiality of the survey despite the 
consent form with the IRB endorsement. In the technical side of communications, the 
internet firewalls in the pharmaceutical firms could had limited e-mails reaching the 
participants. 
The financials results after the FDA intervention in the pharmaceutical firms were 
limited to the recollection and level of knowledge of the participants. The limited 
participation was a major obstacle for the assessment of the financial indicators. The 
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participants, depending on their knowledge and recollection, inferred the financial 
information of the pharmaceutical firms depending on the type of the FDA intervention. 
Recommendations 
 Overcoming the limitations of participation and completeness of the study is 
considered as a specific recommendation. Regarding participation, an alternate approach 
to the use of a professional organization is to recruit and obtain permission directly from 
pharmaceuticals firms. This approach could provide some level of comfort in the 
participants considering the direct clearance by the firms.  
 Completeness of the study depended on the length and number of questions. The 
questions were perceived as repetitive as the participant assessed the pre-FDA and post-
FDA scenarios. This design of repetitiveness is part of the TPB survey structure (Fishbein 
and Ajzen. 2010). The typical TPB survey provides about 50 to 60 questions to address 
the three constructs of attitude, normative beliefs, and perceived behavior control. The 
study targeted two scenarios to assess the research questions: pre-FDA and post-FDA 
interventions. This design led to double the TPB questions. The remaining 10 to 15 
questions were regarding financial indicators, FDA compliance, and demographics.  
 The total questions in the main study were 133. If the study had focused in just 
the after the FDA intervention, the number of usable-complete surveys night have been 
about 45 instead of 21. This number is still well below the initially targeted number of 
160 completed surveys. One recommendation is to reduce the number of questions 
further by focusing only on the construct of belief (attitude) in the study questionnaire 
based on the correlation results. On RQ1, beliefs (attitude) had the highest value of 
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correlation with the outcome of compliance for both FDA scenarios: r (pre-FDA) = 
0.633, p < 0.01 and r (post-FDA) = 0.693, p < 0.01. The other two independent 
constructs, normative beliefs and perceived behavioral control, had non-significant 
correlations with the outcome of compliance in the evaluation of RQ1. This approach 
could further reduce the complexity and the length of the questionnaire influencing the 
number of usable-complete surveys. The concept of the behavior of the decision makers 
remains as a significant element difficult to predict. 
 Recommendations for future research topics based on the models of regression 
analysis from RQ3 with values of R2 = 0.607 (pre-FDA) and of R2 = 0.299 (post-FDA) 
could include other operational financial variables to increase the predictors’ contribution 
in the models. Other financial predictors to be included in the regression analysis could 
be the inventory of goods, marketing costs, and cost of distribution. These topics were 
found in the literature and on-going studies by professional organizations like ISPE. ISPE 
(2014) in their publication on the shortage of medicines also suggested the topics of 
inventory control, the supply of raw materials, the capacity of the manufacturing firms, 
and harmonization of regulations in a global market. 
 All the 1144 participants that were invited to participate in the study were related 
to pharmaceutical companies under the FDA regulations based on their self-disclosed 
information in the ISPE’s database. Since every day the pharmaceutical firms are 
operating in global markets and driving consolidations, future studies could be focused in 
other major markets outside the United States. New manufacturing geographies have 
developed in India and China for the supply of raw materials for the manufacturing of 
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pharmaceuticals products. The literature that I found was mainly focused on the 
American culture. Also, the regulations in other markets are different and evolving. Lack 
of harmonization of regulations will add complexity to the future research. Future studies 
could continue to be segmented by markets and cultures. 
 Based on RQ2, the financial indicators correlated with the outcome of compliance 
with FDA regulations. Management decisions regarding these indicators could influence 
compliance with the FDA interventions. Based on Kendall’s correlation coefficient, τ, the 
compliance of the firms prior to the FDA intervention had a significant correlation with 
investment in facility and equipment (r = |-0.432|, p < 0.05) and compliance expenses (r 
= |-0.497|, p < 0.01). Also, facility and equipment and compliance expenses were 
significantly correlated to actual sales, actual revenues, and market value at p < 0.01. 
Assessment of pharmaceutical management’s behaviors should be conducted to consider 
and accentuate the how to address these financial drivers. 
 In a future study, emphasis should be directed to understand better the influences 
from normative beliefs and perceived control behaviors in management behaviors as 
found in RQ1. Considering the trends of the responses, the overall Normative belief 
indicated to have a stronger influence on the behavior towards the outcome of 
compliance with 392/368 (pre-FDA/post-FDA) of a total of 490 points versus overall 
PBC with a value of 195/182 (pre-FDA/post-FDA) of a total of 490 points. When 
considering the managers’ behaviors, the influence of the opinion from supervisors, 
peers, and relatives on behaviors was stronger than the perceived control in behaviors 
from business related items like budget goals and datelines. 
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Implications 
This research study could be considered unique as it was directed to address an 
area of limited research in management behaviors and on financial decision-making in 
senior management in pharmaceuticals companies which could have led to significant 
shortages of medicines in last 5-6 years. Drug shortage events increased from 61 in 2005 
(Barlas, 2014) to 251 in 2011 (Food Drug Administration [FDA], 2013). Woodcock 
(2012) signaled many of these medicine shortages as a direct consequence of shortfalls in 
compliance with the FDA regulations.  
The comparison of the correlations of the three construct of the TPB with the 
outcome of compliance for the pre-FDA and post-FDA scenarios indicated that the FDA 
intervention had influence in the participants’ behaviors. The correlation of the construct 
of beliefs (attitude) was significant and increased by 9.5%. In the case of perceived 
behavioral control, the correlation with the outcome of compliance increased by 65% 
although it was not significant.  
These trends implied that the FDA intervention impacted the participants’ 
perception on how could they control and influence their behavior for compliance with 
the FDA regulations. The normative beliefs regarding others’ opinions did not show any 
change in the correlation with compliance between the pre-FDA and post-FDA scenarios. 
Peers, supervisors, and quality unit opinions did not alter their influence towards a 
behavior of pro-compliance in the participants. The level of compliance increased after 
the FDA intervention as indicated by the means of the participants’ responses. A 
dependent-means t-test was applied to the two scenarios’ means: pre-FDA and post-FDA 
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considering that the same participants took part in both scenarios. A negative sign to the 
difference of the means indicated that the mean of the compliance of the firms after the 
FDA intervention was larger than before the FDA intervention. A negative t- test 
confirmed that the mean of the post-FDA was larger than the pre-FDA scenario.  
In the regression model following the three construct from the theory of planned 
behavior (TPB) in RQ1, the contribution of the three constructs increased after the FDA 
intervention from 42.1% to 49.2%. This increase signaled that the desired behavior to be 
in compliance with the FDA regulations was favorably impacted. The beliefs (attitude), 
the normative beliefs (peers), and the perceived behavioral control provided a higher 
prediction of behavior after the FDA intervention. These models could be used by 
management to reinforce behaviors allowing a more robust application of the firm’s 
quality systems to minimize drug shortages and to attain a more competitive position for 
the firms. 
 In the seven correlations of the financial indicators in RQ2, the significant 
correlation between stockholders’ equity in both pre-FDA and post-FDA interventions 
signaled the relevance of the firms’ compliance with the FDA and the investors’ 
expectations of the firms’ reputation. Also, the favorable trend in perception of the firms’ 
reputation from the participants’ responses supported the concept that the firms could be 
considered as having achieved a more favorable image by increasing its compliance with 
the FDA regulations. In RQ2, the inverse correlation of investment on facility and 
equipment and compliance expenses with the outcome of compliance could be 
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considered as strong opinion that low level of compliance requires high level of 
investment and compliance expenses. 
In RQ3, the regression model after the FDA intervention was not robust in 
comparison to the contribution of the variables in the pre-FDA scenario. The contribution 
decreased from 60.7%  to 29.9% indicating that other factors were also perceived as 
contributing to the compliance model that were not part of the initial pre-FDA model. 
Elements like inventory, cost of supplies, and capacity could be further limiting the post-
FDA model. This outcome of the study could provide insight into the management 
decision process on what senior leaders’ should consider when dealing with financial 
drivers that could limit the presence of effective quality systems in the pharmaceutical 
manufacturing companies. 
For pharmaceutical firms, the lack of compliance with the FDA regulations could 
be devastating. The results from the lack of compliance could include impact on 
reputation of the firms and an increase in the level of expenses to recover or achieve 
remediation. These performance indicators typically also impact the market value of the 
firms as shown in the correlations of RQ2. Regarding the reputation of the firms, the 
average of the responses from the participants indicated a decreasing trend in the positive 
ratings from eight to six between the pre-FDA and post-FDA interventions.  
In the Pearson correlation for the pre-FDA scenario, investment in facility and 
equipment (r = |-0.468|, p < 0.05) and compliance expenses (r = |-0.558|, p < 0.05) were 
inversely correlated to complince of the firms. The lower the compliance of the firms 
implied the higher the need to increase investment in facilities and equipment as the 
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corresponding compliance. If the FDA intervention escalates into a consent decree, the 
magnitude of all these elements could multiply and become an unacceptable historical 
benchmark within the industry. 
This study has the potential to highlight the desired behaviors in management and 
accentuate the concept that compliance could avoid medicine shortages and be a 
competitive business advantage for the pharmaceutical companies. In RQ1, the Pearson 
correlation of beliefs (attitude) with the outcome of compliance was increased from r = 
0.663 to r = 0.0693 for a 9.5% when comparing the pre-FDA and post-FDA scenarios. 
The perceived behavioral control non-significant correlation with the outcome of 
compliance also increased by about 65% from the pre-FDA (r = 0.183) to the post-FDA 
scenario (r = 0.303). The normative beliefs driven by opinion from others did not shown 
any significant change between the pre-FDA and post-FDA interventions.  
In the regression analysis to the TPB constructs also in RQ1, the R of the models 
increased from 42.1% to 49.2%. This increase in the contribution of the construct 
behaviors in the prediction of compliance reinforced the concept that after the FDA 
intervention, behaviors towards compliance were better recognized by the participants in 
the study. These model could be used by management to reinforce behaviors allowing a 
more robust application of the firms’ quality systems to minimize drug shortages and to 
attain a more competitive position for the firms. Management should ensure clarity to 
subordinates on the expected behavior and influence perceived controls to drive 
compliance of the firms with the FDA regulations. 
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Through this study, I was able to influence pharmaceutical management’s 
awareness on how their decisions, based on their attitudes and behaviors, impacted 
compliance. The inverse relation of compliance of the firms versus investment in 
facilities and compliance expense should be used to demonstrate that the higher the 
compliance the lower these financial factors. Avoiding having low compliance with the 
FDA regulations increases expenses and could lead to interruptions in the supply of some 
essential patented drugs or generic pharmaceutical drugs. The desired management 
behaviors should transform leadership tactics to meet the organization goals and mission, 
while attaining compliance with the CGMP regulations. 
The target of the study, as previously described, was directed to the positive social 
change to avoid placing the patients in danger by not having medicine shortages. Becker 
et al. (2013) found in their study that the incidents of oncological drug shortages affecting 
patients’ treatments increased from 2010 to 2011. Also, stockholders’ equity, as 
demonstrated in RQ2, could be affected if management does not recognize the 
detachment from their mission leading to low compliance and the associated costs from 
the FDA interventions. Considering that any generalization is limited to the sample of 
participants and is based on the correlations and regression analyses conducted in this 
study, if management performance continues with old practices and behaviors, leading to 
poor product quality and further medicine shortages, the risk to patients and the losses to 
stockholders could be unavoidable.  
To project the complexity of addressing the change, change management 
decision-making processes need to be implemented by the pharmaceutical management. 
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The required change process to attain the desired state of avoiding medicine shortages 
has to evolve through the typical change cycle of what, how, and why (Kezar, 2001). The 
potential impact on stakeholders, especially medicine shortages to patients, constituted 
the “why” to conduct this study. Influencing the organizational performance, through 
modification of management behaviors and financial indicators, should minimize or 
eliminate the stakeholders’ impact, leading to positive social change. 
The study alignment to obtain positive social change was directed to encourage 
managers of pharmaceutical organizations to operate and behave with a sound approach 
to compliance with CGMP of the FDA. The main potential social impact was to avoid 
having medicine shortages, due to non-compliance decisions by pharmaceutical 
manufacturing management. The risk of affecting the patient health could be minimized 
or eliminated by avoiding drug shortages as well as the supply of substandard patented or 
generic medicines. Also, the inherent mistrust by the public on companies’ lack of 
commitment towards social responsibilities could be neutralized or reduced enhancing 
the reputation of the firms as indicated in the responses to the study. 
Conclusion 
This research study could be considered unique as it was directed to address an 
area of limited research in management behavior and on the financial decision-making of 
senior management in pharmaceuticals companies, which could have led to significant 
shortages of medicines in last 5-6 years. Despite the limited participation, the outcome of 
the study provided insight into the management decision process on what senior leaders’ 
behaviors should consider and accentuated the need to modify the approach to financial 
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drivers. Emphasis should be directed to better understand the influence of the perceived 
behavioral control versus normative beliefs. Enhancing decision making processes while 
considering behaviors and the financial correlations could reinforce the presence of 
effective quality systems in the pharmaceutical manufacturing companies eliminating or 
minimizing medicine shortages. 
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Appendix A: Permission to Reprint Figure 4 and TPB questionnaire 
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Appendix B: Permission to Reprint Figure 5 
 
 
245 
 
 
Appendix C: G*Power Calculations 
F tests - Linear multiple regression: Fixed model, R² deviation from zero 
Analysis: A priori: Compute required sample size 
Input:  
                     Effect size f²                        = 0.125 
 α err prob = 0.05 
 Power (1-β err prob) = 0.95 
 Number of predictors = 2 
Output:  
                     Noncentrality parameter λ = 15.8750000 
 Critical F = 3.0692864 
 Numerator df = 2 
 Denominator df = 124 
 Total sample size = 127 
 Actual power = 0.9506401 
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Appendix D: Permission from ISPE 
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Appendix E: Pilot study demographics 
 
Table E2 
Management Decision-Makers 
Answer  
Options 
Response 
Percent 
Response 
Count 
Manager 0.0% 0 
Director 57.1% 4 
Vice President 28.6% 2 
Executive 14.3% 1 
President 0.0% 0 
CEO 0.0% 0 
Note: answered question: 7  
          skipped question: 2 
  
 
 
 
 
Table E1 
Age Group of Participants 
Answer 
Options 
Response 
Percent 
Response 
Count 
20-30 0.0% 0 
31-40 0.0% 0 
41-50 28.6% 2 
51-60 42.9% 3 
60+ 14.3% 1 
Prefer not to 
answer 
14.3% 1 
Note: answered question: 7 7 
          skipped question: 2 2 
Table E3 
Operational Function 
Answer 
Options 
Response 
Percent 
Response 
Count 
Manufacturing 14.3% 1 
Quality 57.1% 4 
Logistics 0.0% 0 
Engineering 0.0% 0 
Other (please 
specify) 
28.6% 2 
Note: answered question: 7                  
          skipped question: 2  
Table E4 
Academic Background 
Answer 
Options 
Response  
Percent 
Response  
Count 
High School 0.0% 0 
Bachelors 42.9% 3 
Masters 14.3% 1 
MBA 0.0% 0 
Ph.D. 42.9% 3 
Other (please 
specify) 
0.0% 0 
Note: answered question: 7  
          skipped question: 2  
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Appendix F: Main study demographics 
 
 
 
  
 
 
Table F1 
Age Group of Participants 
Answer 
Options 
Response 
Percent 
Response 
Count 
20-30 0.0% 0 
31-40 0.0% 0 
41-50 31.8% 7 
51-60 50.0% 11 
60+ 13.6% 3 
Prefer not to 
answer 
4.61% 1 
Note: answered question: 22  
          skipped question: 0  
Table F2 
Management Decision-Makers 
Answer 
Options 
Response 
Percent 
Response 
Count 
Manager 27.2% 6 
Director 59.1% 13 
Vice 
President 
9.1% 2 
Executive 4.6% 1 
President 0.0% 0 
CEO 0.0% 0 
Note: answered question: 22  
          skipped question: 0 
  
Table F3 
Operational Function 
Answer  
Options 
Response 
Percent 
Response 
Count 
Manufacturing 22.7% 5 
Quality 22.7% 5 
Logistics 0.0% 0 
Engineering 40.9% 9 
Other (please 
specify) 
13.7% 3 
Note: answered question: 22                 
          skipped question: 0  
Table F4 
Academic Background 
Answer  
Options 
Response 
Percent 
Response 
Count 
High School  4.6% 1 
Bachelors 27.3% 6 
Masters 40.9% 9 
MBA 10.2% 4 
Ph.D.  9.0% 2 
Other (please 
specify) 
0.0% 0 
Note: answered question: 22  
          skipped question: 0  
